The role of DNA repair & regulatory proteins in the maintenance of human telomeres and their control of cellular immortalization by Harvey, Adam
  
 
 
 
The role of DNA repair & regulatory proteins in the maintenance of human telomeres 
and their control of cellular immortalization 
 
A DISSERTATION 
SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL  
 OF THE UNIVERSITY OF MINNESOTA 
BY 
Adam John Harvey 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF  
 
DOCTOR OF PHILOSOPHY 
 
 
Dr. Eric A. Hendrickson 
 
 
 
April 2017 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Adam Harvey 2017 
 
  i 
Acknowledgements 
 
First, I would thank all the current and former members of the Hendrickson laboratory.  It 
has been a wonderful environment to learn how to be a true scientist.  The vast knowledge 
provided by my colleagues helped me with many specific problems I encountered, but 
more generally were just very pleasant and fun people to be around.  I would especially 
like to thank my advisor, Dr. Eric Hendrickson.  He became quite the role model for me, 
both as an intellectual and as a scientist.  I attribute the majority of my scientific 
development not just to his conceptual guidance, but to his investing time, money, and 
training into my success.  No one else will ever have impacted my intellectual development 
in a larger sense than he. 
 
Thank you to my family! My parents, Brien Harvey and Jamie Just, have been a wonderful 
source of support, guidance, and patience.  My brother, Alex Harvey, has also been a fun 
partner to co-mature professionally alongside.  Also, he was an excellent source of video-
game distractions.  
 
Finally, thanks to my wife, Megan Harvey.  She has been with me since the early days of 
my graduate school career and will be so for a lifetime after.  Her support through this 
processes has been invaluable. Her sacrifices have been the foundation of my success. 
  ii 
Dedication 
This dissertation is dedicated to the inspiration of future scientists.   
The world needs a lot more science and a lot less chaos.  
  iii 
Abstract 
Telomeres are the nucleoprotein structures that protect the ends of linear 
chromosomes from recognition as a double-stranded DNA break (DSB).  In the absence 
of proper telomere function, the ends of a chromosome fuse together, creating di-
centromeric chromosomes, which can no longer properly segregate at mitosis.  Thus, 
proper telomere maintenance is absolutely essential for all eukaryotic life.  Unfortunately, 
maintaining telomeres at a size that is protective is problematic.  For example, as a 
consequence of “the end-replication problem,” telomeres shorten incrementally during 
every cell cycle.  These short telomeres can, in turn, function to regulate the lifespan of 
any given cell.  Perhaps not surprisingly, therefore, humans have evolved a vast array of 
genes to enable telomere stability, in order to counteract any premature ageing or cell 
death.  In order to ensure that offspring may begin their life with a default telomere length 
that is sufficient for stability during the organism’s lifespan, stem cells must not be 
subjected to overall telomere shortening.  Thus, all telomere shortening that a stem cell 
occurs during its eternal proliferation must be correspondingly compensated for by a 
lengthening event.  This telomere elongation mechanism in essence confers cellular 
immortality.  The most well-characterized of these cellular immortality pathways is 
controlled by the enzyme telomerase, which precisely elongates telomeres in a stochastic 
way to maintain a telomere length equilibrium.  Unfortunately, this functional, essential 
pathway can also be conscripted to perform pathological reactions.   In human cancer, all 
malignant growths must enable cellular immortalization to allow for their characteristic 
uncontrolled proliferation.  In most cases this is achieved simply by the reactivation of 
telomerase.  Interestingly, 5 to 15% of all human cancers are telomerase negative.  These 
  iv 
cancers can be described as ALT cancers, as the Alternative Lengthening of Telomeres 
pathway enables their immortality.  ALT, which is specific to cancer, achieves telomere 
elongation by aberrant recombination between telomeres.  My research has found that 
DNA repair proteins, such as PARP1, (poly ADP ribose polymerase 1) are critical for both 
the maintenance of the genome and specifically for proper telomere maintenance.  
Furthermore, my research has demonstrated that the mutation of a single gene, ATRX, 
(alpha thalassemia mental retardation on the X chromosome) is an active repressor of 
ALT immortalization.  In summary, I have contributed to the understanding of human 
telomere length maintenance and these studies have implications for human aging and 
the genesis of cancer.   
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TRF1 Telomere repeat factor 1 DsDNA binding protein of shelterin-Very similar in 
structure to TRF2 
TRF2 Telomere repeat factor 2 Appears to be the most essential component of 
Shelterin.  Binds dsDNA TTAGGG 
U-2 OS Clone U-2 osteosarcoma  An ALT cell line taken from a human mesenchymal 
tumor. 
UNG Uracil nucleotide glycosylase Enzyme responsible for the removal of genomic uracil 
XLF Xrcc4-like factor Forms a filament on DNA to facilitate the rapid 
rejoining of broken DNA ends in C-NHEJ 
XRCC1 X-ray cross complementing 
protein 1 
Base-excision repair protein which interacts with LIG3 
XRCC4 X-ray cross complementing 
protein 4 
A cofactor for LIG4 which facilitates C-NHEJ 
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Chapter 1 
Introduction 
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DNA damage, breaks, and repair 
All forms of known life on Earth share the same genetic code, and many genes in the 
human genome can be traced all the way back in evolution to bacteria.  One such 
incredibly well-conserved protein is Ku, a circular, doughnut shaped molecule that is 
responsible for DNA repair in many life-forms, and which is a subject of significant 
importance in Chapter 2 of this thesis.  While the specifics of Ku will be discussed later, 
this single example of genetic conservation throughout evolution underscores the 
necessity of all life to maintain and repair genetic material. 
While some genes may be conserved in all species throughout evolution, Darwinian 
evolution by natural selection requires the existence of heritable genetic mutations.  These 
mutations are caused by some form of DNA damage, an all-encompassing term including 
DNA insertions, deletions, improper covalent modifications, single-strand breaks (SSBs) 
and double-strand breaks (DSBs), as well as larger chromosomal aberrations, some of 
which will be discussed later in detail.  This DNA damage originates from a variety of either 
exogenous or endogenous sources.  Exogenous sources of DNA damage are most 
obvious to non-scientists, as they are often classified as carcinogens, e.g. ionizing 
radiation, UV light, heavy metals etc.  Other sources of exogenous DNA damage can 
include pharmaceutically developed chemotherapies.  Ironically, in the laboratory, these 
exogenous sources of DNA damage can all serve as tools to study DNA, and the proteins 
which protect it. 
Endogenous sources of DNA damage are subtler in their cause, but likely contribute 
to the vast majority of mutations over the lifespan of an individual.  For example, one 
recent study proposed that almost two-thirds of all human cancers are caused by 
endogenous random somatic mutations (Helleday et al. 2014).  These endogenously 
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induced mutations could be independently detected and quantified as exogenous sources 
of damage tend to have unique molecular signatures, e.g. UV exposure causes thymidine-
dimers in DNA.  Although endogenous damage can be caused by (amongst other 
processes) oxidative DNA damage from mitochondrial dysfunction and enzymatically 
catalyzed DNA breaks during immune cell development, the most significant source of 
endogenous DNA damage is likely DNA replication, as the fidelity of DNA polymerases 
cannot match the large number of base pairs in a human cell, approximately 3 billion.  
Taken together, both exogenous and endogenous sources cause DNA damage. 
Most relevant to this discussion is how specific forms of DNA damage, i.e. SSBs and 
DSBs are repaired.  These two categories of DNA damage are defined by either a break 
in one or both strands of the DNA backbone, respectively.  SSBs are the less toxic lesion 
per se, but far more common occurring approximately 10,000 to 50,000 times on a per 
cell, per day basis (Bradley and Kohn 1979, Vilenchik and Knudson 2003).  In isolation, a 
SSB is relatively non-toxic, however if un-repaired a SSB can be readily converted to a 
DSB via DNA replication (Kuzminov 2001).  These DNA DSBs, in contrast, are extremely 
toxic DNA lesions and mechanistically the most difficult for cells to repair (Ciccia and 
Elledge 2010).  There are an estimated 10 spontaneous DNA DSBs per cell, per day 
based on metaphases studies of dividing cells (Martin et al. 1985, Lieber et al. 2003).  The 
proper repair of these lesions is critical to maintain cellular life. 
 
DNA SSB repair and PARP1 
Given the vast incidence of SSBs in every cell, every day, a large array of SSB repair 
proteins have evolved to limit the potential damage of such breaks.  SSBs are 
distinguished as being a nick in the backbone of the DNA, and not damage to the base 
  4 
themselves.  Although there exists a myriad of exogenous and endogenous sources of 
DNA damage, as long as the lesions they cause ultimately result in a SSB, they are 
repaired by a single common pathway (Kuzminov 2001).  Indeed the cellular SSB repair 
pathway is mechanistically rather simple and very robust.  In general, the great danger of 
DNA SSBs is that they can be precursors to DSBs.  With that said, SSBs can pose unique 
challenges to the cell other than simply being readily converted to DNA.  For example, 
SSBs can block gene transcription (Zhou and Doetsch 1993), which if unrepaired, would 
be equivalent to a gene-inactivating  mutation.  Intriguingly, various regions of the genome 
exhibit both variable damage and repair rates.  For example, SSBs can trigger 
transcription coupled repair (TCR), and as such actively transcribed genomic regions tend 
to exhibit different repair kinetics and mutational frequencies than non-transcribed regions 
(Jee et al. 2016).  Changes in the mutational rates can even be differentiated by which 
strand is actually transcribed, as detection of a break is much more likely to occur on the 
actively transcribed strand (Haradhvala et al. 2016).  Thus SSB repair in and of its own 
right is a multifaceted process for preserving genomic integrity. 
While there are many subpathways of SSB repair, they all share common upstream 
recognition proteins, including poly-ADP ribose polymerase 1 (PARP1), which binds SSBs 
with high affinity (Krishnakumar and Kraus 2010).  This physical affinity of PARP1 for SSBs 
is an unbiased biochemical process, and thus PARP1 is ubiquitously involved in all the 
subpathways of SSB repair.  PARP1 is one of 17 PARP family member genes, all which 
are categorized by their ability to post-translationally modify target proteins with poly-ADP-
ribose (PAR) moieties.   Specifically, upon the binding of a SSB, PARP1 hydrolyzes NAD+ 
to generate ADP-ribose, which is then transferred by PARP1 onto a target protein 
(Schreiber et al. 2006).  This reaction can be carried out sequentially to form poly-ADP-
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ribose chains (hence PARP1’s name), where the nascent ADP-ribose can be covalently 
linked to a previously transferred ADP-ribose group, rather than onto a target protein 
(Hassa and Hottiger 2008).  These poly-ADP ribose chains can both elongate and branch 
out, forming large multimers consisting of 40 to 50 ADP-ribose groups.  These large chains 
serve as signaling platforms for the recruitment of trans-acting response factors that 
mediate the subsequent repair. 
Upon binding to a SSB, PARP1 also begins to modify itself with PAR moieties, which 
is thought to serve as a molecular scaffold for the recruitment of downstream SSB repair 
proteins (Gibson and Kraus 2012).  The recruitment of these trans-acting proteins is 
dependent on their possession of PAR-interaction domains, which can be either large 
protein macrodomains, i.e. PARP binding zinc finger (PBZ)-domains, as well as a 8-amino 
acid (mostly basic residues) motif (Kleine and Luscher 2009).  Canonical downstream SSB 
repair proteins include polymerases, such as POLβ and their accessory factors, which 
serve to replace any missing genetic material (Gu et al. 1994).  Even further downstream 
of DNA polymerization is the ligation complex, which consists of X-ray cross 
complementing 1 (XRCC1) and DNA ligase 3 (LIG3), which are responsible to ligate the 
strands back to their proper confirmation, thus completing the reaction (Caldecott 2008). 
It is important to note that not all SSB repair is the same.  One notorious confusion is 
the difference between base excision repair (BER) and SSB repair, as they are functionally 
semi-redundant (Helleday 2011).  BER serves to repair damage to a specific base, rather 
than repair the sugar backbone.  BER functions by first the recognizing one of the many 
forms of base damage, followed by excision of the lesion to form an abasic site.  This 
abasic site is then converted into a gap in the DNA backbone by sequential endonucleic 
cuts.  In essence the result is two proximal SSBs, which is the source of confusing 
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scientific interpretation.  The best example of this is the process of antibody diversification 
via class-switch recombination (CSR), where a cytosine deaminase, activation induced 
deaminase (AID), depurinates genomic cytosine causing its conversion to uracil 
(Muramatsu et al. 2000).  Genomic uracil is a form of base damage, and it is excised by 
DNA uracil glycosylase (UNG).  This causes an abasic site, which is then nicked and 
removed, creating a SSB.  This site is certainly a suitable substrate for PARP1 binding, 
but the processing of this break does not require PARP1, as the pathway is a concerted 
reaction, and independently recruits downstream repair factors.  Thus, while PARP1 could 
impact the rate of this reaction in theory, it is not a BER protein. 
The potential for overlapping functionality between SSB repair and BER has frequently 
enabled the mis-characterization of PARP1 as a BER protein.  For example, PARP1 
inhibitors can trap PARP1 on a transient SSB, and inhibit the canonical BER process from 
completion (Dantzer et al. 1999).  Most tellingly to the importance of this distinction is the 
simple fact that while PARP1-null mice are viable (de Murcia et al. 1997), the loss of “true” 
BER proteins such as DNA polymerase beta (POLβ) (Gu et al. 1994) and XRCC1 (Tebbs 
et al. 2003) are not viable, thus suggesting that these genes serve distinct biological roles 
(Helleday 2011). 
 
DNA DSB repair 
DNA DSBs are extremely toxic DNA lesions and mechanistically the most difficult for 
cells to repair (Ciccia and Elledge 2010).  There are two distinct repair pathways for DNA 
DSBs: homology dependent repair (HDR) and non-homologous end joining (NHEJ).  The 
names of each pathway are self-descriptive. HDR repairs a DSB by utilizing homologous 
(near-identical) genetic material to “copy and paste” the correct genetic material across a 
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break while NHEJ facilitates the ligation of two blunt ends together, irrespective of their 
genetic sequence.  HDR is broken down into many subpathways, including single-strand 
annealing (SSA), synthesis-dependent strand annealing (SDSA), and the classic double 
Holliday junction resolution, commonly referred to as homologous recombination (HR).    
There are subpathways of NHEJ as well - classic NHEJ (C-NHEJ) and alternative NHEJ 
(A-NHEJ).  C-NHEJ is a well-conserved and rapid process which can facilitate the 
rejoining of adjacent ends of a DSB.  A-NHEJ is hallmarked by the requirement for 
microhomology in the DNA sequence between the two adjacent ends to facilitate rejoining 
and ligation.  The distinctions between these subpathways of DSB repair will be discussed 
below. 
 
C-NHEJ and the Ku70/86 heterodimer 
C-NHEJ is the most active DSB repair pathway in the human body.  It is not 
significantly regulated by cell-cycle and is mechanistically simple.  The canonical pathway 
consists of seven key genes: Ku70, Ku86, DNA-PKcs, Artemis, XRCC4, XLF4, and LIG4, 
which are generally sufficient to rejoin most broken ends (Betermier et al. 2014).  Two 
additional genes have been recently identified; one being PAXX (Ochi et al. 2015), a 
paralog of XRCC4 and XLF, and the other being Polµ (Chang et al. 2016), a template 
independent DNA polymerase. Both additional factors appear to be important to rejoin 
specific conformations of the DSB termini (Chang et al. 2016). Nonetheless, C-NHEJ 
begins with the binding of the DSB by the Ku70/86 heterodimer, an extremely abundant 
protein complex which has a high affinity for DNA DSBs.  The mechanism of Ku binding 
to broken DNA ends was first elucidated by the observation that while Ku had a very high 
affinity for dsDNA, it required ends to facilitate its binding (Mimori and Hardin 1986).  Thus 
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it is perhaps not surprising that the structure of this protein complex is ring-like, where the 
minor groove of DNA interacts with protruding, positively charged amino acids of the 
heterodimer, similar to the way that a nut threads onto a bolt (Walker et al. 2001).  The Ku 
heterodimer is largely thought to serve as a structural signal for the recruitment of DNA-
PKcs, the largest known protein kinase (Lieber 2010).  Interestingly, while this kinase is 
able to bind DNA on its own, the presence of Ku increases that affinity by 2 orders of 
magnitude (West et al. 1998).  Upon DNA binding, DNA-PKcs begins to phosphorylate 
several proteins, including itself, which enables both the activation of the DNA damage 
response and the recruitment of the downstream ligation complex.  The signaling events 
include the ataxia telangiectasia mutated – checkpoint kinases 1 and 2 – and tumor 
suppressor protein 53 (ATM-Chk1/2-p53) activation, which signal for cell cycle to stall 
while the damage can be repaired.  DNA-PKcs also facilitates the recruitment of the 
downstream ligation complex via its interaction with X-ray cross-complementing 4 
(XRCC4) (Costantini et al. 2007).  
The ligation complex of C-NHEJ consists of XRCC4, XLF, PAXX and LIG4.  The 
structure of XRCC4, XLF, and PAXX are remarkably similar, and most differ according to 
the relative orientation of a single C-terminal helical domain (Ochi et al. 2015). While PAXX 
has been shown to be essential to facilitate the rejoining of 5’ incompatible ends 
reconstituted in vitro (Chang et al. 2016), PAXX is notably redundant only with XLF in 
living cells for VDJ recombination activity (Lescale et al. 2016). Thus, PAXX may be 
required to repair some rare break conformations, but it appears to be mostly functionally 
redundant with XLF. XRCC4 and XLF form a filamentous complex (presumably PAXX and 
XRCC4 as well), where repeated interactions via their N-terminal “head domains” can 
bridge the gap between the broken ends (Ropars et al. 2011, Andres et al. 2012).  While 
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the filamentous complex structure of XRCC4 and XLF is not debated, there are semi-
conflicting models of how they facilitate repair.  One of the most popular is “the caterpillar 
model” that proposes that the two filaments wrap the DNA beginning from the Ku-bound 
end of the DNA, then through a larger complex-complex interaction, where the two protein-
DNA filaments are attracted to one another, bringing the ends in close proximity for ligation 
(Reid et al. 2015).  Regardless of which model is actually correct, LIG4 is recruited through 
its interaction with XRCC4 and XLF to the site of a break and can facilitate the ligation of 
the two broken strands (Reid et al. 2015). 
Our laboratory has made several significant contributions to our current understanding 
of C-NHEJ.  One of the initial indications that C-NHEJ might be regulated differently in 
humans than in other lower organisms was the finding that Ku86 is essential in human 
cells (Li et al. 2002).  In fact, the only other known organism in which Ku is essential is in 
the fungal organism Ustilago maydis, commonly known as corn smut (de Sena-Tomas et 
al. 2015).  This essential feature in both organisms turns out to be a uniquely evolved role 
for Ku related to telomere maintenance, which will be discussed later (Wang et al. 2009).  
Technically, this observation required the genetic engineering of a conditionally-null 
human KU86F/- cell line.  Upon the addition of the Cre recombinase, these cells lose their 
remaining functional allele of Ku and become null.  Although these cells will ultimately die 
(i.e., Ku is essential) they survive for several days.  Paradoxically, an analysis of these 
dying KU86-null cells revealed that the total NHEJ activity was not at all diminished (Fattah 
et al. 2010).  This was quite a surprising result, as LIG4-/- cells, have almost no detectable 
NHEJ activity (Fattah et al. 2010).  Thus, at the time, it was reasoned that A-NHEJ activity 
must be compensating for the lack of C-NHEJ, and that the steady state level of total 
NHEJ in a KU86-null human cell was due to enhanced A-NHEJ.  While this model turned 
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out to be partially true, In Chapter 2, I will show data that rather than A-NHEJ 
compensating for the total level of NHEJ is a cell, the majority of Ku-independent NHEJ is 
still mediated by LIG4, which implicates a novel Ku-independent direct-to-ligation 
mechanism by LIG4.  The regulation of A-NHEJ by Ku as we had initially proposed will be 
discussed later in this chapter. 
 
HDR 
As aforementioned, HR is now considered a subpathway of HDR.  The distinction 
between the HDR subpathways lies only in the downstream resolution of the homologous 
regions following their recognition, and thus the classic HR pathway remains the best 
example of HDR (Jasin and Rothstein 2013).  The DSB recognition complex for HDR is 
the MRN complex, which consists of proteins encoded by MRE11, RAD50, and NBS1 
(Ciccia and Elledge 2010).  Notably, the HDR and NHEJ recognition complexes can 
accumulate concurrently at the site of a DNA break (Kass and Jasin 2010), which implies 
some level of inter-regulatory actions between the two major pathways.  The most likely 
explanation, is that HDR attempts to repair those breaks which C-NHEJ cannot, a decision 
that may involve additional factors such as the chromatin state of the DNA that is broken 
(Jasin and Rothstein 2013).  The key step that commits the DSB repair pathway to one 
reliant on homology, is the 5’ to 3’ resection of the break, which generates recombinogenic 
3’-overhangs.  This resection is thought to be initiated by MRE11 and another 
exonuclease, CtIP, and results in the release of the Ku70/86 heterodimer (Langerak et al. 
2011).  The importance of end resection in the regulation of these two pathways is further 
evidenced by the effect of p53-binding protein (53BP1), which is an end-binding protein 
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that inhibits the ability of MRN and CtIP to initiate resection, and thus promotes NHEJ 
(Bunting et al. 2010). 
Following end-resection, the resulting recombinogenic 3’-ended ssDNA is used to 
search for homologous sequences.  First, the 3’-end is rapidly bound by replication protein 
A (RPA), a trimeric protein complex that binds ssDNA.  RPA, in turn, recruits the  
ATR/ATRIP kinase complex to initiate a DNA damage response (Cimprich and Cortez 
2008).  In order for HDR to proceed, RPA must first be replaced by Rad51, a filamentous, 
single-strand binding protein that is absolutely required for the search for homologous 
sequences (Shinohara et al. 1993, San Filippo et al. 2008).  Another accessory protein 
Rad54B, appears to bind to the 3’ end of the recombinogenic 3’ ssDNA and facilitate 
strand exchange (Sarai et al. 2006). While in many lower organisms the loss of this protein 
does not appear to dramatically affect HDR (Wesoly et al. 2006), its importance in humans 
was demonstrated by our laboratory via the finding that its mutation was synthetically 
lethal with the loss of LIG4 (Oh et al. 2013).  Thus, recombinogenic ssDNA, coated with 
Rad51 and led by Rad54B appears to be required for the search for homology in humans.  
This complex then facilitates the invasion and search for homologous DNA sequences, by 
displacing adjacent dsDNA and enabling the recombinogenic 3’-ssDNA to base pair with 
a cognate sequence on an adjacent chromosome.  This displacement of native dsDNA by 
the recombinogenic ssDNA, results in the formation of a complex called a D-loop, which 
was originally modeled by Jack Szostak (Szostak et al. 1983).  The mechanism of Rad51’s 
ability to facilitate HDR is best suggested by the crystal structure of the bacterial homolog 
of RAD51, RecA, in complex with ssDNA and dsDNA (Chen et al. 2008).  This mechanism 
depicts an ATP-dependent unwinding of the DNA by RecA, bound to ssDNA, thus 
enabling the ssDNA to hydrogen bound with cognate basepairs.  Upon the recognition of 
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an appropriate homologous sequence, the terminus of the ssDNA-dsDNA boundary can 
serve as a primer to facilitate PCNA-DNA polymerase-dependent synthesis to facilitate 
copying of the appropriate genetic material (Sebesta et al. 2013). 
HDR is largely regulated by the cell cycle, as recombination between sister-chromatids 
is vastly preferred to homologous chromosomes (Ira et al. 2006).  This is most likely an 
evolutionary advantage, as the recombination with the homologous chromosome, rather 
than with an identical sister-chromatid, can cause a loss of heterozygosity (Moynahan and 
Jasin 1997).  Thus, HDR tends to be limited to the S and G2 phases of the cell cycle, to 
ensure the presence of a proper template for such repair.  This regulatory control is 
intimately associated with end resection and appears to be due to the regulation of 53BP1.  
The protection against end resection by 53BP1 requires a binding partner, called RIF-1, 
where together their physical interaction is stabilizing and promotes NHEJ (Chapman et 
al. 2013).  This interaction is antagonized by BRCA1 and serves to remove and/or exclude 
53BP1 from inhibiting end resection (Chapman et al. 2012).  Most importantly, this 
exclusion of 53BP1 by BRCA1’s regulation of RIF-1 is dependent on the cell cycle, and 
this constitutes a regulatory circuit to temporally control the occurrence of end resection, 
and thus HDR, limiting it only to the proper phases of the cell cycle (Escribano-Diaz et al. 
2013). 
BRCA1 and another HDR-gene BRCA2 are both infamously well-known breast cancer 
susceptibility genes, where heterozygotic patients are at significant risk for breast cancer 
later in life (Rahman and Stratton 1998).  One fascinating discovery was that BRCA1/2 
mutant patients who develop breast cancer tend to have tumors that are sensitive to 
PARP1 inhibition (Bryant et al. 2005, Farmer et al. 2005). The prevailing theory is that 
SSBs, which normally would be recognized for repair by PARP1, accumulate over time 
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and in a dividing cell such lesions would be converted to DSBs as a consequence of DNA 
replication, although other molecular models of this synthetic lethality have been proposed 
(Helleday 2011).  Nonetheless, clinical successes of BRCA-mutant breast cancers treated 
with PARP1 inhibitors have been observed for some time (Fong et al. 2009, Tutt et al. 
2010).   
Not all BRCA1/2 mutant breast cancers are sensitive to PARP1 inhibition (Fong et al. 
2009), and the development of PARP1-inhibitor resistance has also been frequently 
observed.  Some of the mechanisms of resistance are quite simple, such as compensatory 
mutations in BRCA1/2, which restore HDR capacity, thus eliminating the synthetic lethality 
(Edwards et al. 2008).  Of more interest to this discussion, a second major mechanism to 
PARP1 inhibitor resistance in BRCA1/2 mutant cancer is a compensatory mutation of 
53BP1 (Lord and Ashworth 2013).  This treatment resistance mechanism in cancer was 
originally implicated by the ability to rescue the embryonic lethality of BRACA1-/- mice 
(Ludwig et al. 1997) with a compensatory mutation in 53BP1 (Cao et al. 2009), which 
together suggests that the requirement for BRCA1 in initiating HDR is abrogated by 
removing 53BP1.  Indeed, the first demonstration that PARP1 inhibitor resistance in 
BRCA1/2-mutant tumors might be related to the status of 53BP1 came from a study in 
mice, where mice that developed PARP1-inhibitor resistant BRCA1/2 cancers had tumor-
specific mutations in 53BP1 (Jaspers et al. 2013).   The proposed mechanism for this 
synthetic interaction is that the absence of end protection alleviates the requirement for 
BRCA-dependent initiation of HR, and thus the synthetic lethality of PARP1 inhibitors in 
BRCA cancers is alleviated. 
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A-NHEJ 
While HDR and C-NHEJ have been well-known and studied for decades, it has 
become apparent that there is an additional minor end-joining pathway present in higher 
eukaryotes.  It has interchangeably been referred to as MMEJ (micro-homology-mediated 
end joining) (McVey and Lee 2008), B-NHEJ (backup-NHEJ) (Mladenov and Iliakis 2011) 
and A-NHEJ (alternative-NHEJ) (Nussenzweig and Nussenzweig 2007), (hereafter, A-
NHEJ).  The existence of A-NHEJ has actually been evident in the literature for decades 
(Roth and Wilson 1986), as evidence continued to mount that Ku-independent end joining, 
which generally required microhomologies between the sequences to facilitate its ligation, 
could occur (Boulton and Jackson 1996).  This pathway was not explicitly defined until a 
kinetic analysis of reactions in the chicken DT40 cell line revealed two discrete end-joining 
mechanisms (Wang et al. 2001). 
The discovery of A-NHEJ revealed that the historical accounts of Ku-independent 
NHEJ events had in fact been all along a discrete DNA DSB repair pathway.  These 
reports had suggested that in the absence of Ku, end joining could occur when facilitated 
by microhomology (1 to 7 bp) at the termini of the break (Kabotyanski et al. 1998).  These 
observations lead to the development of molecular tools to assay the frequency of A-
NHEJ, using the requirement for microhomology as the definitive measure (Verkaik et al. 
2002).  Unfortunately, the protein players responsible for this pathway remained nebulous, 
and to this day are still debated.  Adding to the complexity of the search for bone fide A-
NHEJ proteins, is the fact that A-NHEJ is only found intermittently throughout evolution, 
and is particularly absent in many of the popular genetic model systems making its 
requirements difficult to experimentally ascertain (Simsek and Jasin 2011). 
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The first breakthrough with respect to identifying the proteins mediating A-NHEJ was 
the discovery that the PARP1, XRCC1 and LIG3 genes all appeared to be required for A-
NHEJ (Audebert et al. 2004).  This was followed by independent confirmatory reports that 
LIG3 was required for A-NHEJ, as the majority of LIG4-independent NHEJ was abolished 
by knockdown of LIG3 in mouse embryonic fibroblasts (MEFs) (Wang et al. 2005).  While 
the most definitive data at the time appeared to be related to LIG3, PARP1 became of 
significant interest perhaps in part because of its ease of study via commercially available 
inhibitors. PARP1’s role in A-NHEJ was then elaborated by using synthetic DNA 
substrates with microhomology at their termini (Audebert et al. 2006) and it was shown 
that PARP1 could compete with Ku for DNA ends to facilitate A-NHEJ (Wang et al. 2006).  
Yet these reports consistently relied either on the use of pharmacological inhibition of 
PARP1, or genetic approaches in lower model organisms such that PARP1’s role in 
human cells and in A-NHEJ remained equivocal.  Nonetheless, the interest in A-NHEJ 
continued to rise as it was observed that LIG3-mediated microhomology dependent repair 
was causative of oncogenic translocations in mice (Simsek et al. 2011). 
Seemingly conflicting results reported in the literature are often due to variation in the 
experimental model systems in which the experiments were performed.  Experimental 
findings related to A-NHEJ are certainly one such example of abundantly conflicting 
literature reports.  For example, one of the seminal discoveries concerning A-NHEJ was 
the requirement for microhomology in Ku-independent end joining in yeast (Boulton and 
Jackson 1996).  Yet yeast only possess ancestral homologs of LIG1 and LIG4 (Simsek 
and Jasin 2011), and thus the absence of a discrete LIG3-dependent complex made this 
seminal finding suggestive, but not mechanistically insightful.  The best example of the 
differences between organisms and the regulation of A-NHEJ was the finding that 
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oncogenic translocations are driven by A-NHEJ in mice (Simsek and Jasin 2011).  This is 
commonly reported and microhomologies are often searched for in the discovery of new 
oncogenic translocations.  But in humans, these interchromosomal fusions are 
predominently driven by C-NHEJ, and are not significantly affected by the presence or 
absence of LIG3 (Ghezraoui et al. 2014).  Nonetheless, investigators continue to define 
human cancer translocations by the extent with which there is microhomology, although it 
is likely nothing more than the statistical likelihood of such events (e.g. there is a 1/16 
chance that a translocation will have an AT-AT at is junction).  My work (Chapter 2) 
indicates that A-NHEJ is detectable in the absence of LIG3, which implies that LIG3 is not 
solely responsible for microhomology-mediated repair.  Furthermore, my work suggests 
that while Ku-independent A-NHEJ is LIG3-dependent, the majority of Ku-independent 
repair in cells remains LIG4-dependent, which I have described as “direct-ligation” repair 
(Oh et al. 2014).  Furthermore, in more recent work, I show that PARP1 does not impact 
the cellular capacity for A-NHEJ (Chapter 3).  Thus, while A-NHEJ remains detectable 
and of significant interest, its protein determinants remain uncertain. 
Conceptually, while the end-to-end ligation of broken ends of DNA resembles C-NHEJ, 
the requirement for homology between these broken ends by A-NHEJ presumes a 
different mechanism than the simple joining of non-homologous ends, and rather must 
include some degree of end-resection to reveal micro-homologies.  This process has been 
referred to as “micro-SSA” where resection occurs, but is not sufficient to initiate SSA (a 
process that requires much longer lengths of homology), but is nonetheless resected 
enough to enable the completion of the ligation reaction (Decottignies 2013).   This model 
was originally based on observations from yeast, where both RAD52 and EXO1 (canonical 
SSA genes) were required for the majority of Ku-independent NHEJ (Decottignies 2007).  
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This was later investigated in mammalian cells (mice), which found that CtIP (another end 
resection nuclease) was required for A-NHEJ, but that this effect was actually suppressed 
by RAD52 (Bennardo et al. 2008).  The contrasting role for RAD52 was explained away 
due to the fact that RAD52 in yeast is required for almost all forms of HDR, while it appears 
to be HDR subpathway-specific in mice (Rijkers et al. 1998).  Follow up work has muddied 
the waters even more by showing that other HDR nucleases such as MRN (Rass et al. 
2009), as well as other HDR regulatory factors (such as BRCA1) (Badie et al. 2015), 
appear to be important for A-NHEJ.  Although certainly not unequivocal, these reports 
suggested a model in mammals where a nuclease (e.g., EXO1, CtIP or MRN) is 
responsible for initiating the resection required to reveal microhomologies, but the 
presence of downstream HDR processing factors (e.g., RAD52 or BRCA1) are repressive 
of A-NHEJ. 
 
Telomeres and their regulation 
Telomeres are the nucleoprotein structures that protect the ends of linear 
chromosomes, which would otherwise be biochemically indistinguishable from a DNA 
DSB.  The theory behind telomeres was first elegantly described by Barbara McClintock, 
who was performing irradiation experiments on corn cells.  Notably, while studying the 
inheritance of genetic traits, McClintock observed that when multiple breaks occurred 
across many chromosomes, the chromosomes would continually rearrange over time until 
at some undefined point, they would stop (McClintock 1939).  Later, she postulated that 
the chromosome ends had “healed” and noted that once end healing had occurred, that 
this was a permanent change (McClintock 1941).  Decades later, this end healing would 
of course molecularly be shown to be due to the addition or generation of a telomere. 
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Telomere structure 
While the functional property of telomeres is consistent throughout evolution, their 
molecular constituents are extremely species-specific.  In humans, telomeric DNA 
consists of the hexameric repeat, 5’-TTAGGG-3’ (T2AG3), which is repeated thousands of 
times to form the genetic element of a human telomere.  As a consequence of its repetitive 
nature, the Watson-Crick strandedness of a telomere is often designated by whether it 
contains guanosine (TTAGGG) or cytosine (AATCCC).  The double-stranded repetitive 
sequence extends to the distal end of the chromosome, however the very end of the 
chromosome is not blunt but is processed into a ssDNA 3’ overhang.  This overhang is 
often referred to as the G-overhang as it is generated by the resection of the AATCCC 
strand.  This 3’ G-overhang is inherently recombinogenic, as it is functionally similar to the 
DNA products created by end-resection created during HDR (Stansel et al. 2001).  
Moreover, in a fashion similar to HDR, the G-overhang is thought to invade and base pair 
with preceding repetitive sequences in the telomere, forming a D-loop-like telomeric loop 
(or “t-Loop”).  In HDR such an intermediate would normally be resolved into recombinant 
products but at a telomere this structure appears to be relatively stable.  Importantly, this 
re-invasion of the end of the chromosome into preceding DNA has been postulated to 
“hide the end of the chromosome” from DNA DSB repair-sensing proteins (Stansel et al. 
2001). 
The specialized sequence and structure of a human telomere is enhanced by a 
canonical protein complex called Shelterin.  Shelterin is a 6-member protein complex, 
which forms a proteinaceous cap over the end of the chromosome and which regulates 
telomere dynamics (de Lange 2010).  The six shelterin complex proteins are: 
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• TRF1 and TRF2, which bind to the dsDNA T2AG3 
• POT1, which binds to the ssDNA T2AG3 
• Rap1, TPP1, and TIN2, which mediate protein:protein interactions but do not bind 
DNA themselves 
As a whole, the Shelterin complex coordinates telomere dynamics and stability.  In just 
one example, separation-of-function mutants in the basic domain in the N-terminus of 
TRF2 cause HDR-dependent resolution of the t-loop, and the entire telomere is eliminated 
from the chromosome in the form of a circle (Wang et al. 2004). 
While the fundamental stability of a telomere depends upon how Shelterin interacts 
with various components of the DNA repair and replication machinery, there are many 
levels of telomere dynamics.  For instance, while Shelterin is only a 6-member protein 
complex in humans, there are over 300 reported Shelterin-interacting proteins (Lee et al. 
2011).  These “telomere accessory factors” are also very important for the regulation of 
telomeric structure.  One critical role of these factors is to generate the G-overhang, which 
is thought to be mediated by Apollo, an SNM1 (sensitive to nitrogen mustard 1) family 
nuclease related to the C-NHEJ nuclease, Artemis (Wu et al. 2010).   The absence of 
Apollo results in a dramatic loss of the G-overhang, and is causative of the leading (G-
rich) end to fuse with other chromosomes (Wu et al. 2010).  Importantly, Apollo is recruited 
to the telomere transiently though an interaction with TRF2 (van Overbeek and de Lange 
2006).  This interaction has been crystalized, and determined to occur at a canonical 
“docking site” in TRF2, where proteins with a TRF2-interacting motif, Y-X-L-X-P, can be 
recruited to telomeres to perform essential functions, without themselves having specificity 
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for telomeric DNA (Chen et al. 2008).  Thus, telomere accessory factors recruited by 
Shelterin can perform essential telomere roles. 
In addition to TRF2, many other Shelterin proteins regulate telomere accessory 
factors.  For example, TPP1 was classically thought to be relegated to mediating 
Shelterin:Shelterin interactions (Liu et al. 2004), and was known to regulate telomere 
length (Keegan et al. 2005).  Later, it was discovered that a key TPP1 regulatory domain, 
the TEL patch, is required for telomerase recruitment to the telomere (Nandakumar et al. 
2012).  Patient mutations in the TPP1 TEL patch result in inherited diseases of bone 
marrow failure (Guo et al. 2014).  This implied that while telomerase is a very well-studied 
telomere protein (discussed later) it is nonetheless a “telomere accessory protein,” as its 
functional utility requires Shelterin components to facilitate its recruitment.  
The absence of a functional telomere, either the natural erosion of telomeric DNA by 
“the end replication problem” (discussed later), or by the removal of Shelterin, results in 
phenotypes that resemble the (mis)repair of DSBs.  Indeed, eroded or uncapped 
telomeres are magnets for a bevy of DSB repair factors.  The visualization of such proteins 
with fluorescently-labeled antibodies in metaphase cells results in foci at the telomeres 
called telomere induced foci (TIFs).  For example, the natural erosion of telomeric DNA 
that ultimately triggers cellular senescence is tightly correlated with the appearance of 
TIFs (Sedivy 1998).  Thus, a telomere’s essential function is preventing the end of a 
chromosome from being recognized as a DNA DSB.    
One of the deleterious outcomes of attracting DSB repair proteins to a telomere is that 
fusions and chromosomal translocations can ensue.  For instance, the absence of TRF2 
bound to telomeric DNA permits end:end C-NHEJ-mediated inter-chromosomal fusions, 
and is causative of the transformation of independent linear chromosomes into one 
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“snake-like” mega chromosome (Celli and de Lange 2005).  This phenotype, in turn, is 
dependent on the DNA damage signaling and DSB repair components of a cell.  For 
example, the telomere fusions in a TRF2-/- cell can be rescued by a compensatory 
mutation in ATM (Denchi and de Lange 2007).  Similarly, the TRF2-/- fusion events can 
also be rescued by the loss of C-NHEJ components, such as LIG4 (Celli and de Lange 
2005) or Ku70 (Celli et al. 2006).  Interestingly, in TRF2-/-:Ku70-/- double mutants not only 
is the end-to-end fusion activity rescued (as would be predicted by Ku’s role in C-NHEJ), 
but the telomeres also exhibited high levels of sister-chromatid exchanges, which is a 
hallmark of HDR and a phenotype not observed in the TRF2-/- mutants (Celli et al. 2006).  
Altogether, these data suggest that the absence of Shelterin can induce telomeric fusions 
that are mediated by C-NHEJ.  Moreover, in the accompanying absence of C-NHEJ, or 
more specifically Ku, HDR can also act upon the telomeres. 
The above data suggest that Ku has additional roles at a telomere rather than simply 
facilitating the C-NHEJ-mediated fusing of dysfunctional telomeres.  What that role(s) is, 
however, has been difficult to decipher using model systems.  Thus, in Saccharomyces 
cerevisiae, KU70-null strains exhibit telomere shortening and telomere dysfunction 
(Boulton and Jackson 1998).  However, in Arabidopsis thaliana, the loss of Ku results in 
massive telomere elongation (Riha et al. 2006, Boltz et al. 2014) whereas the loss of Ku 
in DT40 chicken cells has no apparent telomere phenotype (Wei et al. 2002).  To add even 
more confusion to this conundrum is the fact that two different laboratories reported that 
the loss of Ku in mice resulted in either no effect on telomeres (Samper et al. 2000) or 
significant telomere shortening (d'Adda di Fagagna et al. 2001).  Thus, the use of model 
systems has, in the case of Ku and telomere biology, shed no light whatsoever on what 
Ku might be doing in a human cell.  On a superficial level, it is not unreasonable to imagine 
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that Ku could be a telomere protein since it is a DNA end-binding protein and is responsible 
for the protection of those ends, which would be a key feature of a telomeric protein.  
Generally, however, Ku exists to facilitate the rejoining of DNA ends, which is antithetical 
to the purpose of a telomeric protein.  One potential solution to this paradox is evidence 
that Ku binding to DNA ends is generally repressive of other forms of DNA DSB repair 
(Wang et al. 2006, Fattah et al. 2010, Langerak et al. 2011).  The implication of these 
observations would be that Ku bound onto or associated with a telomere protects the 
telomere from other forms of DNA repair, but it itself is not sufficient to initiate C-NHEJ of 
telomeres.  This hypothesis is consistent with genetic work from other species. 
Ku is essential for cellular life in only 2 known species:  Ustilago maydis (corn smut) 
(de Sena-Tomas et al. 2015) and Homo sapiens (Wang et al. 2009).  In both cases, the 
essential role of Ku appears to repress an HDR-dependent telomere rapid deletion (TRD).  
In corn smut, the loss of Ku is causative of a massive G2/M arrest, which is likely due to 
the DNA damage signaling initiated from uncapped telomeres (de Sena-Tomas et al. 
2015).  This arrest, and the TRD, are both able to be rescued by the deletion of MRE11 
(de Sena-Tomas et al. 2015), a key HDR gene.  In humans, KU86-null cells also exhibit 
TIFs and TRD which is coincident with the formation of extra-chromosomal circular 
telomeric DNA molecules, called T-circles, which is the product of HDR-dependent 
resolution of the telomere (Wang et al. 2004, Wang et al. 2009).  Thus, it seems as if Ku 
can be a telomere factor in some species by directly binding onto the telomeric DNA, but 
that in human cells (where Ku’s DNA binding role has been usurped by Shelterin) Ku’s 
role lies predominately in excluding HDR factors from pathologically accessing the 
telomere. 
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In the absence of Ku in human cells many of the chromosomes do not fuse end-to-
end (i.e., a chromosomal translocation); rather, adjacent sister chromatids fuse end to end 
as an intra-chromosomal fusion.  While inter-chromosomal fusions are generally regarded 
as lethal events, intra-chromosomal fusions are causative of prolonged chromosomal 
instability, but are nonetheless viable (Murnane 2010).  These fusions are causative of 
“breakage-fusion-bridging” (BFBs) cycles where, during mitosis as the chromosomes are 
segregated, a chromosome that has a sister-sister fusion would behave as one large di-
centric chromosome (Murnane 2010). This process was originally observed and named 
by Barbara McClintock (McClintock 1939).  Classically it was thought that the BFBs were 
caused by the molecular forces of the opposing spindles.  However, over decades of 
research, evidence has mounted against this model.  One key observation was that the 
mitotic spindle was estimated to only be able to generate 0.5 to 1.5 nN, whereas a mitotic 
chromosome has been estimated to withstand up to 100 nN of force (Houchmandzadeh 
et al. 1997).  Other evidence from Saccharomyces cerevisiae indicates that mitotic 
chromosomes can withstand the spindle force, but are broken by the mitotic process 
(Haber et al. 1984, Lopez et al. 2015).  In human cells, dicentric chromosomes can persist 
from the beginning of anaphase and extend even beyond cytokinesis (Maciejowski et al. 
2015).  Thus, these bridges can persist for several hours following mitosis, and are 
enclosed by the pre-existing nuclear envelope, which connects the two nuclei of the cells 
(Maciejowski et al. 2015).  Ultimately, the nuclear exonuclease TREX1 gains access to 
this bridge, coverts the dsDNA to ssDNA, thus weakening the strand considerably, such 
that torsional strain can ultimately break the connection (Maciejowski et al. 2015).  The 
discovery of this mechanism also explains the observation that BFBs can be causative of 
a localized hypermutation event called chromothripsis, that tends to occur at the point of 
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a BFB, as a significant amount of genetic material is likely to be damaged by this process 
(Li et al. 2014, Maciejowski et al. 2015).  These BFBs also play a critical role in regulating 
the transition of a pre-malignant mortal cell into an immortalized cancerous one.  Thus, 
Ku’s role in human telomere biology appears be to act as a deterrent to HDR and when 
Ku fails to perform this function, intra-chromosomal fusions and BFB cycling result, which 
is ultimately toxic to the cell. 
 
Telomeres, telomerase, and cellular immortality 
As researchers developed our understanding of the semi-conservative nature of DNA 
replication, the observation that DNA polymerases replicated DNA in only one orientation 
(5’>3’) implicated that there could be an “end replication problem.” That is, as the DNA 
replication fork approaches the end of the chromosome the leading strand can be 
completely replicated, whereas the requirement for an RNA primer to initiate lagging 
strand DNA synthesis implied that the terminal nucleotides of the lagging strand could not 
be replicated (Olovnikov 1973).  This conceptual realization had profound implications; i.e. 
as cells continued to divide in absentia of any other regulatory processes, linear 
chromosomes would gradually erode ends-in over consecutive cellular generations.  This 
theory matched the empirical observations of Leonard Hayflick, who reported that 
fibroblast cells seemed to senesce in culture after 40 to 60 population doublings, thus 
infamously refuting the theory that all cells are immortal (Hayflick and Moorhead 1961). 
Later it was determined that this was indeed due to telomere erosion generating TIFs and 
a potent DNA damaging signal that causes cell cycle arrest (Feldser and Greider 2007).  
Furthermore, the realization of the “end replication problem” implicated that there must be 
a hitherto unknown post-replicative process capable of chromosomal end re-elongation. 
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The molecular determinants of these profound ideas would later be confirmed and are 
discussed below. 
In the summer of 2015, I had the privilege of meeting the Nobel Prize winner Dr. 
Elizabeth Blackburn, (awarded for her work on cellular immortalization), with whom I spent 
several hours into the “wee hours of the morning,” as she put it.  In 1985, Dr. Blackburn, 
and her graduate student at the time, Carol Greider, were able to detect the laddering of 
a radiolabeled telomeric DNA probe in cell-free extracts of the single-celled eukaryotic 
organism Tetrahymena thermopilia (Greider and Blackburn 1985).  They noted that the 
telomeric probe was incorporated in a ladder-like fashion, such that each telomeric probe 
was incorporated as an elongating string of DNA in specific length intervals. Shortly 
following this discovery, the enzymatic components of this reaction were identified in 
yeast, the gene names of which were aptly named for the consequence of their mutation: 
Ever Shorter Telomeres-1, 2, and 3 (Lundblad and Szostak 1989).  This enzyme was later 
discovered to also exist in human cancer cells, and ultimately become known to be called 
telomerase  (Morin 1989). 
It is now well accepted that the maintenance of telomere length by telomerase is 
required for cellular life.  In animals, the expression of telomerase is responsible for 
maintaining the telomeric content of dividing stem cells to ensure that subsequent 
generations do not lose telomere length over time.  Strangely, the absence of telomerase 
in mice does not cause any dramatic initial phenotype (Blasco et al. 1997); a paradox later 
explained by the extremely long telomeres of in-bred laboratory strains of mice.  
Nonetheless, these mice exhibited telomere erosion at approximately 5 kb (~10% of their 
original telomere length) every generation.  By the fourth generation, the mice were 
lethargic, sick, and not fertile: attributes confirming the critical function of telomerase to 
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preserving genomic integrity over time (Blasco et al. 1997).  Notably, these phenotypes  
would not take several generations to manifest in humans, as mice have telomeres 
approximately 10X longer than humans (de Lange et al. 1990), and have substantially 
shorter intergenerational time periods of about 6 months.  In addition to germ cells, 
telomerase expression is critical to maintain other proliferative cell types.  Most notably, 
the immune system requires clonal expansion of antigen-activated cells during the 
stimulation of the adaptive immune response.  This rapid clonal expansion can cause 
telomere shortening, even in the presence of telomerase (Epel et al. 2004).  As a 
consequence, immune deficiency is a classic phenotype associated with mutations of 
telomere maintenance genes in mammals.  Thus, telomere length maintenance by 
telomerase is a critical component of many physiological functions. 
Given the importance of telomerase to human life it is not surprising that the complex 
has been extensively studied.  Human telomerase consists of two major subunits: the 
protein component, TERT, and the RNA subunit, TR (Martinez and Blasco 2011).  TERT 
is a large, multi-domain well-conserved reverse transcriptase.  Although TERT has been 
the subject of intense study, the full-length protein has not been crystalized to date. Thus, 
our structural information relies on the crystallization of various domains of the protein, 
including the interface of the protein with the RNA component (Qiao and Cech 2008).  
Another domain of TERT, the TEN domain, partially interacts with telomeric DNA, but this 
binding interface still allows the TR access to the end of the chromosome (Lue 2005, Lue 
and Li 2007).  An additional domain in TERT facilitates its interaction with the TEL patch 
of TPP1, which also enables the recruitment of telomerase to the telomere (Nandakumar 
et al. 2012), as has been discussed earlier in this section.  In addition to TERT’s 
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interactions with telomeric DNA and Shelterin, TERT also makes an essential interaction 
with TR that are required telomere elongation. 
TR has both structural and functional components that enable the formation of a 
functional telomerase complex.  TR has several RNA secondary structures, which form 
loops and hairpins that are critical for TR to interact with both TERT and telomeric DNA.  
Two such loops are especially critical for the interaction of TR and TERT, those being the 
CR4/5 domain (a series of two proximal looped secondary structures) (Bley et al. 2011), 
and the pseudoknot domain (Qiao and Cech 2008).  In addition to these structural 
components, TR is also functionally critical for telomerase’s reverse transcription, as it 
both primes and extends off the terminal end of the G-overhang and provides the template 
for reverse transcription (Nandakumar and Cech 2013) (I accidentally confirmed this 
requirement by wrongfully adding RNAseA to the buffer of several in vitro telomerase 
assays, which were blank).  Thus, TERT and TR are both equally critical for telomerase 
activity. 
De novo telomere elongation is a processive enzymatic reaction, the extent of which 
is generally defined by how many repeats are synthesized prior to the complex’s 
dissociation from the telomere (Greider 1991).  The extent of telomerase’s enzymatic 
processivity varies wildly between species such that, for example, human telomerase is 
much more processive than murine telomerase (Prowse et al. 1993).  The processivity of 
telomerase is likely determined by the TR structure, rather than the enzyme itself, as 
simple mutations in TR can dramatically impact the processivity of telomerase across 
multiple species (Chen and Greider 2003).  In addition to TR being a regulator of 
processivity, the Shelterin proteins TPP1 and POT1 have also been identified as 
regulating this effect of telomerase (Wang et al. 2007).  Lastly, the relative abundance of 
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telomeric ends, compared to the amount of telomerase complexes also affects 
processivity; the fewer complexes there are relative to the amount of chromosomal ends 
results in a more processive enzyme (Wang et al. 2007).  Taken together, these 
observations imply that the degree of telomerase processivity is likely a stochastic effect 
dependent on the abundance of the protein itself, protein:protein interactions and the 
number of telomeres present (the last feature of which is relevant to inter-species 
comparisons and polyploid cancers). 
The dynamic interplay between constitutive telomere shortening due to the end 
replication problem, and telomere re-elongation by telomerase regulates the proliferative 
capacity for normal cellular life.  The evolution of this cellular-lifespan regulatory network 
is likely attributable to it being a strong mechanism to prevent cancer.  According to the 
somatic mutation theory of cancer, a dividing cell that acquires an oncogenic mutation 
enters into a Darwinian evolution scheme, which selects for faster and more invasive cell 
types.  In a feed-forward mechanism, accelerated cellular growth rates are known to be 
contributors of additional genomic mutations, which is referred to as oncogenic-replicative 
stress (Negrini et al. 2010).  Additional mutations in these pre-cancerous cells can 
inactivate various checkpoints which would otherwise provide limitations on cell growth.  
Cells that have been oncogenically activated and have lost various cellular checkpoints 
through mutation can be considered to be “transformed.”  The history of this term 
originates from virology gene transfer, as infection by oncogenic viruses was one of the 
first-discovered direct means of changing healthy cells into cancerous ones (Eddy et al. 
1962).  Notably, in these instances the virus encodes proteins, such as the SV (simian 
virus) 40 large-T antigen, which can simultaneously induce cell growth and inhibit 
checkpoints (Goldstein 1990).  However, in spite of the historical nomenclature regarding 
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oncogenic transformation, the majority of cancers become transformed by non-viral 
means (Negrini et al. 2010). 
The proliferation of transformed cells is ultimately limited by telomere shortening, 
where in the absence of normal cellular checkpoints, cells will enter telomere crisis.  
Telomere crisis is a term used to describe the critically short length of a telomere, where 
the telomere has eroded to a non-functional extent.  The kinetics of telomere erosion that 
leads to crisis in human fibroblasts can be determined using a technique called Single-
Telomere Analysis (STELA), which is a linker-mediated PCR assay using a chromosome-
specific subtelomeric PCR forward primer, and the end of the chromosome as a reverse 
primer to amplify single telomeric ends (Baird et al. 2003).  Thus, the process of telomere 
erosion can be precisely monitored as cells age and enter telomere crisis.  At the point of 
telomere crisis, most cells die, due to the formation of the previously discussed BFBs and 
chromosomal fusions, most of which are lethal. 
An escape from telomere crisis is required for a transformed cell to become a bona 
fide malignancy, and represents one fundamental “Hallmark of Cancer” (Hanahan and 
Weinberg 2011).  Although this escape rarely occurs, Darwinian evolution strongly selects 
those few cells capable of enabling a telomere elongation mechanism (TEM).  There are 
two known TEMs, 1) the reactivation of telomerase or 2) the initiation of the Alternative 
Lengthening of Telomeres (ALT) pathway.  Telomerase reactivation (through gene 
amplification, activating promoter mutations, etc.) occurs in ~85% of cases, while the ALT 
pathway is less common.  The telomerase TEM in cancer is straightforward; the 
restoration of telomerase activity in cancer cells enables them to not be subjected to 
telomere shortening, thus achieving cellular immortality.   One striking example of this 
effect is that the first human cell line to ever be grown continuously in culture, HeLa cells 
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(which express telomerase), were taken from a woman, Henrietta Lacks, in the 1950’s.  
Today, Ms. Lacks would be one of the oldest living (but very likely deceased) people on 
Earth and yet, HeLa cells are robustly still growing in culture to this day. 
In contrast to telomerase, ALT activation is not common although it is enriched in 
several subtypes of cancers.  It is  most often found in malignancies of mesenchymal 
origin, such as osteosarcomas (Henson and Reddel 2010).  For reference, I have 
graphically depicted the process of a malignant cell’s telomere shortening, evasion of cell 
checkpoints, and ultimate escape from telomere crisis through the use of either 
telomerase or ALT (Figure 1.1).  The mechanism of ALT and its genetic regulators will be 
discussed below, and in several subsequent chapters of this dissertation. 
 
ALTernative immortalization, telomeric chromatin, and ATRX 
While ALT only occurs in about 15% of human cancers, it remains an attractive avenue 
for developing new chemotherapies.  This is because ALT is a tumor-specific molecular 
mechanism for telomere elongation, unlike telomerase which is commonly utilized by both 
cancerous cells and healthy (e.g., stem cells) ones.  ALT facilitates telomere elongation 
via a DNA recombination reaction, akin to a telomeric “copy-and-paste” function (Cesare 
and Reddel 2010).  As telomeres are all identical in their DNA sequence content, a short 
telomere can utilize another telomere as a template for HDR-dependent elongation.  This 
allows for cells to elongate all of their telomeres, irrespective of an individual telomere’s 
length, as the reaction is solely dependent on the sequence homology.  Thus, while 
telomerase is a tightly regulated enzymatic function, no such regulation is present for ALT 
cells, and as a consequence individual telomere length can vary wildly in ALT cells, 
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whereas telomerase-positive cells tend to stochastically achieve a relatively consistent 
balance in telomere length. 
Heterogenous telomere length is one of the many hallmarks of an ALT cell (Bryan et 
al. 1995).  The discovery that TRF2 was repressive of HDR-dependent TRD inspired the 
finding that another hallmark of ALT cells is the presence of extra-chromosomal T-circles 
(Wang et al. 2004).  These circular telomeric DNA molecules have been proposed to serve 
as templates for rolling-circle amplification, where a telomeric end using HDR could invade 
the T-circle and then elongate indefinitely around the circular template.  Other hallmarks 
of ALT include “ALT-associated PML bodies” (APBs) (Yeager et al. 1999).  APBs are large 
multimeric DNA:protein complexes, and are proposed to be the site of active telomeric 
recombination within the nucleus (Conomos et al. 2014).  One final hallmark of ALT 
requires experimental manipulation, where the genetic insertion of an exogenous DNA 
element into telomeric DNA will be “copied and pasted” into other telomeres on distinct 
chromosomes (Dunham et al. 2000).  While, these hallmarks of ALT are mechanistically 
understood, the molecular control regarding the initiation of ALT remained somewhat of a 
mystery until the discovery that a gene encoding a chromatin remodeler, α-Thalassemia 
Mental Retardation Syndrome X-linked gene (ATRX), was commonly mutated in ALT 
cancers (Heaphy et al. 2011).  The molecular mechanism of ATRX’s regulation of ALT is 
likely a complicated one, as ATRX’s role as a telomeric chromatin remodeler does not 
have a direct effect on telomere length itself. 
The role of ATRX in the regulation of ALT requires an understanding of the chromatin 
state of telomeres.  Telomeres are generally regarded as heterochromatic, as they are 
largely structural DNA elements that to do not encode any genes.  The importance of this 
heterochromatic state is exemplified by the requirement of SIRT6 for proper telomere 
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homeostasis.  Sirt6 is a histone 3 lysine 9 (H3K9) deacetylase, which removes acetyl 
groups from histone H3 and causes chromatin compaction (Michishita et al. 2008).  The 
loss of SIRT6 in mice is causative of a dramatic premature ageing phenotype and telomere 
dysfunction, presumably because of the mice’s inability to properly condense the 
telomeres into a protective state (Michishita et al. 2008).  Thus, the ability of telomeres to 
compact as heterochromatin is critical to their protective function. 
Although telomeres are heterochromatic, they can be transcribed into non-coding, 
telomeric repeat RNA (TERRA) (Azzalin et al. 2007).  TERRA, in turn, regulates telomeric 
chromatin through an interaction with TRF1 and TRF2 that functions to maintain telomeric 
H3K9me3 and to recruit the origin of replication (ORC) to the telomere for proper DNA 
replication (Deng et al. 2009).  As the expression of any RNA is dependent on the 
chromatin state, TERRA acts in a feedback function, where a more euchromatic telomere 
favors TERRA production, which promotes its transition back to heterochromatin (Eid et 
al. 2015).  Thus, TERRA can be used as a reporter of how compact the telomere is in 
each cell, where higher cellular TERRA-levels imply less of a heterochromatic state. 
While the heterochromatic state of a telomere is important, there are more chromatin 
regulators than just SIRT6 or TERRA.  Indeed, as aforementioned, the mutation of the 
chromatin remodeler, ATRX, is associated with the genesis of ALT.  Recent work has 
uncovered a role for ATRX at the telomere, where it interacts with the H3.3 chaperone, 
DAXX, to facilitate the deposition of H3.3 into telomeric DNA.  This regulatory network was 
first implicated by a series of CHIP-seq experiments in MEFs, which identified that the 
histone variant H3.3 was enriched in telomeric DNA (Goldberg et al. 2010).  In addition, 
distinct H3.3 chaperone complexes were localized to different genomic regions.  Notably, 
while depletion of the H3.3 chaperone, Hira, dramatically affected intragenic levels of 
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H3.3, the depletion of DAXX/ATRX was causative of a loss in telomeric H3.3 (Goldberg et 
al. 2010).  The functional consequence of this was identified soon after, as the loss of 
ATRX in human embryonic stem cells is causative of telomere destabilization (Wong et al. 
2010).  With respect to ALT, the major impact of this telomeric H3.3 regulatory network 
was realized when a subset of cancers lacking ATRX or DAXX, all appeared to have all 
enabled their immortality utilizing the ALT pathway (Heaphy et al. 2011).  Upon a more 
thorough examination of a large array of ALT cancer lines, it was revealed that nearly 
100% of ALT cell lines were either missing, or mutated in ATRX or DAXX (Lovejoy et al. 
2012), although this association was much stronger for ATRX than for DAXX.  Initial 
attempts to establish a causality between ATRX mutation and ALT were performed by cell 
hybridization experiments, which showed that ATRX mutations segregated with the ALT 
phenotype (Bower et al. 2012).  These seminal reports from 2010-2012 spawned a new 
field of investigation into the role of ATRX in regulating and/or preventing the genesis of 
ALT, including my work presented in Chapters 4 and 5.  How the presence or absence 
of a chromatin remodeling complex for H3.3 was regulating ALT, remained mechanistically 
completely unclear. 
While ATRX is a chromatin remodeling protein responsible for H3.3 incorporation, the 
role of H3.3 in inhibiting ALT was first demonstrated by mutation of another H3.3. 
chaperone, ASF1 (O'Sullivan et al. 2014).  ASF1 is histone chaperone that assists with 
HIRA-mediated replication-independent H3.3 deposition into chromatin (Abascal et al. 
2013).  Mutation of ASF1 in telomerase-positive cells resulted in a dramatic induction of 
ALT-activity (O'Sullivan et al. 2014).  Interestingly, this phenotype required the cells to 
have long telomeres, which suggests that one reason human telomere length is so tightly 
regulated is that they are inherently recombinogenic.  As ALT-activation is a mechanism 
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by which cells can escape telomere crisis, the requirement for long telomeres and the lack 
of any obvious patient-mutations in ASF1 make this finding mechanistically insightful, but 
unlikely to be relevant for human disease.  One hypothesis arising from this mechanistic 
insight was that the chromatin state of the telomere may regulate its propensity to be 
accessed by different DNA repair pathways, such that the absence of telomeric H3.3 was 
somehow enabling HDR at the telomere.  This idea was founded based on the frequent 
observation that the chromatin-state of a DNA end can affect DNA DSB pathway choice 
(Miller et al. 2010).  Thus, the prevailing theory is that ATRX-mediated H3.3 incorporation 
into telomeric DNA is repressive of telomeric recombination (O'Sullivan and Almouzni 
2014) and that the loss of this repression permits ALT. 
Given that ablation of ASF1 was sufficient to induce ALT in telomerase-positive cells, 
the consequences of an ATRX mutation is notably different.  In Chapter 4, I will show that 
genetic mutation of ATRX in telomerase-positive cells does not induce ALT.  The lack of 
ALT activity in these cells is especially interesting, as the re-expression of ATRX in ALT 
cells does repress ALT activity (Clynes et al. 2015).  Thus, it appears that ATRX represses 
ALT, but the true persistence of ALT requires additional modifications or processes to 
enable an ALT cell.  In Chapter 5, I confirm this hypothesis by showing that the absence 
of ATRX significantly enhances the frequency of ALT immortalization and, at a molecular 
level, enables telomeric recombinations at critically shortened telomeres. 
 
Rationale 
Telomeres are essential for eukaryotic cellular life.  Their fundamental evolutionary 
purpose is to protect the ends of linear chromosomes from being recognized as a DNA 
DSB.  Intriguingly, multicellular organisms appear to have evolved a programmed cell 
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death capacity, by intentionally not elongating their telomeres.  In humans, this process 
represents one of the strongest tumor-suppressing mechanisms, as virtually all 
malignancies must enable cellular immortality to facilitate limitless growth.  The interplay 
between telomeres and DNA DSB repair is ironically further intertwined, as not only does 
the DSB repair pathway that recognizes a dysfunctional telomere dramatically influence 
that cell’s likelihood of achieving immortality, but 15% of all cancers (ALT+) appear to 
require a subpathway of DSB repair to elongate their telomeres and remain immortalized.  
Thus, the work I present in the following chapters is intended to clarify the regulation of 
pathway choice within DSB repair, the role of DNA break sensing proteins in protecting 
normal telomeres, and the role of ATRX in suppressing the genesis of ALT. 
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Figures 
Figure 1.1 
 
Figure 1.1 Graphical representation of telomere attrition and immortalization.  
 The relationship between telomere length and number of cellular divisions is plotted.  
Healthy cells either maintain their telomeres with telomerase (e.g. stem cells), or gradually 
lose their telomeres due to the end replication problem.  As somatic cells continue to age 
and lose telomeres, they will at some point initiate cellular checkpoints and stop growing, 
referred to as “The Hayflick Limit.”  Cells that are transformed may continue to divide until 
they enter telomere crisis, at which point telomeres no longer function and the 
chromosomes undergo BFB.  At this juncture most cells will die.  Some rare survivors may 
initiate either telomerase re-expression or ALT to enable cellular immortality and become 
malignant. 
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Chapter 2 
DNA Ligase 3 and DNA Ligase 4 carry out genetically distinct forms of end 
joining in human cells 
 
[Published in Oh, S., A. Harvey, J. Zimbric, Y. Wang, T. Nguyen, P. J. Jackson and E. A. 
Hendrickson (2014). DNA Repair 21: 97-110. PMID: 24837021] 
 
Author Contributions: 
• Oh, Sehyun, Zimbric.Y., and Wang, Y. constructed all cell lines used, except for 
Ku:LIG3.  All experiments describing single mutant cells (Figs. 2.1 to 2.7) were 
performed by Oh., S. 
• Harvey, A. was responsible for the experimental design and execution of all 
experiments related to the double-mutant cell line characterization as well as the 
proposed model explaining all results discovered (Figs. 2.8 to 2.12), with 
assistance from Nguyen, T.  This also included working on the construction of 
Ku:LIG3 double mutant. 
• Jackson, P.J. completed construction of the Ku86:LIG3 line. 
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Synopsis 
 
Ku-dependent C-NHEJ is the primary DNA EJing repair pathway in mammals.  
Recently, an additional EJing repair pathway (A-NHEJ) has been described.  Currently, 
the mechanism of A-NHEJ is obscure although a dependency on LIG3 is often implicated.  
To test the requirement for LIG3 in A-NHEJ we constructed a LIG3 conditionally-null 
human cell line using gene targeting.  Nuclear EJing activity appeared unaffected by a 
deficiency in LIG3 as, surprisingly, so were random gene targeting integration events.  In 
contrast, LIG3 was required for mitochondrial function and this defined the gene’s 
essential activity.  Human KU86:LIG3 and KU86:LIG4 double knockout cell lines, however, 
demonstrated that LIG3 is required for the enhanced A-NHEJ activity that is observed in 
KU86-deficient cells.  Most unexpectedly, however, the majority of EJing events remained 
LIG4-dependent.  In conclusion, although human LIG3 has an essential function in 
mitochondrial maintenance, it is dispensable for most types of nuclear DSB repair, except 
for the A-NHEJ events that are normally suppressed by Ku.  Moreover, we describe that 
a robust Ku-independent, LIG4-dependent repair pathway exists in human somatic cells. 
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Introduction 
 
A serious challenge to genomic integrity is the occurrence of a DNA DSB (Lieber 
2010).  To avoid the pathological outcomes that result from even a single unrepaired DNA 
DSB, all cells have developed efficient DSB repair pathways.  In most organisms, there 
are two major pathways: HDR and C-NHEJ (Hartlerode and Scully 2009, Kass and Jasin 
2010).  HDR is preferentially used in lower organisms, however in mammals — and 
particularly in human cells — the majority of DSBs are repaired via C-NHEJ. 
C-NHEJ facilitates the direct ligation of the broken ends of a DSB.  Since the DNA 
termini formed at DSBs are, however, often complex and can contain non-ligatable end 
groups, the repair of such DNA lesions may require the processing of the ends prior to 
ligation (Lieber 2010, Boboila et al. 2012).  This requirement often leads to the loss or 
addition of nucleotides from either side of the DSB, making C-NHEJ “error-prone”.  The 
mechanism of C-NHEJ-mediated DSB repair postulates that Ku binds to the DSB ends, 
where it recruits downstream C-NHEJ factors that facilitate processing (Yano et al. 2011).  
Finally LIG4, in association with XRCC4 and XLF, performs the end ligation reaction 
(Lieber 2010).  This linear, stepwise model for C-NHEJ may be oversimplified as there is 
evidence that LIG4, XRCC4 and XLF may perform roles both upstream and downstream 
in the repair process (Andres et al. 2012, Roy et al. 2012, Cottarel et al. 2013). 
There is an additional EJing pathway present in higher eukaryotes.  It has 
interchangeably been referred to as MMEJ (McVey and Lee 2008), B-NHEJ (Mladenov 
and Iliakis 2011) and A-NHEJ (Nussenzweig and Nussenzweig 2007), (hereafter, A-
NHEJ).  Unlike the HDR and C-NHEJ pathways, which are conserved from bacteria to 
man, the A-NHEJ pathway has evolved in a somewhat checkered manner and can only 
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be detected in about a third of eukaryotic genomes (Simsek and Jasin 2011).  It is 
presumed that an end-binding factor besides Ku is required to bind onto the broken DNA 
ends, stabilize them, protect them from random nuclease degradation and finally funnel 
the ends into the A-NHEJ pathway (Wang et al. 2006).  Then, because microhomology is 
frequently used to mediate the repair event, some end resection is required (Zha et al. 
2009).  Alignment activities to bring the microhomologies into register are also needed, 
followed by the action of a flap-like nuclease to trim non-base paired regions and finally a 
ligation complex to covalently link the ends back together (Gottlich et al. 1998).  Because 
the pathway uses microhomology to mediate the repair event, deletions always 
accompany the repair event, as does loss of one of the blocks of microhomology (Boboila 
et al. 2012). 
Several laboratories have made dedicated attempts to identify A-NHEJ factors.  In 
particular, a brute-force nuclear extract fractionation protocol identified LIG3 (Simsek and 
Jasin 2011), heretofore known only for its role in BER (base excision repair), as the 
candidate ligase required for A-NHEJ (Wang et al. 2005).  Using guilt-by-association as a 
scientific rationale, PARP1 and XRCC1, two proteins known to interact with LIG3 during 
BER, were subsequently identified as also being involved in A-NHEJ (Audebert et al. 
2004, Wang et al. 2006, Cheng et al. 2011).  PARP1 is presumed to compete with Ku for 
binding to broken DNA ends thereby dictating pathway choice (Wang et al. 2006, Cheng 
et al. 2011) whereas XRCC1 appears to act as a chaperone for LIG3 (Caldecott et al. 
1994).  Additional factors have also been implicated in A-NHEJ.  Thus, CtIP and the MRN 
complex — factors known to be involved in the end resection events required for HR — 
have also been implicated in the end resection steps of A-NHEJ (Rass et al. 2009, Xie et 
al. 2009, Zhuang et al. 2009, You and Bailis 2010, Zhang and Jasin 2011). 
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If the factors needed for A-NHEJ are not completely defined and the A-NHEJ reaction 
mechanism nebulous, it is also fair to say that the biological role(s) of A-NHEJ is even 
more poorly understood.  Most of the current interest in A-NHEJ, however, stems from its 
implicated use in the chromosomal translocations that are present in cancer cells.  
Sequencing of human cancer genomes has revealed that many (Bentley et al. 2004, 
Mattarucchi et al. 2008, Tsai et al. 2008), albeit not all (Bunting and Nussenzweig 2013) 
chromosomal translocations have microhomology at their breakpoint junctions, which 
implicates A-NHEJ in their genesis.  This hypothesis gained support from work in which 
LIG3 conditionally-null murine cells showed decreased translocation frequencies and 
reduced microhomology usage (Simsek and Jasin 2010, Gao et al. 2011, Simsek et al. 
2011, Simsek et al. 2011).  An additional biological process where A-NHEJ has been 
implicated is in the random insertion events associated with rAAV (recombinant adeno-
associated virus)-mediated gene targeting.  Although rAAV can mediate high frequency 
gene targeting, the majority of the viral integration events still occur randomly (Khan et al. 
2011).  Moreover, our laboratory has reported that a reduction in the C-NHEJ proteins 
Ku70 (Fattah et al. 2008) and LIG4 (Oh et al. 2013) had almost no impact on the random 
rAAV integration rate — implying that these events may be mediated instead by A-NHEJ.  
In summary, although A-NHEJ was a neglected subject for many years, in the past decade 
it has proven itself to be an increasingly interesting and biologically relevant topic. 
A key feature of A-NHEJ is its dependence on LIG3 (Wang et al. 2005).  Unlike the 
other ligases, LIG3 is molecularly heterogeneous (Lakshmipathy and Campbell 1999, 
Perez-Jannotti et al. 2001, Simsek and Jasin 2011).  Thus, alternative translation initiation 
generates mitochondrial and nuclear forms of LIG3, which either contain or lack a MLS 
(mitochondrial localizing sequence), respectively (Lakshmipathy and Campbell 1999).  
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The existence of LIG3 isoforms implies diverse functional roles for LIG3.  One 
experimental approach to unraveling the complexity of LIG3 is to generate a LIG3-deficient 
model system, which has already been accomplished in the chicken cell line, DT40 
(Arakawa et al. 2012), and in the mouse (Puebla-Osorio et al. 2006, Gao et al. 2011, 
Simsek et al. 2011).  In these systems, the gene is essential due to its presumed 
requirement for mitochondrial DNA replication.  Moreover, in LIG3 conditionally-null mice 
no obvious nuclear DNA repair phenotypes could be detected (Gao et al. 2011, Simsek et 
al. 2011).  The extrapolation of these studies to humans is unfulfilled as neither LIG3 
patients nor LIG3-deficient human cell systems have been described. 
In this study, we conditionally inactivated the LIG3 gene in the HCT116 human cell 
line and confirmed that the loss of LIG3 results in death due to mitochondrial dysfunction.  
We also constructed a cell line that exclusively expressed a mitochondrial-only form of 
LIG3.  The nuclear LIG3 deficiency in this cell line caused a growth retardation, but it did 
not affect the overall NHEJ repair activity nor did it result in hypersensitivity to DNA 
damaging agents.  Unexpectedly, we also demonstrate that LIG3-dependent A-NHEJ 
does not mediate rAAV random integration events.  These findings were extended by 
constructing human cell lines that were doubly-null in either KU86 and LIG3 or KU86 and 
LIG4.  These experiments demonstrated that LIG3 is required for the enhanced A-NHEJ 
activity that is observed in Ku-deficient cells and that the vast majority of repair events in 
a KU86-null cell are still LIG4-dependent.  In conclusion, human LIG3 has an essential 
function in mitochondrial maintenance, however it is dispensable for most nuclear DSB 
repair, except for the A-NHEJ that is normally suppressed by Ku.  In addition, we 
demonstrate that human cells have a robust Ku-independent, but LIG4-dependent EJing 
activity. 
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Material and methods 
 
PCR primers 
The sequences for all primers referenced in the Materials and Methods are listed in Table 
2.1. 
 
Construction of LIG3-null cells 
Conditional and non-conditional knockout LIG3 targeting vectors were constructed as 
described, with a few modifications (Kohli et al. 2004, Khan et al. 2011).  For the 
conditional knockout vector, the left and right homology arms, the latter of which contained 
the floxed exon 5, were generated by PCR.  For the left homology arm, Exon5_LARM_F1 
and Exon5_LARM_SacR1 primers were used.  For the right homology arm, the PCR 
products generated from Exon5_RARM_XhoF1 x Exon5_RARM_R1 primers and 
Exon5_KpnF1 x Exon5_XhoR1 primers were ligated after XhoI restriction enzyme 
digestion.  The relevant homology arms and a NEO (neomycin-resistance) gene cassette 
were assembled together through ligations followed by unique restriction enzyme 
digestions, and then cloned into the pAAV-MCS vector.  A non-conditional knockout 
targeting vector was generated in a similar way, but it did not include the floxed exon 5 
sequences.  To select for productively infected cells, the rAAV-infected cells were 
incubated in 1 mg/ml G418-containing media for approximately 2 weeks.  At this time, 
genomic DNA was purified from all G418-resistant clones and PCR was used to screen 
for the subset of those in which correct targeting had taken place.  Targeted clones were 
screened with Exon5_SC_F2 x NeoR2 primers, and retargeted clones were confirmed by 
LIG3_LArm_F3 x LIG3_RArm_R2 primers. 
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Construction of a KU86flox/-:LIG3mtio/- cell line 
Conditional and knock-in LIG3 targeting vectors were constructed as described above.  
In the first round of targeting, KU86flox/- cells (Wang et al. 2009) were infected with a 
conditional knockout (i.e., “flox:NEO”) vector, as described in the creation of the LIG3flox/- 
cell line.  After confirming correct targeting, clones were Cre-treated, and screened for the 
loss of the drug selection cassette (NEO), but retention of the conditional (floxed) exon, 
thus yielding a KU86flox/-:LIG3+/flox cell line.  In the second round of targeting, these cells 
were infected with a rAAV knock-in vector, which introduced ATC point mutations into the 
two closely spaced ATGs that enable nuclear LIG3 expression.  For the rAAV LIG3 knock-
in targeting vector construction, the left homology arm was PCR-amplified from wild-type 
HCT116 genomic DNA using LIG3Mut_LArmF and LIG3Mut_LArmR primers. The right 
homology arm was amplified using LIG3Mut_RArmF and LIG3Mut_RArm3R primers. 
For the screening of the correctly targeted clones, LIG3pNeDaKI-EF1 x PGK-R2 and 
ZeoF1 x LIG3pNeDaKI-ER3 primer sets were used to ascertain the integrity of the left and 
right homology arms, respectively.  After confirmation of a KU86flox/-:LIG3mtio:NEO/flox cell line, 
clones were transiently treated with Cre recombinase and subcloned to identify for 
KU86flox/-:LIG3mito/- clones.  Screening of the Cre recombinase-treated clones was 
performed with LArmF x LIG3pNeDaKI-ER primers.  
 
Construction of a KU86flox/-:LIG4-/- cell line 
LIG4 targeting vectors were used as described (Oh et al. 2013) in two rounds of gene 
targeting with KU86flox/- cells (Wang et al. 2009) to generate a KU86:LIG4 doubly-mutant 
cell line. 
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LIG3 complementation 
To construct the mitochondrial-only LIG3 cDNA, the second and third ATGs in the ORF 
(open reading frame) of the LIG3 cDNA were mutated to ATC.  This mitochondrial-only 
LIG3 cDNA was cloned into the pcDNA3.1(+) vector with a C-terminal HA epitope tag.  For 
the nuclear-only LIG3, the N-terminal ORF that encodes the MLS was deleted and a 
FLAG-epitope tag was added to the C-terminus.  This modified, nuclear-only LIG3 cDNA 
was also cloned into a modified pcDNA3.1(+) vector, where the NEO gene had been 
replaced with a puromycin-resistance gene.  Complementation constructs were linearized 
by PvuI restriction enzyme digestion and stably transfected into the relevant cell lines with 
Lipofectamine 2000.  For selection, 1 mg/ml G418 and 2 µg/ml puromycin, respectively, 
were used. 
 
Use of an inducible Cre system 
A PiggyBac transposon system (Doherty et al. 2012) was used with slight modification.  
Cells were subcultured into 24-well plates a day before transfection.  A vector expressing 
PiggyBac-transposase (0.4 µg) and a vector containing PiggyBac-CreERt2-transposon 
lacking a GFP marker (0.4 µg) were transfected using Lipofectamine 2000 according to 
the manufacturer’s protocol.  The transfected cells were subcultured 48 hr after 
transfection into a 96-well plate with 2 µg/ml of puromycin in the media for selection.  
Clones stably expressing CreERt2 were subsequently identified by immunoblotting using 
an antibody directed against Cre recombinase (data not shown).  For CreERt2 induction, 
10 nM of 4-hydroxytamoxifen (4-OHT), which was dissolved in ethanol, was used. 
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Immunoblotting 
Whole cell extracts were prepared with RIPA buffer and 30 µg of protein was 
electrophoresed on a 4% to 20% gradient SDS (sodium dodecyl sulfate)-polyacrylamide 
gel and a rabbit, anti-human LIG3 monoclonal antibody (Gene Tex) was used at a 1:1000 
dilution.  HA (Covance) and FLAG (Sigma) antibodies were also used at a 1:1000 dilution.  
The actin antibody (Santa Cruz), which was used for the loading control, was diluted 1:250. 
 
Immunocytochemistry (ICC) 
Cells were plated on multi-chamber slides a day before analysis and subsequently 
fixed with 4% (v/v) paraformaldehyde in phosphate-buffered saline for 10 min.  Slides were 
incubated in antigen retrieval buffer (100 mM Tris, 5% (v/v) urea, pH 9.5) at 95°C for 10 
min.  Permeabilization was performed with 0.1% Triton X-100.  The LIG3 antibody was 
used at a 1:1000 dilution and an Alexa Fluor 488 goat, anti-mouse IgG antibody 
(Invitrogen) was used to visualize LIG3.  DAPI (0.2 µg/ml) was used to stain the nucleus. 
 
Etoposide and MMS (methyl methane sulfonate) sensitivity 
An etoposide sensitivity assay was performed as described (Oh et al. 2013) with slight 
modifications.  The cells were plated on a 6-well cell culture plate approximately 17 to 19 
hr prior to drug treatment.  Etoposide was dissolved in dimethyl sulfoxide to give a 10 mM 
stock solution.  The cells were then incubated in etoposide-containing medium for 7 to 10 
days, fixed and stained with crystal violet.  For the MMS sensitivity test, cells were 
incubated in MMS-containing media for 1 hr and then maintained in drug-free media for 7 
to 10 days.  In all survival experiments the wild-type cells were grown for 7 days and the 
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LIG3 mutant lines were grown for 10 days to accommodate the latter’s slower growth 
phenotype. 
 
DNA EJing assays and plasmid rescue 
The in vivo EJing reporter plasmid pEGFP-Pem1-Ad2 (Fattah et al. 2010) and the total 
A-NHEJ reporter pEJ2 (Bennardo et al. 2008) were used as described.  HindIII- or I-SceI-
digested pEGFP-Pem1-Ad2 or I-SceI-digested pEJ2 plasmid was co-transfected with a 
pCherry plasmid — used as a control of transfection efficiency — into the relevant cell line 
using Lipofectamine 2000.  Green (EGFP) and red (Cherry) fluorescence were measured 
by FACS (fluorescence-activated cell sorting) 24 or 48 hr later.  Repair efficiency was 
presented as a ratio of cells that were doubly positive for red and green over the number 
of cells that were only positive for red fluorescence. 
For plasmid rescue experiments (Fattah et al. 2010), HindIII- or I-SceI-digested 
pEGFP-Pem1-Ad2 plasmid was transfected into the desired cell lines without the pCherry 
plasmid.  Plasmids were rescued 24 hr after transfection using a mini-preparation protocol, 
transformed into E. coli and repaired plasmids were selected on LB plates containing 30 
µg/ml of kanamycin.  All the repair products were analyzed by sequencing, using a variety 
of primers located upstream and downstream of the Ad2 exon sequence. 
 
Microhomology assay 
A DNA microhomology assay was performed as described (Fattah et al. 2010).  Cells 
were subcultured into 6-well plates a day before transfection.  pDVG94 plasmid (2.5 µg) 
digested with EcoRV and AfeI was transfected using Lipofectamine 2000.  Plasmid DNA 
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was recovered using a modified mini-preparation protocol at 24 to 48 hr after transfection.  
Repaired DNA junctions were PCR amplified using FM30 and 5’-radiolabeled DAR5 
primers.  PCR products were then digested with BstXI.  Digested PCR products were 
separated by electrophoresis on a 6% polyacrylamide gel.  The gel was then either dried 
and exposed to film, or stained with SybrGold and imaged on a Storm 840 fluorescent gel 
imager. 
 
rAAV-mediated gene targeting 
pAAV-HPRT-Puro, pAAV-helper, and pAAV-RC vectors were transfected into 70% 
confluent AAV-293 cells in 10 cm cell culture dishes and infectious rAAV-HPRT-Puro virus 
was harvested 3 days later by freeze/thawing as described (Kohli et al. 2004, Khan et al. 
2011).  The virus was subsequently purified using a rAAV virus purification kit and the viral 
titer was quantitated by qPCR.  A day before infection, cells were subcultured into 2 × 105 
cells/well in 6-well cell culture dishes in duplicate.  Before adding virus, the exact number 
of cells was determined by counting one of the duplicate wells, and then virus at a MOI of 
1 × 104 was added to the other well.  Two days after infection, 1% of the cells were plated 
into a 10 cm culture dish without any drug selection and used to determine the plating 
efficiency.  The remaining cells were plated into 10 cm culture dishes with 2 μg/ml 
puromycin.  This medium was replaced 5 days later with puromycin-containing medium 
supplemented with 5 µg/ml of 6TG (6-thioguanine) except for one plate, which was used 
to quantitate the random integration frequency (i.e., those clones that were just G418 
positive).  When the cells had formed visible colonies at approximately 10 to 14 days later, 
the plates were fixed and stained with crystal violet.  
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Results 
 
Generation of a conditionally-null LIG3 HCT116 cell line 
To generate a HCT116 cell line that was conditionally-null for LIG3 expression, a rAAV 
gene-targeting methodology was adopted (Kohli et al. 2004, Khan et al. 2011), similar to 
the targeting strategy that was used to generate a KU86 conditionally-null HCT116 cell 
line (Wang et al. 2009).  The conditional targeting vector contained three LoxP sites 
flanking a NEO (neomycin-resistance) gene and exon 5 of LIG3, respectively (Fig. 2.1A).  
Eight correctly targeted first round clones (LIG3NEO/+; Fig. 2.1B) from 210 G418-resistant 
clones were identified (relative gene targeting frequency: 3.8%).  One of these clones was 
transiently treated with pGK-Cre to remove the NEO selection cassette (Fig. 2.1C).  The 
resulting LIG3flox/+ cell line was subjected to a second round of gene targeting using a non-
conditional knockout vector, in which exon 5 was designed to be simply replaced by a 
floxed NEO gene (Fig. 2.1C).  Ten correctly targeted second round clones were identified 
from 711 G418-resistant clones (relative gene targeting frequency: 1.4%).  Additional 
analysis (data not shown) demonstrated that 9 of the clones were re-targeted (and 
therefore biologically uninteresting) whereas one clone was correctly targeted to the 
second allele (i.e., LIG3flox/NEO; Fig. 2.1D), which was subsequently infected with an AdCre 
virus to remove the NEO gene.  The resulting LIG3flox/− cell line (Fig. 2.1E) was viable and 
when needed, Cre recombinase could be re-introduced to generate LIG3−/− cells (Fig. 
2.1F). 
PCR analyses were used to molecularly confirm the genetic designation of the cell 
lines.  A 662 bp PCR product is diagnostic for the presence of the wild-type LIG3 exon 5 
whereas a 748 bp product should be generated when the floxed exon 5 DNA is used as a 
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substrate (Fig. 2.2A).  As expected, PCR of the parental wild-type LIG3+/+ cell line 
generated only the 662 bp product, whereas PCR of the LIG3flox/+ cell line produced both 
the wild type (662 bp) and the floxed allele (748 bp) fragments (Fig. 2.2A).  In contrast, 
LIG3 conditionally null cell lines — with or without the NEO selection cassette — generated 
only the 748 bp PCR product corresponding to the floxed allele (Fig. 2.2A). 
To assess the conditionality of the cell line, LIG3+/+ and LIG3flox/− cells were infected 
with an increasing amount of AdCre virus, and 5 days later genomic DNA was purified and 
analyzed by PCR and whole cell extracts were prepared and analyzed by immunoblotting.  
As the amount of Cre recombinase increased, the PCR signal from the genomic floxed 
allele (748 bp) decreased until the signal was undetectable (Fig. 2.2B).  Similarly, at the 
protein level, the increasing presence of Cre completely ablated detectable LIG3 protein 
expression (Fig. 2.2C).  In contrast, Cre expression in the parental wild-type LIG3+/+ cells 
had no effect on formation of the exon 5-derived PCR product (662 bp) nor little effect on 
LIG3 protein expression (Fig. 2.2B and C).  From these experiments, we concluded that 
we had successfully constructed a human LIG3flox/− (i.e., conditionally null) cell line. 
 
The mitochondrial form of LIG3 is essential for human somatic cell survival 
To assess the essential nature of LIG3, we initially infected the LIG3flox/NEO cell line 
(Fig. 2.1D) with AdCre and then isolated 22 individual G418-sensitive colonies by limiting 
dilution.  Theoretically, two possible cell lines could have been recovered: LIG3flox/− and 
LIG3−/− (Fig. 2.1E and F, respectively), however all 22 recovered clones had a LIG3flox/− 
genotype and none were LIG3–/–.  This extreme asymmetry in the recovery of Cre-treated 
survivors strongly suggested that the LIG3−/− cell line was not viable. 
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Because the mitochondrial form of LIG3 is essential in mice (Gao et al. 2011, Ruhanen 
et al. 2011, Simsek et al. 2011), we tested whether this activity was conserved in human 
LIG3.  To this end, we complemented the LIG3flox/− cells with a modified LIG3 cDNA that 
could be expressed only in the mitochondria (mL3), and generated a stable LIG3flox/−:mL3 
cell line.  The mL3 expression construct was made by mutating the second and third LIG3 
ATGs to ATCs (Fig. 2.3A).  The nuclear form of LIG3 is normally translated from the 
second ATG, and without the second ATG only the longer mitochondrial-specific version 
of the protein should be made (Lakshmipathy and Campbell 1999).  We mutated the third 
ATG simply as a precaution to ensure that no N-terminally truncated nuclear protein could 
be expressed.  Importantly, after infecting LIG3flox/−:mL3 cells with AdCre virus and isolating 
single cell clones by limiting dilution, we observed that 25 out of 43 were genotypically 
LIG3-null (LIG3−/−:mL3; data not shown) — a result that contrasted sharply with 0 out of 22 
obtained when we tried to establish LIG3-null cells in the absence of mL3 expression. 
We next investigated whether the mitochondrial form of LIG3 could directly rescue the 
lethality of LIG3-deficient cells.  When AdCre virus was used for this experiment, it was 
often difficult to differentiate the viral toxicity caused by the adenovirus from the apoptosis 
induced by the absence of LIG3.  To improve upon this experimental set-up, a tamoxifen-
inducible Cre recombinase was stably introduced into LIG3flox/+, LIG3flox/−, LIG3flox/−:mL3 and 
LIG3flox/−:nL3 (see below) cell lines.  4-OHT (4-hydroxyltamoxifen) treatment completely 
killed LIG3flox/− cells (clone #5) but had little effect on LIG3flox/+ cells (clones #101-1 and 
#101-21), which still had a functional LIG3 allele even after Cre treatment.  Significantly, 
the lethality of LIG3-null cells was significantly rescued by expression of the mitochondrial 
form of LIG3 (Fig. 2.3B; clones #73-5 and #73-6).  From these experiments we concluded 
that the mitochondrial form of LIG3 is essential for human somatic cell viability. 
  52 
Finally, a mitochondrial-exclusive expression pattern of mL3 was verified by 
immunohistochemistry.  In the parental wild-type HCT116 LIG3+/+ cells, LIG3 protein was 
expressed ubiquitously throughout the cell, whereas in LIG3−/−:mL3 cells fluorescent signal 
was detected virtually exclusively in the cytoplasm (Fig. 2.3C). 
 
Complementation of LIG3–/–:mL3 with a nuclear LIG3 cDNA 
With a viable LIG3-null cell line in hand (i.e., LIG3–/–:mL3 cells), we were equipped to 
investigate the phenotypes resulting from the loss of nuclear LIG3 expression.  Before 
beginning these analyses, however, we augmented our reagents with a derivative cell line 
that re-expressed a nuclear-specific LIG3 cDNA.  For this approach, a nuclear-only LIG3 
cDNA, nL3, was generated by deleting the N-terminal MLS from the wild-type cDNA and 
by adding a C-terminal FLAG epitope-tag (Fig. 2.3A).  We isolated stable LIG3–/–:nL3 and 
LIG3–/–:mL3:nL3 cell lines, the later of which exhibited a strong LIG3 ICC signal from the 
nucleus in addition to pan-cytoplasmic staining (Fig. 2.3C).  Importantly, the nuclear-
exclusive form of LIG3 — in contrast to the mitochondrial-exclusive form  — was incapable 
of rescuing the lethality of LIG3-nulls (Fig. 2.3B; clone #12-12). 
 
A LIG3 deficiency causes a growth defect 
While the mitochondrial form of LIG3 rescued the lethality of LIG3-deficient cells, the 
rescued phenotype was not as robust as even LIG3 heterozygous cells (Fig. 2.3B, 
compare clones #73-5 and #73-6 with #101-1 and #101-21).  Thus, we investigated 
whether there was a growth defect associated with the absence of LIG3.  Three thousand 
cells were seeded on day 0 into each well of a 6-well tissue culture dish and the number 
of cells in each well was counted on days 4 to 8 (Fig. 2.4A).  LIG3flox/− cells showed a slight 
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haploinsufficiency for growth, which was significantly exacerbated in the LIG3−/−:mL3 cell 
line.  From these experiments we concluded either that the absence of nuclear LIG3 — or 
inadequate mitochondrial LIG3 — expression results in a proliferation defect. 
 
LIG3-null cells are not sensitive to DNA damaging agents 
Given that LIG3 has been implicated in both SSB (single-strand break) and DSB repair 
pathways (Wang et al. 2005, Caldecott 2007), colony-forming assays were used to 
examine the sensitivity of LIG3-null cells to a variety of DNA damaging agents.  In these 
survival experiments, the wild-type cells were grown for 7 days and the LIG3 mutant lines 
were grown for 10 days to accommodate the latter’s slower growth phenotype.  Etoposide 
is a topoisomerase II inhibitor and a powerful radiomimetic drug that induces DNA DSBs 
(Pacchierotti and Ranaldi 2006).  As a positive control, a LIG4−/− cell line (Oh et al. 2013) 
was, as expected, exquisitely sensitive to etoposide, even at the lowest concentration (Fig. 
2.4B).  In contrast, LIG3flox/−, LIG3−/−:mL3 and LIG3−/−:mL3:nL3 did not exhibit any increased 
sensitivity to etoposide compared to the wild-type parental cells (Fig. 2.4B).  Similarly, the 
LIG3-deficient cell lines were slightly, but not significantly, sensitive to MMS (methyl 
methanesulfonate), an alkylating agent that induces SSBs at low doses and DSBs at high 
doses (Fig. 2.4C).  In conclusion, the absence of LIG3 (and presumably the A-NHEJ DSB 
repair pathway) did result in a slower growth phenotype, but this was not reflected in a 
hypersensitivity to DNA damaging agents. 
 
The absence of LIG3 does not affect the overall DNA EJing activity of human cells 
The total DNA EJing activity of LIG3-null cells was measured using pEGFP-Pem1-
Ad2, an extra-chromosomal reporter assay vector (Seluanov et al. 2004, Wang et al. 2006, 
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Fattah et al. 2010).  The reporter plasmid consists of the GFP gene, which is interrupted 
by a 2.4 kb intron derived from the rat Pem1 gene.  An exon (Ad2) derived from adenovirus 
serotype 2 has been introduced into the middle of the intron and is flanked by HindIII and 
I-SceI restriction enzyme recognition sites (Fig. 2.5A).  Without modification, the GFP gene 
is not expressed because the Ad2 exon is incorporated into GFP mRNA (Fig. 2.5C).  Pre-
digestion of the plasmid with HindIII or I-SceI removes the Ad2 exon and generates a 
linear plasmid with compatible (i.e., ends that can be joined by simple ligation) or 
incompatible (i.e., ends that require some sort of processing before they are rejoined) 
ends, respectively (Fig. 2.5B).  Productive end joining of the linear plasmid after it is 
transfected into the experimental cell line can be quantitated using FACS analysis of GFP 
expression (Fig. 2.5C). 
When the pEGFP-Pem1-Ad2 plasmid was transfected into the parental wild-type cell 
line, approximately 35% of the plasmid was productively end joined regardless of whether 
it had been digested by either HindIII or I-SceI (Fig. 2.5D).  As expected, LIG4-null cells 
were profoundly impaired in this DNA EJing activity and showed only a few percent of 
activity.  In contrast, LIG3flox/− and LIG3−/−:mL3 cell lines had DNA EJing activities 
indistinguishable from wild-type cells (Fig. 2.5D).  Thus, partial or complete deficiencies in 
nuclear LIG3 did not appear to affect the overall DNA EJing activity of human somatic 
cells. 
 
Microhomology-mediated EJing is still detectable in human somatic cells lacking 
nuclear LIG3 expression 
Even though the overall DNA EJing activity was unchanged in LIG3-null cells, it was 
still possible that distinct DNA repair pathways were being used.  To examine this 
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possibility, we next quantitated microhomology-mediated EJing.  To this end, a reporter 
substrate, pDVG94 that is biased towards detecting microhomology-mediated EJing 
events (Verkaik et al. 2002, Weterings et al. 2009, Fattah et al. 2010, Oh et al. 2013) was 
used in vivo to measure this activity of LIG3-deficient cells.  EcoRV and AfeI digestion of 
pDVG94 generates a blunt-ended, linear, double-stranded substrate with 6 bp direct 
repeats at both ends (Fig. 2.6A).  Repair of this substrate by C-NHEJ generally generates 
a product that retains at least some of either repeat, whereas microhomology-mediated 
EJing (i.e., A-NHEJ) produces a unique product that contains only a single repeat, and 
which now forms the recognition sequence for the BstXI restriction enzyme.  The 
linearized pDVG94 plasmid was introduced into the relevant cell lines and 24 hr later the 
DNA was recovered from the cells and repaired junctions were amplified by PCR with 
radiolabeled primers (Fig. 2.6A).  The resulting ~180 bp PCR products were then digested 
with BstXI and subjected to agarose gel electrophoresis.  BstXI-resistant DNA 
corresponds to C-NHEJ-mediated repair events whereas a 120 bp product is diagnostic 
of A-NHEJ/microhomology-mediated EJing.  Wild-type cells generated only ~1% of the 
120 bp product (Fig. 2.6B), consistent with most of the EJing in human somatic cells 
resulting from C-NHEJ (Fattah et al. 2010, Oh et al. 2013).  Similarly, and again as 
expected (Fattah et al. 2010, Oh et al. 2013), a LIG4-null cell line showed highly elevated 
levels of the 120 bp product indicative of a virtually exclusive reliance on A-NHEJ (Fig. 
2.6B).  In contrast, in either the LIG3flox/− or two independent LIG3−/−:mL3 cell lines (clones 
#29 and #35) the amount of the 120 bp product was either slightly elevated or unchanged 
in comparison to wild-type cells (Fig. 2.6B), indicating that LIG3-deficient cells were still 
able to carry out microhomology-mediated EJing. 
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A LIG3 deficiency does not affect the overall rAAV-mediated gene-targeting rate 
AAV infections in humans are apathogenic and this feature has made rAAV-mediated 
gene targeting technology one of the more promising candidates for therapeutic use (Khan 
et al. 2011).  The utility of rAAV, however, is offset by random viral integration events, 
which are not desired and potentially mutagenic.  Thus, increasing the overall correct gene 
targeting frequency is one of the most sought-after advances for rAAV-mediated gene 
targeting technology and for gene therapy in general.  Previous studies from our laboratory 
have indicated that neither HR nor C-NHEJ was responsible for rAAV random integration 
events (Fattah et al. 2008, Oh et al. 2013).  In addition, sequencing results from other 
laboratories had indicated that rAAV random integration events could be mediated by 
microhomology usage (Miller et al. 2005, Nakai et al. 2005). Together, these observations 
led to the hypothesis that rAAV random integrations are mediated by A-NHEJ, and to the 
prediction that disruption of A-NHEJ (e.g., by functionally inactivating LIG3) would ablate 
random integrations and thus improve the correct rAAV-mediated gene-targeting rate. 
To test this hypothesis, we performed gene targeting in a LIG3-null cell line at the 
HPRT (hypoxanthine phosphoribosyl transferase) locus using a rAAV gene targeting 
vector designed to disrupt exon 3 of HPRT.  HPRT is an X-chromosome linked gene and 
the enzyme encoded by HPRT is needed to generate nucleotides through the purine 
salvage pathway (Hladnik et al. 2008).  Cells expressing a wild-type HPRT gene are 
lethally poisoned by the toxic nucleoside analog 6-TG (6-thioguanine), whereas cells with 
a defective HPRT gene can survive in the presence of 6-TG.  Because HCT116 was 
derived from a male patient, it contains only a single X-chromosome and therefore after a 
single round of gene targeting, 6-TG selection could be used to isolate correctly targeted 
clones.  Interestingly, LIG3-null cells showed a 2-fold increase in the frequency of correct 
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targeting (Fig. 2.7B).  Unexpectedly, however, the frequency of random integration events 
was not reduced in LIG3-null cells, but was also actually enhanced (Fig. 2.7A).  
Consequently, there was no statistical difference in the relative gene-targeting rate 
between the wild type and LIG3-null cell lines (Fig. 2.7C).  These data demonstrated (quite 
unexpectedly) that while LIG3 is a general suppressor of rAAV integrations, it does not 
preferentially affect random versus correct targeting events. 
 
The absence of Ku reveals a requirement for LIG3 
The above experiments demonstrated that while the absence of LIG3 resulted in a 
slower growth phenotype, it did not i) make the cells hypersensitive to DNA damaging 
agents, ii) manifest itself in any detectable DNA DSB repair deficiency nor iii) deleteriously 
impact on the process of gene targeting.  Our laboratory (Fattah et al. 2008) and others 
(Guirouilh-Barbat et al. 2007, Bennardo et al. 2008, Mansour et al. 2008, Schulte-Uentrop 
et al. 2008) have shown that cells reduced or deficient for the Ku heterodimer show a 
marked increase in the activity of A-NHEJ.  We therefore reasoned that if LIG3 is mediating 
A-NHEJ repair reactions that are too rare to detect in an otherwise wild-type cell, then 
there might be an observable effect of the absence of nuclear LIG3 in a KU86-null cell.  
To test this hypothesis, we constructed a KU86flox/-:LIG3mito/- doubly mutant human cell 
line.  This was achieved by “knocking-in” ATG  > ATC mutations into one endogenous 
LIG3 allele, and knocking out the second LIG3 allele by rAAV-mediated gene targeting in 
a conditionally-null KU86 cell line (Fig. 2.8A).  After also engineering in the above-
mentioned tamoxifen-inducible Cre recombination system, we confirmed by 
immunofluorescence (Fig. 2.8B) and PCR (Fig. 2.8C) that the KU86flox/-:LIG3mito/- cells only 
expressed mitochondrial LIG3 and were conditionally-null for KU86, respectively.  
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Furthermore, in order to directly compare LIG3 to another DNA ligase in this context, we 
also created a KU86flox/-:LIG4-/- Cre-inducible cell line (Fig. 2.8C).  Although both doubly 
mutant cell lines eventually die due to Ku-regulated telomere defects (Wang et al. 2009), 
they do survive 3 to 7 days post Cre treatment, which was a sufficient time window to 
assay the levels of DNA repair in the cells. 
Consequently, we performed a microhomology assay using the aforementioned 
pDVG94 reporter plasmid (Fig. 2.9A).  We confirmed our previously published finding 
(Fattah et al. 2010) that in the absence of the Ku, there is a large (~20-fold) increase in 
the relative amount of A-NHEJ repair (Fig. 2.9B).  Importantly, the absence of nuclear 
LIG3 in the KU86-deficient cells completely abrogated this increased A-NHEJ (compare 
KU86-/- with KU86-/-:LIG3mito/-; Fig. 2.9B).  Notably, although the absence of LIG4 by itself 
resulted in exceedingly few total repair events (Fig. 2.9D), those that did occur were almost 
exclusively biased towards microhomology and the presence or absence of Ku in the cells 
had no discernible effect on this bias (compare LIG4-/- with KU86-/-:LIG4-/-; Fig. 2.9B).  
Interestingly, the converse was not true.  Thus, the absence of LIG4 in the cells always 
shifted the repair bias towards A-NHEJ regardless of the status of Ku expression (compare 
KU86-/- with KU86-/-:LIG4-/-; Fig. 2.9B). 
  The pDVG94 microhomology assay measures relative A-NHEJ activity.  To 
determine the impact of ligation on absolute levels of A-NHEJ, we performed an additional 
analysis with the aforementioned cell lines using the pEJ2 reporter plasmid.  This plasmid 
contains an I-SceI restriction enzyme site flanked by 8 bp of microhomology situated 
between a promoter and GFP coding sequences (Fig. 2.10A; (Bennardo et al. 2008)).  In 
addition, stop codons have been engineered in all three reading frames to disrupt the 
translation that starts at an N-terminal epitope tag.  Thus, this plasmid can be linearized 
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by I-SceI restriction enzyme digestion and transfected into cells.  Microhomology-
mediated repair removes the stop codons and allows GFP expression, whereas repair by 
C-NHEJ does not.  Consequently, cells were transfected with I-SceI-digested pEJ2 
plasmid and mCherry (as a transfection control) and assayed for A-NHEJ activity.  First, it 
was obvious that in all the cell lines that A-NHEJ is a rare event (Fig. 2.10B), consistent 
with our other analyses.  Nonetheless, the absence of Ku caused a 4-fold increase in GFP-
positive cells and almost all of the increase could be abrogated by the absence of LIG3, 
but not LIG4 (Fig. 2.10C). 
In toto, these data clearly demonstrated a separation of function between the two 
ligases and strongly suggested that nuclear LIG3 does play a significant role in A-NHEJ, 
but only in the absence of Ku. 
 
In the absence of Ku, most EJing remains LIG4-dependent 
All of the above data were consistent with an old model in which the vast majority of 
EJing events in human somatic cells are Ku- and LIG4-dependent and that only a minority 
of repair events are normally repaired through a Ku-suppressible, LIG3-dependent 
pathway (Fig. 2.11A).  This model predicts that in a Ku-deficient human cell, the total EJing 
events should be sensitive to the status of LIG3 and unaffected by the presence in LIG4.  
To test this prediction, we quantitated the total amount of EJing in our cell lines using the 
pEGFP-Pem1-Ad2 reporter plasmid (Fig. 2.12A).  The KU86-/-, LIG3-/-:mL3 and KU86-/-
:LIG3mito/- cell lines had virtually indistinguishable robust total EJing activity whereas a 
Ku86-/-:LIG4-/- cell line was extremely deficient (Fig. 2.12B).  Thus, very unexpectedly, in 
a Ku-deficient human cell line, the vast majority of EJing events remain LIG4-dependent.   
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To extend these findings, we recovered the repaired pEGFP-Pem1-Ad2 plasmids out 
of cells 24 hr post transfection.  These plasmids were analyzed by quantifying the plasmids 
that had simply religated their HindIII-linearized ends (“perfect rejoins”; (Fattah et al. 
2010)).  The repaired plasmids recovered from cells were amplified by colony PCR, and 
the products were then re-digested with HindIII and analyzed by gel electrophoresis (Fig. 
2.12C).  As we had previously observed (Fattah et al. 2010), the absence of Ku increased 
the frequency of perfect rejoins (Fig. 2.12D), however the absence of LIG3 had no impact 
on this process (compare KU86-/- with KU86-/-:LIG3mito/-; Fig. 2.12D).  Interestingly,       
KU86-/-:LIG4-/- (and LIG4-/-) cells carried out almost exclusively perfect rejoining, 
implicating therefore, by default, LIG1 in this process (Paul et al. 2013). 
Altogether, these data demonstrated that LIG4 is still required for most of the Ku-
independent EJing events in human cells.  Moreover, they demonstrate that LIG3 is 
required for much of the Ku-suppressible A-NHEJ activity.  And finally, the data suggest 
that at least some of the perfect rejoining and A-NHEJ observed in either wild type or Ku-
deficient cells can be mediated by an additional pathway, which we infer perforce to be 
LIG1-mediated (Paul et al. 2013). 
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Discussion 
 
LIG3 has an essential mitochondrial function 
We have generated a viable human somatic cell line that lacks the expression of 
nuclear LIG3.  Somewhat paradoxically, we nonetheless demonstrate that LIG3 is an 
essential gene.  Thus, no living null cells could be isolated after an AdCre infection of the 
LIG3flox/– cell line.  In contrast, after complementing the LIG3flox/− cell line with a 
mitochondrial-specific cDNA isoform of LIG3, we readily isolated viable LIG3-null 
(LIG3−/−:mL3) cells.  Therefore, LIG3 is dispensable in the nucleus of human cells but 
essential in mitochondria. 
A similar conclusion that LIG3 is essential for mitochondrial function was reached 
using the chicken cell line, DT40 (Arakawa et al. 2012), and in the mouse (Puebla-Osorio 
et al. 2006, Gao et al. 2011, Simsek et al. 2011).  What the essential activity of 
mitochondrial LIG3 is, however, is unclear.  One obvious function would be a requirement 
for LIG3 in Okazaki fragment maturation during mitochondrial DNA replication.  LIG1 
mediates Okazaki fragment maturation in the nucleus (Ellenberger and Tomkinson 2008, 
Zheng and Shen 2011), but since LIG1 lacks a MLS and it is not detected in mitochondria, 
it is clear that some other ligase must perform this function in mitochondria (Arakawa et 
al. 2012, Le Chalony et al. 2012).  Similarly, since LIG4 also lacks a MLS, is non-essential, 
and appears to be involved exclusively in C-NHEJ, it is also a poor candidate (Oh et al. 
2013).  In contrast, the mitochondrial-specific isoform of LIG3 should be able to mediate 
the ligation of Okazkai fragments, which are very similar to the repair intermediates that 
LIG3 is known to ligate together during BER (Caldecott et al. 1994, Frosina et al. 1996). 
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rAAV random integrations are not mediated solely by LIG3/A-NHEJ 
Correct gene targeting events require HR, and the (much more frequent) random 
integrations of the targeting vector are presumably facilitated by DNA EJing pathways (i.e., 
C-NHEJ, A-NHEJ or both).  Indeed, large-scale whole-genome sequencing results 
demonstrated that rAAV random integration events were mediated by some form of NHEJ 
(Miller et al. 2005, Nakai et al. 2005).  Reductions, however, in the expression of Ku did 
not significantly impact the frequency of random integrations of rAAV vectors during gene 
targeting (Fattah et al. 2008).  Similar observations have been made for LIG4-null cells 
(Oh et al. 2013) suggesting strongly that C-NHEJ is not required for this process.  
Together, these observations led to the hypothesis that rAAV random integrations are 
instead mediated by A-NHEJ, and to the prediction that disruption of A-NHEJ (e.g., by 
functionally inactivating LIG3) would significantly improve the correct rAAV-mediated 
gene-targeting rate. 
Surprisingly, no such effect was observed (Fig. 2.7) and the random rAAV integration 
frequency was actually (~3-fold) elevated, demonstrating that LIG3 could even be viewed 
as a suppressor of these events.  A parsimonious explanation for these results is that if 
random rAAV integrations are neither mediated by LIG4 nor LIG3 then they may be 
mediated by LIG1 (see also Fig. 2.11B).  Although LIG1 is predominately thought of as a 
DNA replication-linked ligase, it is enzymatically capable of resealing the staggered ends 
of the DSBs generated during random rAAV integration (Ellenberger and Tomkinson 
2008).  Unfortunately, LIG1 is an essential gene in the HCT116 cell line (unpublished 
data), which precludes gene targeting experiments and a direct test of the hypothesis. 
Alternatively, we propose that in the absence of any one particular ligase that rAAV 
integration is performed by the remaining ligases.  There is precedent from other cellular 
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activities for the mammalian ligases being redundant.  This is especially true of LIG1 and 
LIG3.  Thus, viable murine LIG1-null MEFs actually proliferate rather normally, suggesting 
that some other ligase must be compensating for LIG1 during DNA replication (Bentley et 
al. 1996, Bentley et al. 2002, Le Chalony et al. 2012).  Similarly, the co-depletion of LIG1 
in murine LIG3-knockout cells sensitized the cells to MMS exposure, an activity previously 
thought to be solely the purview of LIG3 (Gao et al. 2011).  Perhaps the most compelling 
case for genetic redundancy comes from work in the chicken DT40 cell line, where single, 
double and or triple mutants were generated to establish that LIG1 and LIG3 are 
functionally redundant for viability (Arakawa et al. 2012).  A similar conclusion that LIG1 
and LIG3 are functionally redundant for in vitro end joining in human extracts was obtained 
by reducing the levels of each, or both, protein(s) using RNA interference or neutralizing 
antibodies (Liang et al. 2008).  If this redundancy between LIG1 and LIG3 extends to rAAV 
random integration it provides a plausible explanation for the lack of a compelling 
phenotype for this process in the LIG3-null human cells. 
 
LIG3 is required for A-NHEJ events normally suppressed by Ku 
In order to generate a 120 bp BstXI-dependent restriction product from the pDVG94 
plasmid a unique repair event is required: both ends of the blunt-ended plasmid must be 
resected and the 6 nt long complementary strands must be precisely annealed and ligated.  
This repair product can be detected only at low levels (a few percent of the total) in wild-
type cells and has been widely interpreted as being produced by A-NHEJ (Verkaik et al. 
2002, Fattah et al. 2010).  Moreover, when cells are mutated for any of the canonical C-
NHEJ genes, the 120 bp fragment becomes virtually the sole repair product (Fig. 2.6 and 
2.9; (Fattah et al. 2010)).  All of these observations led to the prediction that the ablation 
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of A-NHEJ should block the formation of this repair product.  However, the appearance of 
the 120 bp product was completely unaffected by the absence of nuclear LIG3 (Fig. 2.6 
and 2.9).  A trivial explanation is that the cell line is leaky and expresses some LIG3 in the 
nucleus.  While we cannot unequivocally rule out this possibility, we do not believe that 
this is a likely explanation.  First, we mutated not only the normally-used ATG for the 
nuclear form of LIG3, but a downstream ATG as well to ensure that not even truncated 
forms of the protein would be expressed.  In addition, a mitochondrial-exclusive 
expression pattern of the mL3 construct was confirmed by immunocytochemistry (Fig. 
2.3C and 2.8B).  Still if mL3 protein did leak into nucleus, even at undetectable levels, this 
would likely have functional relevance since even low levels of LIG3 are sufficient for 
effective A-NHEJ (Windhofer et al. 2007).  Finally, we also note that all of our repair data 
was generated using episomal reporter vectors that may not always faithfully represent 
endogenous DNA repair events, which are, perforce, chromosomal in nature (Mao et al. 
2008). 
An alternative attractive possibility is that LIG3 is redundant with LIG1 in the A-NHEJ 
pathway (Katyal and McKinnon 2011).  This hypothesis, which we elaborated above as a 
possible explanation for the absence of an anticipated effect on gene targeting, would 
explain the continued production of the 120 bp product even in the absence of LIG3.  In 
almost every experimental situation where the expression of both LIG1 and LIG3 has been 
reduced, the resultant repair activity is significantly less than when either ligase is 
individually reduced (Liang et al. 2008, Gao et al. 2011, Arakawa et al. 2012).  Thus, our 
data suggests that there are redundant LIG1- and LIG3-dependent forms of A-NHEJ, 
although only the LIG3-branch appears to be suppressible by Ku (see also Fig. 2.11). 
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It is unclear what biological function this Ku-suppressible, LIG3-dependent A-NHEJ 
activity serves.  To our knowledge, the only nuclear DSB “activity” that can currently be 
ascribed to LIG3 in C-NHEJ-proficient cells is the ability to facilitate chromosomal 
translocations (Simsek et al. 2011); an activity that seems untenable as an evolutionary 
explanation for the presence of LIG3.  We note, however, that although nuclear LIG3-null 
cells exhibit no obvious DSB repair phenotypes per se, they do exhibit a growth defect, 
implying that the absence of LIG3 is deleterious for the normal progression of cell division.  
However, this requirement for LIG3 could simply be related to its role in BER, an activity 
likely needed for efficacious cell cycle progression (Krokan and Bjoras 2013).  In addition, 
we propose that there may be transient periods in the cell cycle when Ku’s activity is 
suppressed, and where LIG3-dependent A-NHEJ can be engaged in a beneficial manner.  
An obvious time for this would be during S-phase.  Thus, cells normally require HR to 
accurately re-start/repair stalled/broken replication forks (Ghosal and Chen 2013), and the 
repression of C-NHEJ via the suppression of Ku is likely instrumental in this process.  The 
DNA ligase required for these HR transactions is unknown but our data is consistent with 
the recent suggestion that LIG3 may be required for at least Fanconi anemia pathway-
mediated HR processes (Huang and Li 2013).  Whether LIG3-dependent A-NHEJ 
activities could also be utilized in this situation is clearly a question that deserves additional 
investigation. 
 
A new model for EJing in human somatic cells 
Previous studies of EJing in human cells had postulated a model of DSB repair that 
consisted of a predominant Ku-dependent, LIG4-dependent C-NHEJ pathway and a minor 
Ku-suppressible, LIG3-dependent pathway (Fig. 2.11A; (Bennardo et al. 2008, Fattah et 
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al. 2010, Boboila et al. 2012)).  Here we demonstrate that this model is, at best, over-
simplified.  Thus, our data show that there is a constant low level of A-NHEJ in human 
cells that is unaffected by the presence or absence of LIG3 (Fig. 2.6 and 2.10).  We ascribe 
this activity to LIG1 and propose that the LIG1-dependent branch of A-NHEJ is separable 
from the LIG3-dependent branch (Fig. 2.11B).  Moreover, we demonstrate that the LIG3-
dependent branch of A-NHEJ is uniquely Ku-suppressible (Fig. 2.9 and 2.11B).  Most 
interestingly, however, this work has demonstrated that there is a large fraction of EJing 
events that are Ku-independent, but nonetheless LIG4-dependent (Fig. 2.12).  In a 
previous study we had demonstrated a robust EJing activity in Ku-deficient human somatic 
cells and had inferred that this activity was likely due to LIG3-dependent A-NHEJ (Fattah 
et al. 2010).  However, the experiments presented here show that little of this Ku-
independent activity is actually LIG3-dependent, but is instead LIG4-dependent.  
Interestingly, but in retrospect not unexpectedly, this Ku-independent, LIG4-dependent 
activity is capable of performing sticky-ended ligations at very high frequency (Fig. 2.12C; 
(Fattah et al. 2010)).  Thus, we propose that there may a hierarchical order to C-NHEJ in 
which direct ligation of repair events is first attempted and only if that fails is Ku recruited 
to enable more complicated downstream processes such as end resection and 
polymerization before ligation ensues (Fig. 2.11B).  Our postulated model is consistent 
with the recent demonstration that XRCC4 and XLF can facilitate the bridging of DNA ends 
for subsequent LIG4-dependent ligation (Mahaney et al. 2013). 
In summary, these studies have revealed that human LIG3 is an essential gene due 
to its requirement in mitochondrial function.  Moreover, we demonstrate that while nuclear 
LIG3 is not required for random gene targeting integrations, it is required for mediating the 
enhanced A-NHEJ repair events observed in the absence of Ku.  Finally, we have 
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identified a novel EJing activity observed in the absence of Ku that is LIG4-dependent.  
Altogether, these observations enhance our understanding of EJing in human somatic 
cells. 
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Tables 
Table 2.1.  List of PCR primers 
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Figures 
Figure 2.1 
 
Figure 2.1.  Scheme for the functional inactivation of the human LIG3 locus.  
A) A cartoon of part of the LIG3 genomic locus (LIG3+/+). The numbered rectangles 
represent exons and lines in between are introns. The conditional knockout vector has 
three loxP sites (filled triangles) that flank a NEO cassette and exon 5, respectively. B) 
After the first round of targeting, G418-resistant clones were selected and among them, 
correctly targeted clones (LIG3NEO/+) were identified by PCR. The LIG3NEO/+ clones were 
treated with pGK-Cre to remove the NEO gene prior to the second round of targeting, 
which generated LIG3flox/+clones. C) A G418-sensitive LIG3flox/+ clone was targeted with 
an exon 5 knockout vector. D) A correctly targeted clone, LIG3flox/NEO, was treated with 
AdCre to derive a G418-sensitive LIG3flox/− clone, depicted in E). AdCre treatment of 
LIG3flox/NEO can also generate a LIG3−/− clone, depicted in (F), if the recombination 
happens in both alleles. F) AdCre treatment of LIG3flox/− clones results in LIG3−/− cells. 
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Figure 2.2 
 
 
Figure 2.2.  Generation of a LIG3 conditionally-null cell line. 
A) PCR confirmation of LIG3flox/− cells. A primer set, LIG3_LArm_F3 (F3) and 
LIG3_RArm_R2 (R2), which yield differently sized PCR products from the floxed allele 
(748 bp) and wild-type allele (662 bp) were used.  With the same primer set, an allele 
containing the NEO gene generated a band over 3 kb and the loxP-only allele yielded a 
97 bp product, but they are not shown in this figure.  B) The floxed allele disappears after 
AdCre infection.  With increasing amounts of AdCre virus, the 748 bp PCR product derived 
from the floxed allele disappeared in the LIG3flox/− clone.  In contrast, the expression of 
Cre did not affect the LIG3+/+ control cells.  C) Western blot analysis confirms the loss of 
LIG3 protein.  Protein samples were produced in parallel to the DNA samples in (B).  
Increasing amount of AdCre virus correlated with decreasing amount of LIG3 protein only 
in the experimental cell line.  
  71 
Figure 2.3 
 
Figure 2.3.  Complementation with a mitochondrial-only LIG3 cDNA rescues the 
lethality of LIG3−/− cells.  
A) Constructs used for complementation. To make a mitochondrial-only LIG3 (mL3), the 
second and third ATGs were mutated to ATCs. For the nuclear-only LIG3 (nL3) 
construction, the N-terminal MLS sequence was deleted. mL3 and nL3 were subsequently 
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modified with C-terminal HA- and FLAG- epitope tags, respectively. B) Cre-recombinase 
linked to the estrogen receptor (CreERt2) was stably expressed in LIG3flox/+, LIG3flox/−, 
LIG3flox/−:mL3 and LIG3flox/−:nL3 cell lines. #101-1 and #101-21 are two independent 
LIG3flox/+:CreERt2 clones. #73-5 and #73-6 are two independent LIG3flox/−:mL3:CreERt2 clones. 
Cells were plated onto 6-well plates and a day afterwards 4-OHT was added to induce 
Cre recombination. Cells were maintained either in 4-OHT containing media or EtOH-
containing media, which served as a negative control, for 2 to 3 weeks until they formed 
colonies, which were then fixed and stained by crystal violet. C) Nuclear and mitochondrial 
localization of LIG3 in complemented clones. In wild-type HCT116 cells, LIG3 is expressed 
cell-wide. In contrast, LIG3−/−:mL3 cells showed a mitochondrial-exclusive expression 
pattern. In LIG3−/−:mL3:nL3 cells, mL3 is detected in the cytoplasm and nL3 is over-expressed 
in the nucleus. 
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Figure 2.4 
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Figure 2.4.  A LIG3 deficiency causes growth retardation, but not hypersensitivity 
to DNA damaging agents. 
A) Three thousand cells were plated on day 0 and their growth was subsequently 
assessed by counting trypan blue-excluding cells at the indicated days. The average of 
two independent experiments, each done in triplicate, is shown.  B) Etoposide sensitivity.  
Three hundred cells were plated a day before etoposide treatment. Survival was 
normalized by setting the value obtained from no etoposide treatment as 100 percent.  As 
a positive control, a LIG4−/− cell line, which is known to be extremely sensitive to etoposide, 
was used.  The plotted values are the average of three independent experiments.  C) 
MMS sensitivity was performed in a similar way to the etoposide sensitivity test, except 
for the drug-treatment time: cells were incubated in MMS-containing media for 1 hr. 
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Figure 2.5 
 
Figure 2.5.  A LIG3 deficiency does not affect total end-joining activity.   
A) A cartoon of the pEGFP-Pem1-Ad2 repair substrate used for analysis of DNA end-
joining activity.  Expression of the GFP cassette is driven by the CMV promoter and 
terminated by the SV40 polyA sequence.  The GFP coding sequence is interrupted by a 
2.4 kb intron containing an adenovirus exon (Ad), which is flanked by HindIII and I-SceI 
restriction enzyme recognition sites.  Splice donor (SD) and splice acceptor (SA) sites are 
also shown.  B) HindIII digestion generates compatible ends with 4 nt overhangs, whereas 
I-SceI digestion produces incompatible ends, that require some processing before they 
can be rejoined.  C) The starting substrate is GFP negative because the Ad exon is 
efficiently spliced into the middle of the GFP ORF, inactivating the GFP activity.  Cleavage 
with either HindIII or I-SceI removes the Ad exon and, upon successful intracellular 
plasmid circularization, GFP expression is restored and can be quantitated by flow 
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cytometry.  D) The impact of LIG3 deficiency on end joining.  A LIG4-null cell line was 
used as a negative control.  The plotted values are the average of three independent 
experiments. 
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Figure 2.6 
 
Figure 2.6.  LIG3-null cells have normal microhomology-mediated end-joining 
activity.   
A) After EcoRV and AfeI restriction enzyme digestion, the reporter substrate, pDVG94, 
becomes a blunt-ended linear plasmid with 6 bp direct repeats at both ends.  Repair via 
C-NHEJ generally retains at least part of either repeat, whereas A-NHEJ generates only 
a single repeat and a novel restriction enzyme site that can be cleaved by BstXI.  Repaired 
junctions were amplified by PCR using radiolabeled primers and the 180 bp PCR product 
was subjected to BstXI restriction enzyme digestion.  The 180 bp uncut product represents 
repair via C-NHEJ whereas the 120 bp digested product represents A-NHEJ-mediated 
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repair.  B) Both LIG3 heterozygous (LIG3flox/-) and LIG3-null (LIG3-/-:mL3) cells have similar 
microhomology end-joining activity to the wild-type control.  A LIG4-/- cell line was used as 
a positive control. 
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Figure 2.7 
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Figure 2.7.  A LIG3 deficiency does not affect the relative frequency of rAAV-
mediated gene targeting at the HPRT locus.   
A) rAAV random integration frequency. The random integration frequency was determined 
as the number of puromycin-resistant clones normalized by plating efficiency.  B) rAAV 
gene targeting frequency.  The gene targeting frequency was determined as the number 
of both puromycin and 6-thioguanine-resistant clones normalized by plating efficiency.  C) 
The relative frequency of rAAV gene targeting represents the ratio of the correct targeting 
events versus the total viral integration events.  LIG3-null cells showed both higher random 
integration and gene targeting frequencies and hence overall there was no difference in 
relative gene targeting frequency. 
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Figure 2.8 
 
 
Figure 2.8  Scheme for the construction of a KU86:LIG3 doubly-deficient human cell 
line.  
A) A cartoon of part of the LIG3 genomic locus showing the three relevant ATGs in exon 
2 and the approximate location of the mitochondrial localization sequence (MLS, green 
rectangle) and the portion of LIII that encodes the nuclear isoform (Nuclear, orange 
rectangle). The numbered rectangles represent exons and lines in between are introns; 
exon 1 (non-coding), exon 3 and additional downstream exons are not shown. The 
conditional knockout vector had three loxP sites (filled triangles) that flanked a neomycin 
drug resistance gene (NEO, blue rectangle) and exon 5, respectively. After first round 
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targeting the NEO gene was removed by transiently treating the cells with Cre 
recombinase (+Cre). The second round of gene targeting utilized a vector into which the 
second and third ATGs had been mutated to ATCs. Following correct gene targeting and 
a repeated Cre treatment a LIG3mito/− cell line was constructed. B) Mitochondrial-exclusive 
localization of LIG3 in LIG3mito/− cells. In KU86flox/− cells, LIG3 was localized cell-wide. In 
contrast, KU86flox/−:LIG3mito/− cells showed a mitochondrial-exclusive expression pattern. 
DAPI was used to identify the nuclei. C) PCR analysis was used to demonstrate that the 
addition (+) of 4-OHT induced efficient conversion of the KU86flox/− configuration to a 
recombined KU86−/− state in all 3 of the indicated cell lines. 
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Figure 2.9 
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Figure 2.9.  LIG3 is required for microhomology-mediated A-NHEJ events normally 
repressed by Ku.   
A) The reporter substrate, pDVG94, described in Figure 5 was used with the indicated cell 
lines. The 180 bp uncut product represents repair via C-NHEJ whereas the 120 bp 
digested product represents A-NHEJ-mediated repair.  Note that the enhanced A-NHEJ 
repair observed in a KU86-/- cell line was completely abrogated in a KU86-/-:LIG3mito/- cell 
line.  B) Four independent assays comparable to that shown in panel (A) were averaged 
and the error bars represent the standard error of the mean. 
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Figure 2.10 
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Figure 2.10.  LIG3, and not LIG4, is required for microhomology-mediated EJing 
events normally repressed by Ku. 
  A) A diagram of the reporter substrate, pEJ2.  The gray rectangle with the arrow 
represents a transcriptional promoter.  The brown rectangle (tag) represents and in-frame 
epitope tag.  The orange rectangle is expanded below to show an I-SceI restriction 
enzyme recognition site and the red rectangle represents translational stops in all 3 
reading frames (stop).  These elements are flanked by 8 bp of a direct repeat 
(CAAGCCCG) that permits microhomology-mediated repair.  The green rectangle (GFP) 
represents the coding sequences for green fluorescent protein.  Repair of the I-SceI-
linearized pEJ2 by C-NHEJ retains the stop cassette and does not permit GFP expression 
whereas repair by A-NHEJ deletes out the stop element and allows GFP expression.  B) 
The indicated cell lines were transfected with the I-SceI-linearized pEJ2 reporter and then 
either left untreated (-Cre) or treated with 4-OHT to induce Cre (+Cre) expression.  C) 
Four independent experiments similar to the one shown in panel (B) were averaged and 
presented as the fold change relative to wild type. 
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Figure 2.11 
 
 
 
Figure 2.11.  A new model for EJing pathways in human somatic cells  
A) The old model for EJing.  A DSB could be repaired by one of two pathways.  The first 
and most active was the Ku-dependent, LIG4-dependent C-NHEJ pathway and the 
second was the minor Ku-suppressible, LIG3-dependent A-NHEJ pathway.  B) A 
proposed new model posits that all DSB substrates are first subjected to a LIG4-mediated 
rejoining event, which is relatively successful.  Only when this rejoining event fails is Ku 
recruited for facilitating additional processing events.  LIG4 is, however, subsequently re-
recruited to finish these repair events.  Thus, C-NHEJ is actually composed of 2 separate 
pathways, one of which is Ku dependent and one of which is not.  Both pathways are, 
however, dependent upon LIG4.  Moreover, the A-NHEJ pathway also bifurcates and can 
either be mediated by LIG1 or LIG3 and only the later of which is Ku-suppressible. 
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Figure 2.12 
 
Figure 2.12.  Ku-independent EJing is LIG4-dependent.   
A) Profiles of EJing assays using the reporter pEGFP-Pem1-Ad2 described in Figure 4 
transfected into the indicated cell lines.   B) Four independent assays comparable to that 
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shown in panel (A) were averaged and the error bars represent the standard error of the 
mean.  C) Repaired plasmids were recovered from the indicated cell lines, propagated 
thorough bacteria and then either left untreated (-HindIII) or subjected to restriction 
enzyme digestion (+HindIII) and then analyzed by agarose gel electrophoresis.  The 
appearance of a diagnostic doublet following restriction enzyme digestion indicates that 
perfect rejoining occurred.  All of the gels show a marker lane on the left followed by 4 
lanes containing independently isolated plasmids.  D) 18 to 40 independent plasmids 
similar to the four shown in panel (C) were quantitated for each of the indicated cell lines 
and scored for the occurrence of perfect joins. 
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Synopsis 
 
PARP1 has been well studied and is clinically important because of its synthetic 
lethality with BRCA1 and BRCA2 mutations, which are causative for inherited breast and 
ovarian cancers.  Biochemically, PARP1 is a single-stranded DNA break repair protein, is 
needed for preserving genomic integrity, and has been implicated in a bevy of additional 
cellular pathways and processes.  Because of PARP1’s influence on so many cellular 
pathways, its precise contribution to human cellular biology remains relatively obscure.  
To molecularly address this deficiency, we utilized gene editing to construct genetically-
null PARP1 human cancer cells.  As expected, we found a specific role for PARP1 in an 
alternative form of DSB repair.  In addition, however, we also observed cell cycle 
progression defects and elevated endogenous DNA damage signaling.  Moreover, we 
found evidence of telomere defects, which are likely the strongest contributor to the 
apparent genomic instability.  Specifically, PARP1-/- cells have short telomeres that 
frequently co-localize with markers of endogenous DNA damage signaling.  Our data 
suggest that while PARP1 does not participate significantly in DNA DSB repair itself, it 
does prevent the incidence of DSBs, particularly at telomeres, presumably by preventing 
replication-induced DNA damage. 
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Introduction 
 
PARP1 is a ubiquitously and very abundantly expressed protein that post-
translationally modifies target proteins with PAR moieties using NAD+ as its source.   
Impressively, the sheer abundance of these post-translational modifications in cells 
enabled researchers to discover such modifications prior to any information about the 
protein(s) responsible for their catalysis (Hayaishi and Ueda 1977).  Of the 17-known 
PARP-domain-containing proteins (named PARP1 through PARP17, respectively), 
PARP1 is the most ubiquitous and most active within eukaryotic cells, as its genetic 
deletion alone causes a dramatic loss in the amount of detectable PAR within cells (Bock 
and Chang 2016).  Because PARP1 is the most abundant PARP and because PARylation 
is thought to be an important signaling process, it is not surprising that PARP1 has been 
implicated in a vast array of cellular processes, including cellular metabolism, cell cycle 
regulation, DNA replication, and DNA break repair (Mangerich and Burkle 2012).  PARP1 
has been studied biochemically in vitro and extensively by genetic knockout in vivo in 
model organisms including mice (Wang et al. 1995), plants (Boltz et al. 2014), and flies 
(Miwa et al. 1999), as well as in chicken DT-40 cells (Hochegger et al. 2006).  These 
reports generally conclude that PARP1 is important to preserve genomic integrity, and 
that it primarily participates in the repair of SSBs (Helleday 2011).  To date there has been 
no phenotypic characterization of the genetic knockout of PARP1 in human somatic cells, 
as the field has either relied on RNAi knockdowns, or, primarily, by utilizing one of the 
many available inhibitors to PARP1 (Krishnakumar and Kraus 2010, Gibson and Kraus 
2012).  The use of RNAi, however, rarely completely eliminates PARP1 from a given cell, 
potentially obscuring relevant phenotypes.  In a complementary fashion, PARP inhibitors 
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generally have a dominant-negative effect on cellular PARP1 by trapping PARP1 at a SSB 
in a DNA-bound state (Godon et al. 2008, Strom et al. 2011, Murai et al. 2012).  Thus, the 
normal role of PARP1 in human cells remains somewhat poorly defined. 
PARP1 is well-known because it exhibits synthetic lethality with BRCA1 and BRCA2 
(Bryant et al. 2005, Farmer et al. 2005).  A prevailing theory is that SSBs, which normally 
would be recognized for repair by PARP1, can accumulate over time such lesions would 
be converted to DSBs as a consequence of DNA replication (Helleday 2011).  Because 
BRCA1 and BRCA2 are required for the HDR of these DSBs it has been postulated that 
it is this activity of BRCA1- and BRCA2-dependent repair that is required to preserve a 
viable level of genomic integrity (Rosen and Pishvaian 2014).  This pathway, while clearly 
relevant to explain the impact of PARP1’s absence on survival may, however, only be part 
of the story.  For example, PARP1’s association with the replication fork is required for 
Chk1-dependent activation in response to replication stress (Min et al. 2013).  Therefore, 
the absence of PARP1 might also dysregulate the integrity of replication forks in addition 
to resulting in a higher frequency of lesions. 
Besides impinging upon HDR, PARP1 has been implicated in the repair of DSBs by 
actively regulating NHEJ.  NHEJ involves the end-to-end ligation of two broken ends of 
double-stranded DNA, and can be sub-categorized as C-NHEJ or A-NHEJ pathways.  The 
C-NHEJ pathway is dependent on the Ku70/86 heterodimer, a ring-shaped protein 
complex that binds the ends of broken DNA.  The binding of the ubiquitously expressed 
and very abundant Ku heterodimer and subsequent activation of the C-NHEJ pathway can 
occur within seconds of a DSB occurring and is inherently repressive of A-NHEJ (Fattah 
et al. 2010, Shahar et al. 2012, Oh et al. 2014).  Accordingly, A-NHEJ is thought to be a 
minor or back-up repair pathway in normal cells.  The hallmark of A-NHEJ is the use of 
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microhomology, which also constitutes a molecular signature that remains at the site of 
repair, to facilitate the ligation of the two DNA ends (Ciccia and Elledge 2010).  One 
documented pathological role for A-NHEJ is likely its involvement in oncogenic 
chromosomal translocations in mice (Simsek et al. 2011), although this is probably not the 
case in human somatic cells (Ghezraoui et al. 2014).  PARP1 has been implicated in the 
regulation of A-NHEJ, which was partially a consequence of discovering that PARP1-
associated proteins, such as XRCC1, were required for A-NHEJ (Audebert et al. 2004, 
Wang et al. 2005, Wang et al. 2006, Audebert et al. 2008).  Finally, it has been suggested 
that the DNA binding activity of PARP1 could compete with Ku to enable A-NHEJ to occur 
in place of C-NHEJ (Wang et al. 2006), or repress Ku’s ability to access the DNA break 
(Hochegger et al. 2006). 
Telomeres are the repetitive DNA:protein structures that serve to protect the ends of 
linear chromosomes from recognition as a DSB (Doksani and de Lange 2014).  They are 
well known to regulate aging, as they gradually shorten over time due to the end replication 
problem.  Moreover, and of important clinical significance, the activation of a telomere re-
elongation pathway is a key requirement for malignant progression (Hanahan and 
Weinberg 2011).  Telomeres appear to be difficult regions of the genome for DNA 
replication to occur (Verdun and Karlseder 2007), which is likely due to both the repetitive 
nature of telomeric DNA, combined with their tendency to form G-quadruplex structures 
(Smith and Feigon 1992, Parkinson et al. 2002).  PARP1 has been identified as a 
telomere-binding protein and has been implicated in the regulation of telomere length 
maintenance (Gomez et al. 2006, Wang et al. 2007, Giannone et al. 2010, Salvati et al. 
2010).  Confusingly, the influence of PARP1 loss-of-function in the mouse has been 
reported to result in telomere shortening (d'Adda di Fagagna et al. 1999) or to have no 
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impact what-so-ever (Samper et al. 2001).  Similarly, there is a lack of agreement about 
the role of PARP1 in telomere length maintenance in human cells as the use of either 
RNAi against PARP1 (Beneke et al. 2008) or inhibitors to PARP1 (Beneke et al. 2008, 
Lee et al. 2015) resulted in either telomere shortening (Beneke et al. 2008) or lengthening 
(Lee et al. 2015).  Since some of these findings seem mutually exclusive and are likely 
due to differences in the experimental systems employed, a role for PARP1 in mammalian 
telomere maintenance is still controversial. 
To experimentally address this issue, we utilized gene editing to generate PARP1-null 
human somatic cells.  Human PARP1-null cells are viable and exhibit spontaneous DNA 
damage, which tends to localize at telomeres, and is co-incident with short telomeres.  We 
further find that this is likely not due to a defect in DSB repair per se, but rather reflects an 
inability to mitigate damage associated with DNA replication. 
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Results 
 
Creation of PARP1-null cells 
We utilized gene targeting in human HCT116 cells to functionally inactivate PARP1 by 
an exon-replacement strategy (Hirata et al. 2002).  We designed a gene targeting 
construct in a rAAV, such that correct targeting would result in the replacement of PARP1 
exon 4 with a NEO drug selectable marker (Fig. 3.1A).  Correct gene targeting was 
screened for by using PCR primer pairs with one primer that flanked the targeting construct 
combined with an internal primer specific to the drug selectable marker.  After successful 
gene targeting, the drug selectable marker was removed by Cre-recombinase, thus 
generating a null allele.  Two rounds of targeting were required to generate a diploid null 
cell line, which was confirmed using PCR primers that flank exon 4 (Fig. 3.1B; Fig. 3.2A).  
In a scenario where a gene exhibits no strong selective pressure, Mendelian genetics 
would predict that when targeting a heterozygotic cell line, there is an equivalent 50% 
chance of targeting either the already targeted allele (“re-targeting”) or targeting the 
second, still functional allele.  During the second round of PARP1 targeting, only 3 of 72 
correctly targeted clones resulted in the loss of the second PARP1 allele (i.e., 69 of 72 
clones were re-targeted) (Table 3.1).  This exceptional disequilibrium in the gene targeting 
frequency is usually a hallmark of genes that provide a significant growth disadvantage 
when absent (Dang et al. 2006, Fattah et al. 2008, Ruis et al. 2008).  Thus, although 
isolation of three independent PARP1-null clones was unequivocal evidence that PARP1 
is not essential in human HCT116 cells, the frequency with which these clones were 
obtained was also a first indication that PARP1 had an important role in human cellular 
biology. 
  97 
We next sought to complement these cells with either an empty vector, or a wild type 
(WT) PARP1 cDNA, which was integrated randomly into the genome by a PiggyBac 
transposon system (Doherty et al. 2012).  The restoration of PARP1 protein in the null 
cells was confirmed by western blot (Fig. 3.1C; Fig. 3.2C).  A series of complemented 
clones in which PARP1 was either under- (“low”), ~normally- (“medium”) or over- (“high”) 
expressed were generated for each of the three null cell lines (Fig. 3.1c; Fig. 3.2C).  In 
order to validate that the complemented clones contained active protein, a PARP-activity 
assay was performed, which confirmed both the successful ablation of PARP activity in 
the null cells, as well as their functional complementation (Fig. 3.1D).  Interestingly, even 
the lowest levels of complementing PARP1 expression could fully rescue PARP activity 
(Fig. 3.1d).  An obvious phenotype of the PARP1-/- cells was their slow growth, as they 
exhibited an almost 50% reduction in doubling time (Fig. 3.1E; Fig. 3.2B).  Again, this 
phenotype could be completely rescued by the re-expression of even low levels of PARP1 
(Fig. 3.1E).  In summary, these data compellingly demonstrated that PARP1 is not 
essential in human somatic cells, but that its absence results in significant deficits to both 
proliferation and survival. 
 
PARP1-null cells accumulate in the G2 phase of the cell cycle 
To better understand the cellular growth defect of PARP1-null cells, we investigated 
whether it was correlated with deficits in cell cycle progression.  In asynchronous 
populations, the null cells exhibited a modest increase in the number of cells in G2, 
compared to both WT, and the complemented cells when their DNA content was analyzed 
(Fig. 3.3A).  In order to better understand this G2 accumulation, cells were synchronized 
at G1/S with serum starvation, followed by an overnight incubation in thymidine (in the 
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presence of serum), which transiently arrested the cells at the G1/S transition.  After 
releasing the cells into standard medium, the cell cycle profile of the cells was determined 
(Fig. 3.3B).  The PARP1-null cells progressed through the cell cycle at approximately the 
same rate as either WT or complemented cells, but after S-phase, dramatically 
accumulated in the G2 phase.  This is best exemplified by the amount of PARP1-null cells 
remaining in G2 (36.4%) at the 12 hr time point, in comparison to the rest of the genotypes 
(12% to 18%), which were successfully able to continue through mitosis and into the 
subsequent G1 phase (Fig. 3.3B).  The accumulation of PARP1-null cells in G2, suggested 
that the cells were experiencing an elevated level of DNA damage that was, in turn, 
activating the G2/M checkpoint.  Consistent with this interpretation, PARP1-null cells had 
elevated levels of p53, with respect to control lines (Fig. 3.3C; Fig. 3.4). 
 
PARP1 modulates, but is not required for A-NHEJ 
The spontaneous elevation of p53 expression in asynchronously growing PARP1-null 
cells suggested that the absence of PARP1 was contributing to an accumulation of DNA 
damage.  Given the aforementioned reports of PARP1’s role in DSB repair, we next 
measured the cells’ capacity for this activity.  Cells were transfected with a linearized 
plasmid-reporter, pDVG94, allowed 48 hr to enact repair, and then circularized plasmids 
were recovered from the transfected cells.  Cells have two options to repair the linearized 
plasmid.  They can simply re-ligate the ends together, which is indicative of C-NHEJ and 
which can be quantitated as a ~180 bp PCR product when primers flanking the repair 
junction are utilized (Fig. 3.5A).  Alternatively, cells which utilize the 6 bp of microhomology 
present at the linearized ends to repair the plasmid create a diagnostic restriction enzyme 
recognition site for BstxI.  Cleavage of the PCR products generated with primers flanking 
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the repair junction with BstXI generates a 120 bp fragment (and a 60 bp fragment) and 
the appearance of this product versus the 180 bp product enables a relative measure of 
A-NHEJ versus C-NHEJ activity (Fig. 3.5A) (Verkaik et al. 2002).  In wild type cells 
approximately 15% of the repair products could be ascribed to A-NHEJ (Fig. 3.5B, C).  As 
a positive control we also analyzed the same plasmid rejoining in a cell line defective in 
DNA Ligase 4 (LIG4) (Oh et al. 2013).  As expected (Fattah et al. 2010, Oh et al. 2014) 
these cells carried out virtually exclusively (97%) A-NHEJ (Fig. 3.5B, C; Fig. 3.6).  
Consistent with previous studies (Audebert et al. 2004, Wang et al. 2005, Wang et al. 
2006, Audebert et al. 2008), the PARP1-null cells showed a statistically significant deficit 
in A-NHEJ (Fig. 3.5B, C).  The deficit, however, was rather small (<2-fold), and importantly 
could not be phenocopied by treating wild type cells with a PARP1 inhibitor, olaparib (Fig. 
3.6).  To clarify these results, we next induced A-NHEJ activity by pretreating cells with 
the DNA-PKcs inhibitor, NU7441 (Leahy et al. 2004), which should increase the relative 
amount of A-NHEJ by inhibiting the Ku/DNA-PKcs-dependent C-NHEJ pathway.  All 
genotypes, except as anticipated, LIG4-null cells, showed enhanced A-NHEJ activity in 
the presence of NU7441 (Fig. 3.5B, C).  Importantly, however, the PARP1-null cells 
showed increases in A-NHEJ activity comparable to the wild-type and complemented 
clones (Fig. 3.5B, C).  Most provocatively, the treatment of LIG4- and DNA-PKcs-null 
clones with olaparib was completely ineffective in inhibiting A-NHEJ (Fig. 3.6).  Thus, the 
absence of PARP1 did not affect the cellular capacity for A-NHEJ in all situations where 
A-NHEJ activity was either genetically or chemically enhanced. 
Since previous models had suggested that PARP1 may compete for DSBs with the 
Ku heterodimer (Hochegger et al. 2006, Wang et al. 2006) we carried out an additional 
experiment to test whether or not the converse of our conclusion that PARP1 activity might 
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be C-NHEJ dependent was true: i.e., whether the absence of PARP1 affects C-NHEJ.  
PARP1-/- cells and relevant controls were transfected with the pEGFP-Pem1-Ad2 reporter 
of C-NHEJ activity (Seluanov et al. 2004).  As expected, a LIG4-null cell line showed 
greatly reduced activity in this assay (Fig. 3.5D; Fig. 3.7).  In contrast, the presence or 
absence of PARP1 had no effect on the levels of C-NHEJ in the various cell lines (Fig. 
3.5D; Fig. 3.7).  Thus, we conclude that PARP1 does not participate (significantly) in either 
C-NHEJ- or A-NHEJ-mediated DSB repair in human cells. 
 
PARP1 is required for proper telomere maintenance 
The above experiments demonstrated that although PARP1-null cells seemed to be 
sensing significant amounts of DNA damage or stress, they had only mild deficits in the 
repair of such damage.  Thus, we hypothesized that this damage might be associated with 
stalled or stressed DNA replication forks.  One region of particular interest was telomeres 
(Janson et al. 2015), as PARP1 had been identified as a telomere-binding protein, and 
some previous reports of telomere shortening have been associated with PARP1 inhibition 
or inactivation (Gomez et al. 2006, Wang et al. 2007, Giannone et al. 2010, Salvati et al. 
2010).  To explore this possibility, we analyzed metaphase spreads from wild type and 
PARP1-/- cells.  PARP1-/- metaphases were frequently distorted, a hallmark of genomic 
instability, and exhibited a significant increase in the amount of signal-free ends, after 
labeling the telomeres with a PNA-probe (Fig. 3.8A, B).  Thus, PARP1-/- cells appeared to 
have at least a subset of very short telomeres.  Deficits in telomere length were confirmed 
by Southern blotting.  Initial screening of several subclones of WT, PARP1-/-, and PARP1-
/-:+PARP1 complemented cells demonstrated that the null cells had significantly shorter 
telomeres than WT cells (Fig. 3.8C).  We did note that this phenotype was variable, i.e. 
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some null clones were shorter than others, and not all of the complemented clones 
restored the telomere length to WT levels.  We attribute this to the fact that telomere length 
can be variable on a clonal basis in telomerase-immortalized cancer cells.  Thus, to 
properly analyze the capability of PARP1 expression to complement the PARP1-/- cells, 
we created more independent complemented clones, along with empty vector controls, 
and re-screened their telomere lengths.  Whereas none of the empty vector (EV)-
containing clones complemented telomere length, the majority of the PARP1-expressing 
clones did restore telomere length, albeit usually not to wild type lengths (Fig. 3.8D).  Thus, 
we conclude that PARP1 prevents abnormal telomere shortening, but it does not 
significantly contribute to telomere lengthening.   
Given the aforementioned observed G2/M cell cycle arrest, we probed for any 
connection between the spontaneous DNA damage and the shortened telomere 
phenotype.  We utilized an IF-FISH hybrid assay, which combines immunoflouresence of 
proteins with FISH to co-visualize proteins and DNA sequences.  We implemented this 
assay in the various cell lines for both telomeric DNA and 53BP1, a common marker of 
DNA DSBs (Huyen et al. 2004, Dimitrova et al. 2008).  In PARP1-null cells there was a 
higher spontaneous frequency of 53BP1 foci (Fig. 3.9A, C), and these foci tended to co-
localize (telomere dysfunction-induced foci; TIFs) with telomeric DNA (Fig. 3.9A, B).  
Importantly both the elevated 53BP1 foci and the TIFs could be completely suppressed 
by the re-expression of PARP1 in the PARP1-null cells (Fig. 3.9).  Together, these data 
demonstrated that the telomeres of PARP1-null cells are short and that they are prone to 
incurring significant amounts of DNA damage. 
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PARP1 affects cellular immortalization 
To confirm and extend the conclusion that PARP1-null cells have dysfunctional 
telomeres, we next tested whether PARP1-null cells could survive a “telomere challenge”.  
In these experiments, a dominant negative telomerase (DN-hTERT) is expressed in cells 
to shorten their telomeres and force them into a “crisis” that is very much akin to the crisis 
that primary cells encounter as they evade senescence on their way to cellular immortality 
(Hendrickson and Baird 2015).  Following the replicative erosion induced by the 
expression of DN-hTERT, cells normally undergo a period of slow growth and genetic 
instability due to the resulting shorten telomeres, but ultimately re-establish wild-type 
telomerase expression and telomere maintenance (Jones et al. 2014, Liddiard et al. 2016).  
Indeed, when DN-hTERT was expressed in wild type cells, all clones (15/15) analyzed 
escaped the subsequent crisis and continued to proliferate for at least 80 days, (or in some 
cases 120 days), after which point the experiment was intentionally terminated (Fig. 3.10).  
In stark contrast, only 1 of 10 PARP1-null clones was able to escape and immortalize (Fig. 
3.10).  These data demonstrated that the telomere dysfunction observed in PARP1-null 
cells severely compromised their ability to re-establish telomere maintenance in the face 
of gradual telomere erosion. 
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Discussion 
 
PARP1 has been the subject of intense study in multiple model organisms.  In spite of 
this, the molecular mechanism of PARP1 action in certain cellular transactions is still 
unclear.  For example, whereas PARP1 loss-of-function mutations were initially 
discovered to be synthetically lethal with BRCA1 and BRCA2 mutations (Bryant et al. 
2005), some cancer patients with such mutations have not benefited from PARP1 
inhibition (Fong et al. 2009), and many tumors that are BRCA1- and BRCA2-proficient can 
likewise be sensitized by PARP1 inhibition (Gelmon et al. 2010, Garnett et al. 2012).  Thus, 
although there is no dispute that PARP1 inhibition can cause synthetic lethality in BRCA1 
and BRCA2 mutant tumors, the molecular mechanism of that lethality is yet to be fully 
elucidated.  One explanation for this ambiguity is that a common feature of PARP1 
inhibitors is that they can have dominant-negative effects in cell lines that contain the 
target protein (Godon et al. 2008).  While the results drawn from those experiments are 
not in any way invalid, it can be difficult to discern the effect of non-functional protein 
versus the absence of that protein.  Here, we genetically ablated PARP1 in a BRCA1- and 
BRCA2-positive cancer cell line, HCT116, to better understand the role of PARP1 in an 
otherwise normal background.  Unexpectedly, we find little evidence of significant DSB 
repair defects, but observe an increase in cells accumulating at the G2/M checkpoint, likely 
resulting from an accumulation of DSBs.  We further show that these DSBs tend to occur 
in telomeric DNA, which contribute to checkpoint activation, and further limit the cell’s 
proliferation and subsequent ability to handle telomere stress. 
One novel finding from these studies is the demonstration that PARP1 is a non-
essential gene in transformed human somatic cells.  Our ability to isolate three 
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independent PARP1-null clones is unequivocal evidence that PARP1 is not required for 
survival.  With that said, there has never been, to our knowledge, a human patient 
described anywhere in the world who is/was PARP1-null.  Indeed, our own gene targeting 
studies argue strongly that PARP1, although not technically essential, is nonetheless so 
important that the development of a viable human is unlikely.  Gene targeting is a 
completely egalitarian process and either allele in a diploid cell is as equally likely to be 
modified as the other (Hendrickson 2008).  During the second round of PARP1 targeting 
however, 69 of 72 clones were re-targeted and only 3 of 72 correctly targeted clones 
resulted in the loss of the second PARP1 allele (Table 5.1).  This exceptional 
disequilibrium in the gene targeting frequency is a hallmark of genes that provide a 
significant growth disadvantage when absent (Dang et al. 2006, Fattah et al. 2008, Ruis 
et al. 2008).  This finding was unexpected, as PARP1-null mice are viable and fertile(Wang 
et al. 1995, de Murcia et al. 1997), and suggests a difference between PARP1 in humans 
and mice. Our subsequent demonstration that there are significant deficits in PARP1-null 
cells with telomere maintenance are completely consistent with this conclusion.  Thus, the 
three independent PARP1-null clones notwithstanding, we predict that in the context of 
the embryonic development in humans that PARP1 will be essential. 
An additional key finding we present is the lack of a significant effect on A-NHEJ 
caused by the absence of PARP1 (Fig. 3.5; Fig. 3.6).  While it is compelling that PARP1 
inhibition can result in diminished end-joining activity in many cell types, we suggest that 
PARP1 is not a critical A-NHEJ gene.   Such mischaracterization has historical precedent, 
as PARP1 has been previously mislabeled as a core BER gene (Helleday 2011).   This 
was originally suggested by the finding that PARP1-/- MEFs were hypersensitive to BER-
sensitizing alkylating agents, such as methyl-methane sulfonate (Dantzer et al. 1999).  
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However, subsequent investigation demonstrated that the inhibition of PARP1 was simply 
either trapping a BER-intermediate (Strom et al. 2011) or modulating the terminal ligation 
step (de Murcia and Menissier de Murcia 1994) and that PARP1 was not an integral 
component of the BER machinery.  We hypothesize that such a similar scenario exists for 
A-NHEJ and PARP1.  The lack of a strong A-NHEJ phenotype for PARP1-/- human cells 
is consistent with emerging molecular evidence detailing the mechanism of A-NHEJ itself.  
Rather than a discrete subpathway of NHEJ, it now appears that A-NHEJ may rather be 
a HDR subpathway which is engaged when canonical HDR fails to find the appropriate 
homologous template for proper repair.  Several independent reports support this 
emerging theory.  First, conceptually, the requirement for microhomology at the ligation 
junction underlies a requirement for some degree of DNA-resection, followed by homology 
searching, both of which are much more akin to HDR than NHEJ.  Moreover, reports have 
confirmed that the homology searching in A-NHEJ is dependent on the MRN complex and 
CtIP (Bennardo et al. 2008, Rass et al. 2009), as well as BRCA1 (Badie et al. 2015), all of 
which are canonical HDR genes.  In addition, the kinetics of A-NHEJ are similar to HDR 
and distinct from C-NHEJ (Wang et al. 2001).  In toto, these reports are consistent with A-
NHEJ being a subpathway of HDR.  If this model is true, then the key regulatory A-NHEJ 
genes are more than likely to be the upstream HDR repair genes, rather than PARP1.  
Thus, we suggest that while PARP1 inhibition could affect A-NHEJ activity in certain 
experimental models, it is not a canonical A-NHEJ gene.  With this said, a small, albeit 
significant and reproducible, deficit in A-NHEJ activity was observed in PARP1-null cells 
— intriguingly however, only when they were proficient for DNA-PKcs (and therefore 
presumably C-NHEJ) (Fig. 3.5, Fig. 3.6).  This deficit is more compatible with the more 
widely accepted models of A-NHEJ being a salvage pathway for ineffective C-NHEJ 
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(Iliakis 2009).  Needless to say, these models are not mutually exclusive and A-NHEJ 
could be the salvage pathway for both unsuccessful HDR and C-NHEJ.  In this scenario, 
the presence (or absence) of PARP1 seems to impact the C-NHEJ salvage subpathway 
more than the HDR one.  All of these models clearly deserve further experimentation. 
The role of PARP1 in telomere maintenance has remained an ambiguous, yet 
intriguing, concept.  To date, the majority of work has described a role for PARP1 in 
mediating aberrant DNA repair at uncapped or damage telomeres, specifically causing the 
fusion of sister-chromatid telomeres (Salvati et al. 2010, Sfeir and de Lange 2012, Badie 
et al. 2015, Rai et al. 2016).  Thus, these reports have implied that PARP1 is actively 
repressed from binding to functional telomeric DNA.  Yet, other reports have indicated a 
functional interaction withTRF2, a principal component of the Shelterin complex (Gomez 
et al. 2006).  PARP1 was also independently identified as a Shelterin binding protein by 
an unbiased mass-spectroscopy approach (Giannone et al. 2010).  Consistent with those 
reports is the fact that PARP1 possesses a canonical TRF2-interacting motif (F/Y-X-L-X-
P): 737YTLIP741 (Chen et al. 2008).  Reports of the role of PARP1 in MEFs are conflicting: 
certain PARP1-/- MEFs exhibit telomere shortening (Gomez et al. 2006, Wang et al. 2007), 
whereas in other studies reported there was no appreciable telomere phenotype (Samper 
et al. 2001).  Our data strongly suggest that one of the critical roles of PARP1 in human 
somatic cells is to maintain telomeric integrity.  The most likely scenario is that PARP1 is 
preferentially recruited to telomeres, through its interaction with Shelterin, to help regulate 
the repair of SSBs caused, or encountered by, the DNA replication machinery.  Thus, the 
absence of PARP1 could result in the conversion of these telomeric SSBs to DSBs by 
DNA replication, resulting in a telomere shortening phenotype, DNA DSB signaling, and 
genomic instability — all of which we observed (Figs. 3.8 and 3.9).  Importantly, we do not 
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suggest that PARP1 is a telomere lengthening protein; it does not function akin to 
telomerase and the re-introduction of PARP1 to PARP1-null cells did not result in 
extensive telomere elongation.  Rather, we posit that the presence of PARP1 allows for 
longer telomeres to maintain their stability.  This is evidenced by the variation we observed 
in the extent of the telomere length restoration in PARP1-null complemented cells.  The 
absence of PARP1 does cause telomere shortening (albeit indirectly), but the re-
expression of PARP1 in these cells only allowed cells to stabilize the longer telomeres 
that were subsequently generated by the clonal variation in telomerase-positive cancer 
cells (Fig. 3.8).  Thus, we conclude that PARP1’s primary role is in preserving telomere 
length. 
Recently, our laboratories have examined the contributions of the C-NHEJ and A-
NHEJ pathways in facilitating the fusion of short dysfunctional telomeres in human cells 
following replicative erosion (Jones et al. 2014, Liddiard et al. 2016).  These studies 
identified LIG 3 as being essential for cells to escape the subsequent crisis and survive 
(Jones et al. 2014).  Here we utilized this assay to confirm that PARP1-null cells have a 
role in telomere length maintenance.  Thus, the expression of DN-hTERT in cells shortens 
their telomeres and forces them into a telomere crisis.  In order to survive this crisis, cells 
must somehow re-establish telomere lengthening and then stabilize these new telomeres.  
The near inability of PARP1-null cells to do this (Fig. 3.10) is completely consistent with 
our posited role for PARP1 in telomere length maintenance. 
Finally, we note that our data have clinical implications.  Thus, PARP1 inhibitors are 
currently being extensively utilized in the clinic.  Our demonstration here that the absence 
of PARP1 in human cells leads to aberrant telomere maintenance suggests that there may 
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be significant long-term repercussions to the chemical inhibition of PARP1 in human cells 
that might not be immediately evident. 
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Materials and Methods 
 
Cell culture 
HCT116 cells were purchased from the ATCC and maintained in McCoy’s 5A media 
supplemented with 10% FBS, 1% glutamine, and 1% penicillin/streptomycin.  Cells were 
maintained in 10 cm plates and passaged every 3 to 5 days.  To initiate telomere erosion 
in HCT116 cells expressing DN-hTERT, the cells were transduced with amphotropic 
retroviral vectors containing a DN-hTERT cDNA (Hahn et al. 1999) as described (Preto et 
al. 2004).  For cell synchronization studies, cells were cultured for 16 hr in McCoy’s 5A 
media containing 0.1% FBS, and subsequently grown in 2 mM thymidine for 24 hr.  Cells 
were then released into complete McCoy’s 5A media and collected by trypsinization at the 
indicated times. 
 
Gene targeting and PARP1 knockouts 
The PARP1 gene knockout by exon replacement with rAAV was performed by rAAV-
mediated gene targeting.  Briefly, homology arms were constructed by PCR, flanked by a 
LoxP-IRES-Neo-LoxP cassette, and ligated into an rAAV production vector.  Producer 
293-AAV cells were co-transfected with pAAV Helper and pAAV Rep/Cap, as described 
(Khan et al. 2011).  Target wild type HCT116 cells (1 x 105) were plated approximately 24 
hr prior to rAAV-infection in a 6-well plate.  Cells were infected with virus-containing media, 
and 48 hr-post infection, the cells were single-cell subcloned in the presence of 0.5 mg/mL 
G418.  Drug-resistant colonies were collected ~2 weeks after infection, and the correct 
replacement of exon 4 was screened by PCR.  Correctly targeted clones were plated (1 x 
105) and infected with an adenoviral vector expressing the Cre-recombinase to remove 
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the drug selectable marker by Cre-recombination.  Cells were again single cell sub-cloned, 
and screened for correct Cre recombination events by PCR flanking exon 4.  This process 
was repeated stepwise to remove the second PARP1 allele. 
 
DNA repair assays 
All transfections were performed on 5 x 105 cells with Lipofectamine 3000 in 6-well 
plates, which had been subcultured 24 hr prior to transfection.  For the A-NHEJ reporter 
assay, we transfected 2.5 µg of linearized pDVG94 into target cells and allowed 24 hr for 
repair.  The cells were subsequently collected by trypsinization, and re-circularized 
plasmids were recovered using conventional small-scale plasmid DNA isolation, as proper 
repair of the linearized junction by human cells creates a circularized DNA product which 
is accordingly recoverable.  Repaired DNA junctions were PCR amplified using the FM30 
and DAR5 primers (Verkaik et al. 2002).  PCR products were then digested with the BstXI 
restriction enzyme.  Digested PCR products were resolved by electrophoresis on a 6% 
polyacrylamide gel.  The gel was then stained with SybrGold and imaged on a Typhoon 
FLA 9500 imager. 
For the FACS-based NHEJ reporter assay, we first subcloned the ISce-I coding 
sequences from an expression plasmid (Jasin 1996) and added a C-terminal T2A-
mCherry epitope by fusion PCR.  We then cloned this expression construct into a pcDNA 
3.1 expression vector.  For each NHEJ FACS assay, 1.25 µg of pGEM-Ad2-EGFP was 
co-transfected with the ISceI-T2A-mChery plasmid into 5 x 105 cells in 6-well plates.  24 
hr following transfection, cells were collected by trypsinization, fixed with 4% 
formaldehyde, and subjected to FACS analysis. 
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Telomere/terminal restriction fragment (TRF) assay 
Genomic DNA was extracted from ~1 x 107 cells, and 50 µg of genomic DNA was 
digested with HinfI and RsaI, as described (Henson et al. 2009).  For each sample, 12 µg 
of digested genomic DNA was resolved overnight on a 0.7% agarose 1 x TBE gel.  This 
gel was depurinated, denatured, and neutralized, followed by overnight capillary transfer 
to a nitrocellulose membrane.  The membranes were pre-hybridized for 1 hr with Church’s 
buffer, then hybridized with a γ-P32-endlabeled telomere probe in 4X SSC at 55oC 
overnight.  Membranes were washed 3 times with 4X SSC and once with 4X SSC + 0.1% 
SDS, each for 30 min, exposed to a phosphorimaging screen, and detected and 
quantitated with a Typhoon phosphoimager. 
 
Immunofluorescence and telomere FISH (IF-FISH) 
This assay was performed as described (Conomos et al. 2014, Napier et al. 2015).  
Briefly, cells (1 x 105) were plated on chamber slides, and allowed to grow for 24 hr.  Cells 
were washed once with PBS, then fixed with 4% formaldehyde in 1X PBS.  Blocking and 
RNaseA treatment (0.1 mg/mL) were performed in antibody dilution media (ABDIL; 20 mM 
Tris-HCl pH 7.4, 0.2% fish gelatin, 2% BSA, 0.1% Triton X-100, 150 mM NaCl, and 0.1% 
sodium azide) at room temperature for 30 min.  Cells were stained with a 53BP1 antibody 
(Ab36823), which was diluted in ABDIL for 1 hr, washed 3 times with 1X PBS + 
0.1%Tween-20 (PBST), and incubated with an Alexa-488 goat IgG secondary antibody 
diluted in ABDIL for 1 hr.  Cells were washed in PBST, fixed with 4% formaldehyde and 
prepared for FISH hybridization.  A Telo-C PNA probe was hybridized to the slides at 80o 
in hybridization buffer (10 mM Tris-HCl pH 7.4, 4 mM Na2HPO4, 0.5 mM citric acid, 1.25 
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mM MgCl2, 0.25% blocking reagent and 70% formamide).  Slides were washed, 
counterstained with DAPI, and mounted with ProLong Gold (ThermoFisher).  Microscopy 
was performed with a Nikon-TiE deconvolution bright-field microscope with a 60X 
objective. 
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Tables 
 
Table 3.1.  PARP1 gene targeting results 
Desired Genotype  Targeted/Random 
Insertion 
Number of 
Targeted Clones 
Expected Number of 
Desired Clones 
Parp1+/- 23/96 23 23 
Parp1-/- 72/139 3 36 
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Figures  
Figure 3.1 
 
Figure 3.1.  Construction and confirmation of PARP1-null cells  
A)  PARP1 knockout HCT116 cells were constructed by rAAV-mediated gene targeting.  
Exon replacement of the 4th exon (open green rectangle) of the PARP1 gene with a floxed, 
Neo-cassette (orange rectangle) occurs by HDR, which can be subsequently removed by 
Cre-recombinase to result in the removal of the 4th exon, causing a frame-shift mutation.  
Two rounds of gene targeting were performed to eliminate both alleles in this diploid cell 
line.  Red arrows depict PCR primers to monitor gene status.  Red triangles represent 
LoxP sites.  B)  PCR confirming the conversion of one wild-type (WT) allele to a null allele 
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in a PARP1+/- cell and the conversion of both wild-type alleles to null in PARP1-/- null cells.  
C)  Western blot confirmation of the loss of PARP1 expression and confirmation of 
complementation of the null cells with PARP1 protein.  D)  A PARP1 activity assay 
demonstrates that the wild type and indicated complemented cells exhibited WT-levels of 
parylation, while the null cells lacked such activity.  E)  Growth curve depicting that the 
absence of PARP1 results in a slow growth phenotype.  
  
  116 
Figure 3.2 
 
Figure 3.2.  Characterization of the 3 independent PARP1-null cell lines. 
A) A PCR analysis is shown using primers that flanked exon 4.  The wild type (WT) allele 
PCR product migrates slightly slower than the PCR product corresponding to the null 
allele.  The genotypes and clone designations are shown above the gel.  B) PARP1-null 
cell lines show a significant proliferation defect.  Cells from the indicated cell lines were 
seeded into dishes and then the total cell number was monitored by trypan blue staining 
at days 4 to 7 post plating.  C) A Western blot analysis of the PARP1-null subclone #22 
cell line.  PARP1 protein is shown in green and as a loading control, the Ku70 protein is 
shown in red.  The red smears on the far left in the unmarked lane are protein standard 
markers.  PARP1-null clones expressing only the empty vector contained no detectable 
PARP1 protein whereas the complemented clones expressed various levels of PARP1 
protein. 
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Figure 3.3 
 
 
Figure 3.3.  Parp1-null cells exhibit a G2-growth arrest. 
 A)  The DNA content of asynchronously growing cells exhibited a modest, constitutive G2 
cell cycle accumulation.  B)  A time course study of thymidine-block synchronized cells.  
After release, all cells appeared to progress through S-phase at approximately the same 
rate, but many PARP1-null cells did not progress through mitosis, but rather exhibited a 
G2/M cell cycle accumulation.  C)  Western blot evidence for increased p53 expression in 
PARP1-/- cells.  Ku70 was used as a loading control. 
  
  118 
Figure 3.4 
 
 
Figure 3.4.  Levels of p53 protein in the PARP1-null cells. 
The indicated cell lines were exposed to +/- 25 J/m2 UV radiation, and whole cell lysates 
were collected 24 hr later.  Western blot analyses were subsequently performed for 
PARP1, p53, and, as a loading control, Ku70.  The PARP1-/- cells exhibited elevated levels 
of spontaneous p53 signaling.  However, all the cell lines were capable of additional 
signaling via increased p53 expression following UV irradiation.  
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Figure 3.5 
 
Figure 3.5.  The impact of the absence of PARP1 on A- or C-NHEJ. 
 A) Schematic of the pDVG94 plasmid.  B) The indicated cell lines were treated with 1 µM 
of the DNA-PKcs inhibitor, NU7441, for 4 hr, and then transfected with linearized pDVG94.  
Cells were allowed 24 hr to repair the linearized template (still in the presence or absence 
of inhibitor), then plasmids were extracted, and the region spanning the cut site was 
amplified by PCR, followed by digestion with BstXI.  C) Quantitation of three experiments 
similar to panel B.  PARP1-/- cells exhibited a significant (p = 0.01) ~2-fold  reduction in 
baseline A-NHEJ activity but were not statistically different from wild type cells under 
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induced conditions.  D)  The indicated cell lines were transfected with linearized pGEM-
Ad2-EGFP plasmid and subjected to flow cytometry analysis.  Only DNA LIG4-/- cells 
exhibited a significant defect in DNA repair. 
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Figure 3.6 
 
 
Figure 3.6.  PARP1 inhibition does not affect A-NHEJ activity.   
The indicated cell lines were either left untreated (-) or treated (+) with 3 µM of olaparib, a 
PARP1 inhibitor, for 4 hr, and then transfected with a linearized pDVG94 plasmid.  The 
indicated cell lines were allowed 24 hr to repair the linearized template (still in the presence 
or absence of inhibitor), and then plasmids were extracted, and the region spanning the 
cut-site was amplified by PCR, digested with the BstXI restriction enzyme and then 
analyzed by gel electrophoresis.  The % of A-NHEJ, as described in the legend to Fig. 3B, 
was determined and is shown below the gel.  N.B.  The sensitivity of HDR-defective 
(FANCA-null) cells to the same concentration of olaparib was used as a positive control 
to demonstrate that the olaparib used in this experiment was active (data not shown). 
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Figure 3.7 
 
Figure 3.7. The absence of PARP1 does not affect C-NHEJ activity. 
  A) Schematic of the pGEM-Ad2-EGFP NHEJ reporter.  The rectangular boxes 
correspond to the indicated protein open reading frames.  SD and SA indicate splice donor 
and acceptor sequences.  This reporter must be linearized and repaired within the 
indicated intronic regions (resulting in the lack of retention of the Ad sequences), to enable 
GFP expression.  B) A schematic of the mCherry vector used in this assay to control for 
transfection efficiency.  C) A representative set of FACS images for the indicated cell lines.  
The numbers within the panels represent the fraction of cells that were GFP or RFP 
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positive, respectively.  The formula for determining the percent repair is shown below the 
panels.  Only the LIG4-null cells were deficient in this assay (see Fig. 3.5d). 
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Figure 3.8 
 
 
Figure 3.8.  PARP1-null cells exhibit telomere dysfunction.   
A) PARP1-null cells have an increased frequency of signal free ends, which is quantified 
in (B). Metaphase spreads were prepared from the indicated cell lines and then stain with 
a telomeric PNA probe (red spots) and then counter-stained with DAPI (blue).  C)  A TRF 
analysis of the the telomere length of the indicated cell lines.  For many of the cell lines, 
independent subclones were isolated and these are indicated by the clone #.  Genomic 
DNA from the indicated cell lines was prepared, digested to completion with frequent 
cutting restriction enzymes and the residual DNA was electrophoresed onto an agarose 
gel and then transferred to nitrocellulose.  The blot was subsequently hybridized with a 
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radioactive telomeric probe.  Since telomere length is variable from chromosome end to 
chromosome end and from cell to cell, a smear results.  The mid-point of the telomeric 
smear is indicated with a green point.  D) PARP1-/- cells have short telomeres, which can 
be rescued by complementation.  In order to evaluate the clonal effect of telomere length, 
we derived empty vector containing (yellow rectangles), and complemented clones (green 
rectangles), from a given parental null clone (red rectangle) and then determined their 
telomere length by TRF analysis as shown in (C).  The average telomere length by as 
determined by densitometry is shown. 
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Figure 3.9 
 
Figure 3.9.  Spontaneous DNA damage foci in PARP1-/- cells co-localize with 
telomeres. 
A) The indicated cells were immunostained for 53BP1 (green), fixed, and then 
subsequently probed for telomeric DNA with a PNA FISH probe (red) and for total DNA 
with DAPI (blue).  PARP1-/- cells had an elevated level of 53BP1 foci, which tended to 
colocalize with telomeric DNA.  B) The number of telomeric ends and overlapping 53BP1 
foci (TIFs) on a per cell basis from images similar to panel (A) were averaged and graphed 
+/-1 standard deviation.  PARP1-/- cells had a statistically significant increase in the 
frequency of TIFs compared to the control cell lines.  C) Quantification of just 53BP1 
foci/cell on a per cell basis from images similar to panel (A) were averaged and graphed 
+/-1 standard deviation.  PARP1-/- cells had an increased level of endogenous 53BP1 foci, 
which was indicative of DNA damage. 
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Figure 3.10 
 
Figure 3.10. PARP1-/- cells are severely compromised in surviving telomeric stress.  
 Growth curves plotting population doublings (PD) and days in culture.  Cells were 
transduced with lentiviruses encoding DNhTERT, which is causative of telomere erosion 
over time.  Each line represents an independent subclone.  For some of the wild type 
cones the experiment was intentionally terminated after 80 days and for other only after 
120 days.  For PARP1-null cells, only a single subclone (green line) survived beyond 40 
days. 
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Synopsis 
 
The unlimited proliferation of cancer cells requires a mechanism to prevent telomere 
shortening.  ALT is a homologous recombination-mediated mechanism of telomere 
elongation used in tumors, including osteosarcomas, soft tissue sarcoma subtypes, and 
glial brain tumors.  Mutations in the ATRX/DAXX chromatin remodeling complex have 
been reported in tumors and cell lines that use the ALT mechanism, suggesting that ATRX 
may be an ALT repressor.  We show here that knockout or knockdown of ATRX in mortal 
cells or immortal telomerase-positive cells is insufficient to activate ALT.  Notably, 
however, in SV40-transformed mortal fibroblasts ATRX loss results in either a significant 
increase in the proportion of cell lines activating ALT (instead of telomerase) or in a 
significant decrease in the time prior to ALT activation.  These data indicate that loss of 
ATRX function cooperates with one or more as-yet unidentified genetic or epigenetic 
alterations to activate ALT.  Moreover, transient ATRX expression in ALT positive/ATRX-
negative cells represses ALT activity.  These data provide the first direct, functional 
evidence that ATRX represses ALT. 
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Introduction 
 
Telomeres are repetitive DNA structures located at the ends of chromosomes that 
shorten with each cell division (Harley et al. 1990).  When telomeres become sufficiently 
shortened, the cell will enter a permanent proliferation arrest termed senescence. In order 
to become immortalized, cancer cells require a mechanism of telomere length 
maintenance.  There are two mechanisms currently known to maintain telomere length in 
human cells: the reverse transcriptase enzyme telomerase and the recombination-
mediated DNA synthesis mechanism called ALT (Greider and Blackburn 1985, Bryan et 
al. 1995).  Telomerase activation can occur through numerous means, including loss of 
repressors, transcriptional upregulation or amplification of the genes encoding a 
telomerase subunit, TERT and/or TERC, and mutations in the TERT promoter (Reddel 
2014).  Somatic cell hybridization analyses showed that ALT activation occurs through 
loss of one or more repressor molecules that are present in normal somatic cells and in 
telomerase positive cells (Bryan et al. 1995, Perrem et al. 1999).  More recently, it was 
found that inactivating mutations in one or other of the genes encoding the ATRX/DAXX 
chromatin remodeling complex, most commonly ATRX, are very common in ALT positive 
tumors and cell lines (Heaphy et al. 2011, Cheung et al. 2012, Lovejoy et al. 2012, 
Schwartzentruber et al. 2012, Chen et al. 2014).  ATRX loss was also highly correlated 
with ALT in a panel of 19 ALT/telomerase cell line hybrids (Bower et al. 2012).  ATRX has 
been proposed to have numerous diverse functions, including chromatin remodeling, viral 
resistance, and fidelity of chromatin separation during cell division, as well as binding to 
tandem DNA repeats (Xue et al. 2003, Ritchie et al. 2008, Law et al. 2010, Lukashchuk 
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and Everett 2010). Nonetheless, these data suggest the hypothesis that ATRX may be an 
ALT repressor. 
In human cell culture models of immortalization, the first events required for this 
process usually involve inactivation of the p53 and pRB/p16INK4a tumor suppressor 
pathways by, for example, expression of one or more oncoproteins such as the SV40 large 
T antigen, which allows the cells to continue dividing beyond the point at which control 
cultures become senescent.  After a finite number of additional cell divisions, however, the 
cells cease proliferation and the culture enters crisis, until a rare cell (approximately 1 in 
107 fibroblasts and 1 in 105 epithelial cells) escapes crisis through spontaneous activation 
of a TEM, and the cell culture becomes immortal (Girardi et al. 1966, Huschtscha and 
Holliday 1983, Ide et al. 1984, Counter et al. 1992).  In fibroblast cultures, the probability 
that ALT will be activated is approximately the same as for activation of telomerase, 
whereas epithelial cells are much more likely to activate telomerase; this reflects the 
situation in human cancers where carcinomas are usually telomerase-positive and ALT is 
most prevalent in cancers of mesenchymal origin (Colgin and Reddel 1999).  It has long 
been assumed that activation of a TEM and escape from crisis involves spontaneous 
genetic or epigenetic events, that different events are required for activation of ALT and 
telomerase and, based on the frequency of their occurrence, that activation of each TEM 
requires one or more "hits". 
In this study, we determined whether loss of ATRX is one of the genetic events 
involved in activating ALT, comparing epithelial cells with fibroblasts.  To this end, we 
genetically disrupted ATRX in immortal telomerase positive epithelial cells to determine 
whether loss of ATRX was sufficient to activate ALT.  As these cells did not activate the 
ALT mechanism, we went on to knock down ATRX in SV40-transformed pre-crisis cells.  
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In cells of epithelial origin, a reduction in ATRX also did not lead to ALT activation.  
However, in pre-crisis SV40-transformed fibroblasts derived from two different sources, 
the knockdown of ATRX led either to an increased frequency of ALT activation or a 
decrease in the time of crisis prior to immortalization via the ALT mechanism.  Just as 
importantly, the transient expression of exogenous ATRX in three independent ALT-
positive, ATRX-negative cell lines led to a reduction in C-circles and APBs, two markers 
of ALT activity.  These data provide the first functional evidence that ATRX acts as a 
repressor of the ALT mechanism in cells of mesenchymal origin. 
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Results 
 
ATRX gene knockout does not activate ALT in a telomerase-positive cell line 
Previous findings in tumor cells and cell lines have shown a correlation between ALT 
and absence of ATRX at the protein or gene level.  To determine whether knockout of 
ATRX in the telomerase-positive epithelial cell line HCT116 activated the ALT mechanism, 
we used two targeting strategies: CRISPR/CRISPR-associated systems (Cas)9 and 
recombinant adeno-associated virus (rAAV). Following single cell cloning of HCT116 cells 
co-transfected with CRISPR/Cas9 (Chen et al. 2013), correctly targeted clones were 
identified by restriction enzyme analysis of a PCR product that encompassed the CRISPR 
target (Figure 4.1A).  HCT116 clones with a disrupted ATRX were resistant to digestion 
with the SmlI restriction enzyme due to removal of the SmlI recognition site, which was 
verified by Sanger sequencing.  As a second method to knock out ATRX, an rAAV gene 
targeting vector was constructed to replace exon 5 of ATRX, and four clones resistant to 
G418 were analyzed for correct integration of the construct using primers that flank the 
proposed integration site (Figure 4.1B).  Absence of ATRX protein expression in knockout 
clones constructed using either the CRISPR/Cas9 or rAAV method was confirmed by 
Western blot (Figure 4.1C). 
We analyzed the ATRX knockout HCT116 cells to determine whether the ALT 
mechanism was activated. Similar to wild-type HCT116 cells, ATRX knockout HCT116 
cells were negative for C-circles, partially single-stranded circles of C-rich telomeric DNA 
that are highly associated with the ALT mechanism (Henson et al. 2009) (Figure 1D).  We 
also found all ATRX knockout HCT116 clones expressed telomerase activity as 
determined by the TRAP assay (Figure 4.1E).  Telomere length was assessed by 
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Southern blot 29 population doublings (PDs) after cloning and did not show the elongated 
and heterogeneous telomere length profile that is characteristic of cells that utilize ALT 
(Figure 4.1F).  These data demonstrate that the knockout of ATRX in telomerase-positive 
carcinoma cells is not sufficient to activate the ALT mechanism. 
 
ATRX depletion in epithelial cells does not promote ALT activation 
Epithelial-derived cell lines and tumors preferentially activate telomerase (Colgin and 
Reddel 1999, Henson et al. 2009), and cells that are telomerase-positive generally 
express ATRX (Bower et al. 2012, Lovejoy et al. 2012).  We therefore determined whether 
loss of ATRX promoted ALT activation in SV40-transformed mammary epithelial cells.  
Two epithelial cell strains derived from individual SV40-transformation events, Bre80 T5 
and Bre80 T8, were transduced with an empty vector (vector), scrambled control shRNA 
(sc), green fluorescent protein (GFP), or an shRNA targeting ATRX or DAXX.  One of five 
control cultures (Bre80 T5 GFP; Table 1), and six of ten shATRX or shDAXX cultures 
emerged from crisis.  Each immortal line was assessed for ATRX and DAXX expression 
(Figure 4.2A).  Bre80 T5 GFP cells expressed ATRX and DAXX protein.  The four shATRX 
and two shDAXX immortal lines lacked ATRX and DAXX expression, respectively. 
All immortal cultures exhibited a period of crisis that ranged from 64 to 166 days 
(Figure 4.2B).  All immortal cultures were positive by the TRAP assay for telomerase 
activity (Figure 4.2C) and negative for the presence of C-circles (Figure 4.2D), together 
indicating that all seven cultures activated telomerase.  These results demonstrate that 
ATRX depletion in epithelial cells does not promote ALT activation.  Furthermore, these 
data, together with the HCT116 ATRX knockout data, indicate that neither telomerase 
activity nor activation of telomerase is dependent upon the presence of ATRX. 
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ATRX knockdown in fibroblasts increases the proportion of cells activating ALT 
Since we did not obtain any immortal epithelial cell lines that had activated the ALT 
mechanism, we next examined the effect of ATRX depletion in fibroblasts.  The prevalence 
of ALT in tumors is skewed towards those of mesenchymal origin (Ulaner et al. 2003, 
Henson and Reddel 2010, Heaphy et al. 2011).  We therefore determined whether 
fibroblasts derived from the same breast sample as Bre80 epithelial cells, with a similar 
genetic background, had a greater propensity toward ALT activation when ATRX 
expression was depleted.  Two independent SV40-transformed, mortal breast fibroblast 
cultures, Fre80-3T and Fre80-4Tii, were transduced with either a vector encoding a 
scrambled shRNA sequence or an shATRX vector.  Transduced cells and untransduced 
(parental) controls were maintained in culture until cultures either escaped from crisis and 
became immortal, or failed to escape from crisis and became non-viable. ATRX and DAXX 
proteins were both expressed by each control (scrambled shRNA or parental) culture, and 
ATRX was efficiently suppressed in each shATRX culture at a pre-crisis time point (Figure 
4.3A).  Six out of 13 control cell strains became immortalized, whereas 12 of 16 
shATRXtransduced cultures became immortal (Table 4.1).  Expression of ATRX and 
DAXX proteins in the immortalized cultures (Figure 4.3B) remained similar to that of pre-
crisis cells.  All immortal cultures exhibited a period of crisis, and the mean length of crisis 
between control and shATRX cultures was not significantly different (50 versus 52 days; 
Table 4.1).  The TEM of each immortal culture was determined using the TRAP and C-
circle assays.  Of six control cultures that became immortal, five cultures exhibited 
telomerase activity by the TRAP assay, while the remaining culture was negative for 
telomerase activity (Figure 4.3C).  Only two of 12 immortal shATRX cell lines showed 
telomerase activity.  The results of the C-circle assay correlated inversely with those of 
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the TRAP assay: each TRAP positive sample was negative for C-circles, and vice versa 
(Figure 4.3D).  The results demonstrate that the induced loss of ATRX significantly 
promotes ALT activation, as 10 of 12 shATRX-transduced cultures activated the ALT 
mechanism, while only one of six control cultures was ALT-positive (p = 0.01, Fisher’s 
exact test).  These data provide the first functional evidence that, in fibroblasts, ATRX loss 
facilitates ALT activation. 
 
ATRX knockdown decreases the time required for occurrence of immortalization  
We then depleted ATRX in two clonal SV40-transformed pre-crisis fibroblast strains 
from a different source. In addition, we also knocked down DAXX, as both proteins act 
together as chromatin remodelers and one or both is mutated in pancreatic 
neuroendocrine tumors with an ALT-like phenotype (Lewis et al. 2010, Heaphy et al. 
2011).  ATRX and DAXX proteins were expressed by both pre-crisis strains (JFCF6/T.1/P 
and JFCF-6/T.5K) (Figure 4.4A, lanes labeled parental and mortal).  shATRX and shDAXX 
lentivirus were used to efficiently knock down ATRX or DAXX in both fibroblast cell strains 
(Figure 4.4A, shATRX and shDAXX mortal samples).  Transduction of the empty vector 
(vector) or scrambled shRNA control (sc) did not affect endogenous ATRX or DAXX 
expression.  Each mortal culture was passaged through a period of crisis until it became 
immortal.  Growth curves were plotted for each cell line to examine whether there was a 
change in the length of crisis in shATRX or shDAXX cultures compared to controls (Figure 
4.4B).  Six out of eight control cultures showed a distinct period of crisis, ranging from 13 
to 78 days (Table 4.1).  Compared to immortal control cultures, shATRX- or shDAXX-
transduced cell lines became immortalized after a significantly reduced length of time in 
crisis (range: 0 to 28 days; p < 0.05, Mann Whitney test). 
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Spontaneous loss of ATRX expression is also associated with the activation of ALT  
ATRX and DAXX protein expression was analyzed in each immortal JFCF-6 cell line 
(Figure 4A, immortal lanes).  ATRX expression was spontaneously lost in 7 of 8 immortal 
control cultures, as well as in one immortal shDAXX culture.  In contrast, spontaneous 
loss of DAXX was not observed in any immortal culture.  ATRX knockdown was 
maintained in all shATRX-transduced cultures after they became immortalized.  Similarly, 
substantial knockdown of DAXX was maintained after immortalization of both shDAXX-
transduced cultures.  We sequenced all 35 exons of ATRX to determine whether ATRX 
protein loss was due to mutation, and identified a premature stop codon in two cell lines 
that spontaneously lost ATRX expression (ATRX exon 9 of the JFCF-6/T.5K-vector cell 
line and ATRX exon 10 of the JFCF-6/T.5K-shDAXX culture).  The ATRX sequence was 
wildtype in the remaining six immortal cultures that spontaneously lost ATRX expression, 
indicating that in these cells ATRX protein is not expressed for reasons other than changes 
in the coding sequence. 
We examined the temporal correlation between spontaneous loss of ATRX expression 
and crisis in three JFCF-6/T.1/P lines, two of which (unmodified parental and vector-
transduced) spontaneously lost, and one of which (sc1) maintained ATRX protein 
expression after immortalization (Figure 4.5). In both JFCF-6/T.1/P-parental and -vector 
lines, spontaneous loss of ATRX occurred early during culture crisis.  In contrast, the 
JFCF-6/T.1/P-sc1 culture maintained ATRX expression through crisis.  These data 
demonstrate that spontaneous loss of ATRX can be an early event in the process of 
cellular immortalization. 
The TEM that was activated in each immortal JFCF-6/T.1/P- and JFCF-6/T.5K-derived 
culture was assessed.  Every culture was negative for telomerase activity, both before and 
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after immortalization, as demonstrated by the TRAP assay (Figure 4.6A).  All cultures were 
negative for C-circles prior to immortalization and all post-crisis cultures were C-circle 
positive (Figure 4.6B).  Telomere length was assessed by Southern blot in each cell line 
at a minimum of two time points, before and after immortalization, and in each case the 
immortalized cultures exhibited the heterogeneous telomere length pattern characteristic 
of ALT, contrasting with the more homogeneous telomere lengths in the pre-crisis cells 
(Figure 4.6C).  Thus, all immortal JFCF-6-derived fibroblast cell lines activated the ALT 
mechanism: eight control and 10 shATRX/shDAXX cultures.  Spontaneous loss of ATRX 
was observed in 7 of 8 control cultures and in one shDAXX cell line.  These data are clear 
confirmation that ATRX loss facilitates ALT activation in fibroblasts. 
 
ATRX expression represses the ALT phenotype  
Given that the loss of ATRX promoted activation of the ALT mechanism in fibroblasts, 
we wanted to determine whether restoration of ATRX expression would repress the ALT 
phenotype.  Exogenous ATRX was expressed in three ALT cell lines of mesenchymal 
origin that lack ATRX expression (GM847, JFCF-6/T.5K-sc1 and U-2 OS).  ATRX protein 
expression was examined at 2, 4, 6 and 8 days following transfection with an empty vector 
(EV) or an ATRX expression construct.  Maximal ATRX protein expression was observed 
2 days following transfection, and decreased rapidly, returning to undetectable levels by 
day 6 in all cell lines examined (Figure 4.7A).  Exogenous expression of ATRX did not 
affect DAXX expression in any cell line.  Furthermore, ATRX transfection did not affect the 
growth rate or cell cycle kinetics in any of the three cell lines tested (data not shown). 
As C-circle levels are indicative of ALT and rapidly respond to perturbations in ALT 
activity (Henson et al. 2009), we determined whether C-circle levels changed in response 
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to ATRX transfection.  The level of C-circles was significantly reduced following ATRX 
expression in each of the three cell lines examined compared to untreated, FuGENE-
treated or EV-transfected cells (Figure 4.7B). 
APBs are highly correlative with the ALT mechanism (Yeager et al. 1999), and 
previous studies have demonstrated inhibition of ALT activity results in a decrease in 
APBs (Jiang et al. 2005).  Therefore, as a further indication that ATRX expression affects 
the ALT phenotype, APBs were quantified in ALT cells transiently expressing ATRX.  The 
percentage of ATRX-positive nuclei that also contained APBs was significantly reduced 
compared to the level of APB-positive nuclei in EV-transfected cultures at days 2 and 4 in 
all cell lines examined (Figure 4.7C).  By day 6, there were insufficient ATRX-positive 
nuclei to count ATRX-positive/APB-positive nuclei.  These results provide further direct 
evidence that ATRX represses the ALT mechanism. 
As an additional control, GM847 cells were transfected either with an EV or a plasmid 
encoding GFP.  The percentage of GM847 nuclei that were positive for both GFP and 
APBs (80, 81 and 80% at days 2, 4 and 6, respectively) was not significantly different to 
the percentage of APB-positive nuclei in an EV-transfected culture (75, 87 and 81% at 
days 2, 4 and 6, respectively).  These data confirm that the percentage of nuclei containing 
APBs was not affected by expression of an irrelevant exogenous protein.  We also 
examined whether transient ATRX expression affected mean telomere length or the 
overall telomere length heterogeneity.  Neither the mean telomere length nor the telomere 
length heterogeneity of GM847, JFCF-6/T.5K-sc1 or U-2 OS was affected by the transient 
expression of ATRX (Figure 4.7D).  Therefore rapid changes in telomere length did not 
occur in response to transient ATRX expression in ALT cells, and long-term ATRX 
expression may be required for changes in telomere length to occur. 
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Discussion  
 
Mutations in members of the ATRX/DAXX chromatin remodeling complex have been 
implicated in the ALT mechanism, in both ALT positive cell lines and tumor samples 
(Henson and Reddel 2010, Heaphy et al. 2011, Bower et al. 2012, Lovejoy et al. 2012).  
Although a previous study was unable to demonstrate immortalization of SV40-
transformed BJ fibroblasts following ATRX knockdown (Lovejoy et al. 2012), we found that 
depletion of ATRX facilitates immortalization of fibroblasts, increasing the proportion of 
cells that activate ALT compared to telomerase activation (Fre80 cultures) and decreasing 
the time in crisis prior to immortalization (JFCF-6 cultures).  There was no evidence that 
the effect of ATRX depletion was different in these two sets of cultures: there was an 
insufficient number of Fre80 cultures which spontaneously activated ALT in the absence 
of ATRX knockdown to see a significant effect on length of crisis and, conversely, all of 
the spontaneously immortalized JFCF-6 cultures in this study activated ALT, making it 
impossible to observe an increased proportion of ALT-positive cultures following ATRX 
knockdown.  The data are consistent with the hypothesis that 1) activation of ALT and 
telomerase in the context of inactivated p53 and pRb/p16INK4a tumor suppressor 
pathways each requires at least two genetic or epigenetic events, 2) that the events are 
different for the two TEMs, and 3) that one of the events for activating ALT is the loss of 
ATRX function.  In pre-crisis cells that have undergone none of the events required for 
activation of either ALT or telomerase, experimentally depleting ATRX would result in 
fewer additional events being required for activation of ALT, which would both increase 
the probability that ALT becomes activated and decrease the time required for 
immortalization to occur. 
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Spontaneous ATRX loss was observed in eight immortal JFCF-6 fibroblast cultures; 
the time course of ATRX loss was examined in two of these cultures, and in both cases 
this occurred early in crisis.  This is also consistent with the hypothesis that ATRX loss-of-
function is one of at least two genetic events required for escape from crisis via activation 
of ALT.  It is not possible to conclude from this limited number of observations whether 
ATRX loss is usually the first event, possibly contributing to the probability that the 
additional event(s) will occur, or whether the order of the events is stochastic.  The reason 
for spontaneous ATRX loss was determined to be a mutation that resulted in a premature 
stop codon in two immortal lines.  The absence of an exonic mutation in the other lines is 
consistent with a previous report of 12 ALT positive cell lines (including two JFCF-6 lines) 
that had wild-type ATRX sequence but lacked or had abnormal ATRX protein expression 
(Lovejoy et al. 2012).  Absence of ATRX protein expression in the presence of wild-type 
ATRX sequence may potentially be due to epigenetic changes, miRNA targeting or post-
translational modifications.  The presence of ATRX expression in a small number of ALT-
positive cell lines suggests that there are other proteins whose loss can have the same 
functional outcome as loss of ATRX expression.  The higher frequency of ALT activation 
in JFCF-6 compared to Fre80 cells may indicate that the respective pre-crisis cultures may 
have accumulated different pre-disposing genetic or epigenetic events.  Nevertheless, the 
activation of ALT in all cell lines that spontaneously lost ATRX provides additional 
evidence for its role as an ALT suppressor. 
Successful knockout of ATRX using CRISPR/Cas9 technology or rAAV in epithelial-
derived HCT116 colon carcinoma cells did not affect telomerase expression nor activate 
ALT.  This indicates that telomerase activity does not require the presence of functional 
ATRX.  The lack of any ALT immortalized epithelial cell lines in the breast epithelial cell 
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experiments, in contrast to the results with breast stromal fibroblasts derived from the 
same individual, is consistent with the observation that ALT positive tumors are more 
frequently of mesenchymal, rather than epithelial, origin (Henson et al. 2002) and support 
the concept that there are inherent cell type differences, and possibly requirements, with 
regard to cellular immortalization (Lafferty-Whyte et al. 2009).  The genetic events required 
to activate telomerase in cell types, including epithelia, where low levels of telomerase 
activity occur physiologically, may differ from the events required to activate telomerase 
in cell types such as fibroblasts where telomerase activity is normally undetectable, and 
presumably tightly repressed.  If this is the case, then in epithelial cells where ATRX is 
experimentally depleted, the probability of the additional events required to activate 
telomerase occurring may still be greater than the probability of activating ALT. 
Transient ATRX expression repressed the ALT mechanism in three separate ALT-
positive/ATRX-negative cell lines.  This is the first functional evidence that ATRX 
expression is able to repress the ALT mechanism.  ALT repression clearly resulted from 
ATRX expression, as when ATRX was expressed, both C-circle levels and the proportion 
of APB positive nuclei decreased.  Both C-circle and APB levels returned to control levels 
following the loss of ATRX protein overexpression.  The mechanism by which ATRX 
represses the phenotypic ALT markers is unknown but may include facilitating replication 
and resolving G-quadruplex secondary structures (Law et al. 2010).  An attractive 
alternative hypothesis is that the chromatin remodeling capabilities of ATRX are critical, 
as alterations in the heterochromatic state of telomeres and chromatin-associated proteins 
have been implicated in the ALT mechanism (Jiang et al. 2011, Conomos et al. 2014, 
Episkopou et al. 2014, O'Sullivan et al. 2014).  Thus, silencing of the histone chaperone 
ASF1 induces the ALT phenotype (O'Sullivan et al. 2014) and the NuRD-ZNF827 complex 
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is present at ALT telomeres and causes histone hypoacetylation, a marker of closed 
chromatin (Conomos et al. 2014).  Confusingly however, decondensation of telomeric 
chromatin, as determined by micrococcal nuclease digestion, has also been shown in ALT 
cells (Episkopou et al. 2014).  Despite these somewhat contradictory results implying that 
ALT telomeres may be more heterochromatic or euchromatic depending upon the model 
system utilized, a consistent feature is that chromatin is somehow altered in all these cells 
and that this alteration seems likely causative, rather than simply an indirect effect.  Further 
studies that determine the requirement for altered telomeric chromatin status in ALT, and 
how chromatin remodelers play an essential role in this process, are likely to yield 
important insights into the ALT mechanism. 
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Materials and Methods  
 
Cell culture  
JFCF-6/T.1/P and JFCF-6/T.5K cell strains were derived from independent 
SV40transformation events of mortal jejunal fibroblasts from a male cystic fibrosis patient.  
GM847DM cells (referred to as GM847) were derived from Lesch-Nyhan syndrome human 
fibroblasts immortalized with SV40 (Pereira-Smith and Smith 1988).  HT1080, 293 and U-
2 OS cells were obtained from the American Type Culture Collection (ATCC).  Two 
separate SV40-transformed breast stromal fibroblast cell strains, Fre80-3T and Fre80-
4Tii, were also used in the current studies (Kaul et al. 2011).  All of these strains and lines 
were cultured in DMEM with 10% fetal bovine serum (FBS).  Two individual SV40-
transformed Bre80 cell strains, breast stromal epithelial cells derived from the same 
individual as the Fre80 fibroblasts, were cultured in MCDB-170 serum-free medium (Life 
Technologies).  The HCT116 colon carcinoma cell line (ATCC) and its derivatives were 
cultured in McCoy’s 5A medium supplemented with 10% FBS, penicillin and streptomycin 
(each 100 U/mL), and 5 mM L-glutamine. All cultures were grown in a humidified incubator 
at 37oC with 5% CO2.  Crisis was defined as a time period during which the cell culture 
underwent less than 1 PD per 7 days.  The cell lines were confirmed to be free of 
Mycoplasma species and the identity confirmed using short tandem repeat profiling by 
CellBank Australia (Sydney, Australia). 
 
Lentiviral infection  
Lentiviral constructs encoding a scrambled control shRNA in one of two vectors 
(pLKO.1 or pLKO.5), GFP (pLKO.1 vector), shATRX [constructs 13590 (pLKO.1 vector) 
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and 342811 (pLKO.5 vector)] or shDAXX [construct 3800 (pLKO.1 vector)], as well as the 
pLKO.1 empty vector were obtained from Sigma.  Lentivirus was produced and target cells 
were infected with equivalent multiplicities of infection.  Infected cells were continuously 
cultured in medium supplemented with 0.5 µg/mL puromycin.  Three sublines were 
established from each JFCF-6/T.1/P- and JFCF-6/T.5KshATRX-1 mass culture prior to 
immortalization.  The following cell strains/lines were transduced with pLKO.1-scrambled: 
JFCF-6/T.1/P-sc1, JFCF-6/T.5K-sc1, Bre80 T5 sc, Fre80-3T sc1-3 and Fre80-4Tii sc1-3; 
the remaining scrambled-shRNA control lines were transduced with a pLKO.5scrambled 
shRNA vector.  Fre80-3T shATRX-1, Fre80-4Tii shATRX-4, Bre80 T5 shATRX-2 and 
Bre80 T8 shATRX-3, -4, -5 lines were transduced with shATRX construct 342811, while 
the remaining shATRX lines were transduced with shATRX construct 13590. 
 
Transfection  
An ATRX expression vector, pCMV6-Entry-ATRX, the empty vector pCMV6-Entry and 
a GFP-expressing vector, pCMV6-AC-GFP, were obtained from OriGene.  Transfection 
with either vector was performed using FuGENE reagent (Promega).  Cells were 
harvested at the indicated time points post-transfection and analyzed as described.  The 
mean percentage (± SEM) of ATRX-positive nuclei at day 2 in GM847, JFCF-6/T.5K-sc1 
and U-2 OS cells was 50 ± 11, 18 ± 2 and 26 ± 2%, respectively.  At day 4, the mean 
ATRX-positive nuclei percentage (± SEM) in GM847, JFCF-6/T.5Ksc1 and U-2 OS cells 
was 39 ± 17, 10 ± 2 and 19 ± 4%, respectively. 
 
  146 
CRISPR/Cas9 ATRX knockout   
The ATRX cDNA was screened by ZiFiT to determine a CRISPR target in exon 9 of 
ATRX (Hwang et al. 2013).  Two complementary oligos were designed by ZiFit, 
ATRXex9_1 and ATRXex9_2 (Table 4.2), and were subsequently annealed and ligated 
into a CRISPR RNA expression plasmid (MLM3636; Addgene).  The resulting plasmid 
was co-transfected with a Cas9 nuclease expression plasmid (41815; Addgene) into wild-
type HCT116.  Cells were subcloned, and screened for correct targeting by interrogating 
the disruption of an SmlI restriction enzyme site that lies directly adjacent to the target 
sequence cut by the Cas9 endonuclease.  Targeting PCR was performed using 
ATRXex9F and ATRXex9R (Table 4.2), and products were subjected to SmlI digestion.  
Sanger sequencing of the correctly modified clones was performed with ATRXex9SeqF 
to confirm that an early stop codon was inserted or a frame-shift mutation had occurred. 
 
rAAV-mediated ATRX knockout   
A knockout rAAV vector was constructed as described, with slight modifications (Kohli 
et al. 2004, Khan et al. 2011, Luo et al. 2014).  The fifth exon of the ATRX was targeted, 
as it has been reported that disruption of this exon results in an ATRX knockout (Leung et 
al. 2013).  Accordingly, the left and right homology arms were constructed by PCR with 
primer pairs, ATRX LarmF and ATRX LarmR, and with ATRX RarmF and ATRX RarmR, 
respectively (Table 4.2).  These PCR products were combined with a neomycin resistance 
gene, and an rAAV vector backbone, and used in a Golden Gate ligation reaction to 
generate the rAAV ATRXKO.  Following virus production and infection of wild-type 
HCT116 cells, neomycin resistant sub-clones were screened by PCR with ATRX TargF 
  147 
and ATRX IresR primers (Table 4.2) to identify correctly targeted clones.  Clones were 
continuously cultured in media containing 1 mg/mL G418. 
 
Immunoblot analysis  
Cell lysate preparation and protein detection was performed as described (Bower et 
al. 2012).  Briefly, protein lysates were prepared from harvested cells, separated by 
electrophoresis using a Tris-acetate gel, transferred to PVDF membrane, and the 
membrane was probed for protein using the antibodies indicated in each figure.  
Antibodies used: ATRX (Sigma, HPA001906 or GeneTex, GTX629703), DAXX (Sigma, 
HPA008736), γ-tubulin (Sigma, T5192) and Ku70 (Santa Cruz, sc-9033). 
 
APB detection  
APB analysis was performed by cytocentrifuging cells onto SuperFrost Plus slides 
using a Shandon Cytospin 4.  Cells were then fixed with 4% formaldehyde and 
permeabilized with 0.1% Triton X-100. Blocking and RNase A treatment were 
simultaneously performed by incubating slides with 0.1 mg/mL RNase A diluted in 
antibody dilution buffer (ABDIL; 20 mM Tris-HCl, pH 7.5, 0.2% fish gelatin, 2% BSA, 0.1% 
Triton X-100, 150 mM NaCl, 0.1% sodium azide).  Cells were stained with antibodies 
specific for ATRX (Sigma, HPA001906), TRF2 (Merck Millipore, OP129) and PML (Santa 
Cruz, sc-9862) diluted in ABDIL for 2 h at 37oC in a humidified chamber.  Following washes 
in PBS with 0.1% Tween-20 (PBST), cells were stained with appropriate AlexaFluor 
secondary antibodies for 30 min at 37oC in a humidified chamber.  Subsequent to an 
additional set of PBST washes, nuclei were counterstained with DAPI and mounted using 
DABCO anti-fade mounting media.  Images were obtained on an Imager.M1 microscope 
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(Zeiss) and analysis performed using ZEN software (Zeiss). Statistical analyses were 
performed using GraphPad Prism 5.0. 
 
C-circle assay  
The C-circle assay was performed as described (Henson et al. 2009).  C-circle signal 
was quantified using ImageQuant software and background corrected by edge 
subtraction.  Quantitation of the C-circle signal in the ATRX expression experiments was 
performed by normalizing the signal obtained for each sample to the amount of DNA used 
per reaction, followed by comparison to the signal obtained on the corresponding day post-
transfection with the empty vector pCMV6-Entry. 
 
Terminal restriction fragment (TRF) assay  
Telomere length was assessed essentially as described (Bower et al. 2012).  
Equivalent amounts of genomic DNA were digested with HinfI and RsaI and separated 
using either standard or pulsed field gel electrophoresis.  The resulting gel was hybridized 
either in-gel or after transfer to Hybond XL (GE Healthcare) membrane using a radioactive 
(TTAGGG)3 oligonucleotide probe. Detection of radioactive signal was performed using a 
phosphor-imaging screen and the signal measured using a Typhoon Trio (GE Healthcare). 
 
Telomere repeat amplification protocol (TRAP)  
The TRAP assay was used to assess telomerase activity as described (Bower et al. 
2012).  Lysates were prepared using CHAPS buffer and equal amounts of lysate were 
used in each TRAP reaction.  The TRAP products were separated on a PAGE gel and the 
gel was stained with SYBR Gold. Gels were scanned on a Typhoon Trio. 
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ATRX sequencing  
ATRX was sequenced using described primers and conditions (Jiao et al. 2011).  PCR 
products were purified and sent to the Australian Genome Research Facility for Sanger 
sequencing.  Sequence analysis was performed using CodonCode Aligner. 
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Tables 
Table 4.1.  Pre- and post-crisis protein and telomere lengthening mechanism 
characterization of cell strains and cell lines.   
Parental 
Cell Strain 
Expression 
vector 
Pre-crisis 
Days 
in 
Crisis 
Post-crisis 
TEM 
Protein C-
Circles TRAP TRF# 
Protein 
ATRX DAXX ATRX DAXX 
Bre80 T5 
GFP nd nd 166 - + - + + TEL 
ev-1 nd nd 136* -     - 
ev-2 nd nd 264* -     - 
ev-3 nd nd 264* -     - 
sc nd nd 187* -     - 
shATRX-1 nd nd 109* -     - 
shATRX-2 nd nd 107 - + nd - + TEL 
shATRX-3 nd nd 64 - + nd - + TEL 
shDAXX-1 nd nd 98 - + nd + - TEL 
shDAXX-2 nd nd 77 - + nd + - TEL 
           
Bre80 T8 
shATRX-1 nd nd 92 - + - - + TEL 
shATRX-2 nd nd 97 - + - - + TEL 
shATRX-3 nd nd 102*      - 
shATRX-4 nd nd 102*      - 
shATRX-5 nd nd 102*      - 
           
Fre80-3T 
sc1 + + 65 - +  + + TEL 
sc2 + + 23 - +  + + TEL 
sc3 + + 124*      - 
sc4 + + 22 - +  + + TEL 
sc5 + + 99 - +  + + TEL 
sc6 + + 30 - +  + + TEL 
shATRX-1 nd nd 62 + +  + + TEL 
shATRX-2 - + 125*       
shATRX-3 - + 99 - + nd - + TEL 
shATRX-4 - + 158*      - 
shATRX-5 - + 125*      - 
shATRX-6 - + 158*      - 
shATRX-7 - + 0 - + nd low + TEL 
           
Fre80-4Tii 
none + + 60 + - ALT + + ALT 
sc1 nd nd 87*      - 
sc2 + + 87*      - 
  151 
Table 4.1 Pre- and post-crisis protein and telomere lengthening mechanism 
characterization of cell strains and cell lines. (Continued) 
Parental 
Cell Strain 
Expression 
vector 
Pre-crisis 
Days 
in 
Crisis 
Post-crisis 
TEM 
Protein C-
Circles TRAP TRF# 
Protein 
ATRX DAXX ATRX DAXX 
Fre80-4Tii 
sc3 + + 87*      - 
sc4 + + 78*      - 
sc5 + + 82*      - 
sc6 + + 82*      - 
shATRX-1 nd nd 31 + - + - + ALT 
shATRX-2 nd nd 93 + - nd - nd ALT 
shATRX-3 nd nd 112 + - + - + ALT 
shATRX-4 - + 14 + - + - + ALT 
shATRX-5 - + 27 + - nd - + ALT 
shATRX-6 - + 44 + - nd - + ALT 
shATRX-7 - + 57 + - nd - + ALT 
shATRX-8 - + 46 + - nd - + ALT 
shATRX-9 - + 42 + - nd - + ALT 
           
JFCF-
6/T.1/P 
None + + 44 + - + - + ALT 
ev nd nd 13 + - + - + ALT 
sc1 + + 42 + - + + + ALT 
sc2 + + 78 + - + - + ALT 
shATRX-1 - + 0 + - + - + ALT 
shATRX-2 - + 0 + - + - + ALT 
shATRX-3 - + 0 + - + - + ALT 
shATRX-4 - + 0 + - + - + ALT 
shDAXX + - 0 + - + + - ALT 
           
JFCF-
6/T.5K 
None + + 0 + - + - + ALT 
ev + + 48 + - + - + ALT 
sc1 + + 46 + - + - + ALT 
sc2 + + 0 + - + - + ALT 
shATRX-1 - + 12 + - + - + ALT 
shATRX-2 - + 26 + - + - + ALT 
shATRX-3 - + 28 + - + - + ALT 
shATRX-4 - + 21 + - + - + ALT 
shDAXX + - 0 + - + - - ALT 
 
  TRF
# Telomers had ALT like length +  Positive signal 
ev Empty Vector -  Negative signal 
sc Scrambled control nd  Not determined 
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Table 4.2.  List of PCR primers 
Oligo Name Sequence (5’-3’) 
ATRX LarmF atacatagcggccgcaggtcctttgcctgatacac 
ATRX LarmR tattactagtgaccctggaggacactcttc 
ATRX RarmF ataactcgaggatgagaatgacagggaacttgg 
ATRX RarmR atattgcggccgcgtgaattgaagagagaggctgt 
ATRX TargF gaggtggatgttaagggcatg 
ATRX IresR gcttccagaggaactgcttcc 
ATRX IntF ctaaccagtgggaatgtctc 
ATRX IntR cagggaacaaggtttaataagcac 
ATRXex9_1 acaccgtttctgtcggtcgcctcaag 
ATRXex9_2 aaaacttgaggcgaccgacagaaacg 
ATRXex9F agtggaactgaacaagaagtgg 
ATRXex9R gaaggcacagttgataaagacacg 
ATRXex9SeqF cctgtttccctttctaattccc 
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Figures 
Figure 4.1 
2  
Figure 4.1.  An ATRX knockout is compatible with telomerase activity.  
A) PCR across the region of the ATRX targeted by CRISPR/Cas9 treatment in HCT116 
cells shows that all clones contain modifications that result in disruption of the SmlI 
restriction enzyme recognition sequence compared to wild-type (WT).  Note that ATRX is 
located on the X chromosome and HCT116 is derived from a male, making the gene 
hemizygous.  B) PCR confirming correct gene targeting by rAAV using ATRX IntF and 
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ATRX IntR primers (Table 4.1).  Wild-type cells should show a band of 1217 bp, while 
correctly targeted clones yield of band of 2186 bp.  C) Western blot analysis was 
conducted to confirm the lack of ATRX expression in all CRISPR/Cas9 and rAAV correctly-
targeted HCT116 clones.  Ku70 was used as a loading control.  Telomere maintenance 
status was analyzed (D, C-circle, E, TRAP and F, TRF assays) in both wild-type and 
ATRX-knockout HCT116 cells. DNA from U-2 OS cells was used as a positive control for 
the C-circle and TRF assays and a negative control for the TRAP assay.  All HCT116 
clones were telomerase-positive/ALT-negative by these criteria. 
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Figure 4.2 
 
Figure 4.2.  Depletion of ATRX does not induce ALT in epithelial cells.  
A) The indicated Bre80 epithelial cultures were analyzed for ATRX and DAXX protein 
expression at a time point after immortalization; γ-tubulin was used as a loading control.  
B) Growth curves of each immortalized Bre80 T5 and Bre80 T8 cell line.  The number of 
days in culture since transduction is indicated on the x-axis, while the y-axis indicates the 
number of PDs the culture has undergone post-transduction.  C) Telomerase activity was 
assessed in each immortal culture using the TRAP assay.  U-2 OS and HeLa cell lysates 
were used as negative and positive controls, respectively.  D) The presence of C-circles 
in each immortal Bre80 T5 and Bre80 T8 cell line was determined.  DNA from GM847 
cells was used as a positive control. 
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Figure 4.3 
 
Figure 4.3.  ATRX loss promotes ALT activation in breast fibroblasts.  
A) ATRX and DAXX protein expression was analyzed in mortal (pre-crisis) Fre80-3T and 
Fre80-4Tii fibroblasts transduced with the indicated vectors, as well as untransduced 
parental Fre80-4Tii cells.  293 cells were included as a positive control and γ-tubulin was 
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used as a loading control.  B) All immortal cultures were assessed for the levels of ATRX 
and DAXX protein expression by Western blot.  γ-tubulin was used as a loading control 
and HT1080 cells were used as a positive control.  C) All immortal fibroblasts lines were 
examined for the presence of telomerase activity using the TRAP assay.  GM847 and U-
2 OS cells were used as negative controls and HT1080 cells used as a positive control.  
D) The presence of C-circles was determined in each immortal cell line.  GM847 cells were 
included as a positive control.  Samples with C-circle levels above background (-Φ29 
negative control) were regarded as ALT-positive. 
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Figure 4.4 
 
Figure 4.4.  Spontaneous loss of ATRX during immortalization.  
A) JFCF-6/T.1/P and JFCF-6/T.5K cells that were unmodified (parental) or transduced 
with an empty vector (vector), a scrambled shRNA control (sc), shATRX or shDAXX were 
analyzed by Western blot for the expression of ATRX and DAXX proteins.  All cultures 
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were analyzed at a mortal and immortal time point, as indicated by the “+” above each 
lane. γ-tubulin was used as a loading control.  B) Growth curves of each immortalized 
JFCF-6/T.1/P and JFCF-6/T.5K cell line.  The days in culture and cumulative PDs were 
calculated subsequent to SV40 transformation. 
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Figure 4.5 
 
Figure 4.5.  ATRX loss corresponds to a period of growth crisis.  
ATRX and DAXX protein levels of three immortal JFCF-6/T.1/P cell lines (parental, vector 
and sc1) were analyzed at multiple PDs indicated on the corresponding growth curves; 
crisis was defined as the cell culture undergoing less than 1 PD/7 days.  γ-tubulin was 
used as a loading control. 
  
  161 
Figure 4.6 
 
Figure 4.6.  Loss of ATRX promotes fibroblast immortalization.  
TEM status of JFCF-6/T.1/P and JFCF-6/T.5K cell lines treated as described for Figure 4 
was analyzed.  A) Telomerase activity was assessed using the TRAP assay.  Each sample 
was assessed at both mortal and immortal time points, indicated by the “+” above each 
lane. GM847 or U-2 OS cell lysates were used as negative controls and HT1080 served 
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as a positive control.  B) The presence of C-circles was assessed at both mortal and 
immortal time points in each cell line.  C) Mean telomere length analysis using the TRF 
assay was performed on each cell line for at least two time points (mortal and immortal).  
The triangle above each set of samples indicates increasing PDs. 
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Figure 4.7 
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Figure 4.7.  ATRX expression represses the ALT mechanism.  
A) ATRX and DAXX protein analysis of untreated control, FuGENE-treated, empty vector 
(EV)- or ATRX-transfected cultures at days 2, 4, 6 and 8 post-transfection in GM847, 
JFCF-6/T.5K-sc1 or U-2 OS cells.  γ-tubulin was used as a loading control.  The blots 
shown are representative of at least three separate transfections.  B) The level of C-circles 
was assessed in each untreated control, FuGENE-treated, EV- or ATRX-transfected 
GM847, JFCF-6/T.5K-sc1 or U-2 OS cell culture at 2, 4, 6 and 8 days post-transfection.  
C-circle levels were normalized to the quantity of DNA used for each reaction, followed by 
normalization to the EV-transfected control at the relevant day post-transfection.  Bars 
indicate the mean ± SEM; n = 3. * p < 0.05, ** p < 0.005 and *** p < 0.0001.  C) APB-
positive nuclei were quantified in untreated, FuGENE-treated and EV- or ATRX-
transfected GM847, JFCF-6/T.5K-sc1 or U-2 OS cells at the indicated day post-
transfection.  A nucleus was scored APB-positive when TRF2 and PML colocalized; 
ATRX/APB-positive nuclei also showed nuclear ATRX staining.  The bars represent the 
mean ± SEM; n = 3 to 5; at least 100 nuclei were counted in the untreated, FuGENE-
treated or EV-transfected cultures and at least 100 ATRX-positive nuclei were counted in 
the ATRX-transfected cultures.  D) Mean telomere length analysis was determined by TRF 
analysis in GM847, JFCF-6/T.5Ksc1 or U-2 OS cell cultures treated as indicated above 
each lane.  * p < 0.05, § p < 0.01, ** p < 0.005, §§ p < 0.001, *** p < 0.0005, §§§ p < 0.0001.  
nd = not determined due to lack of ATRX-positive nuclei. 
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Synopsis 
 
The most consistent requirement of malignant progression is an escape from telomere 
crisis.  This escape requires the activation of a telomere maintenance mechanism – either 
telomerase expression or the Alternative Lengthening of Telomeres (ALT) pathway – 
which confers cellular immortality.  Whilst the mechanism of telomerase-mediated 
telomere maintenance is relatively well understood, the molecular requirements for the 
initiation of ALT are less clear.  To date, one of the strongest candidate ALT-regulatory 
genes is ATRX, which is almost always (>90%) mutated in ALT cancers.  Here, we 
demonstrate that the loss of ATRX enhanced by four orders of magnitude the frequency 
of ALT immortalization in transformed, but non-immortalized, human cells.  In contrast, we 
show that telomerase-positive, ATRX-null cells, which are forced to undergo a second 
telomere crisis are only able to initiate ALT-like telomere lengthening but cannot achieve 
an immortal ALT-state.  Interestingly, however, many of these events were length and 
chromosome specific, implying the presence of cis-acting determinants.  Our data provide 
the first definitive distinction between ATRX’s molecular control of ALT-activity and the 
cellular program of an immortalized ALT-cancer. 
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Introduction 
 
Telomeres are repetitive DNA-protein elements that protect the ends of linear 
chromosomes and prevent their recognition as a double-stranded DNA break (O'Sullivan 
and Karlseder 2010, Napier et al. 2015).  As a consequence of the end-replication problem 
telomeres shorten every successive cell cycle and such shortening ultimately limits the 
proliferative capacity of cells by eliciting a p53-dependent G1/S cell cycle arrest that acts 
as a stringent tumor suppressive mechanism (Olovnikov 1973).  In the absence of a 
functional cell-cycle arrest, continued cell division and telomere erosion ultimately results 
in a period of telomere dysfunction, referred to as crisis.  Telomere dysfunction during 
crisis leads to large-scale genomic rearrangements that can drive clonal evolution and 
tumour progression (Lin et al. 2010, Roger et al. 2013), from which cells can escape by 
activating a TEM.  The majority of malignancies, as well as stem cells, germ cells and 
single-celled organisms, almost exclusively utilize an enzyme complex called telomerase 
as their primary TEM (Hanahan and Weinberg 2000, Ju and Lenhard Rudolph 2008).  
However 10% of malignancies, predominantly those of mesenchymal origin (Henson and 
Reddel 2010), do not express telomerase, but instead maintain their telomeres via the 
ALT mechanism (Shay et al. 2012, Pickett and Reddel 2015). 
ALT cancers enable telomere extension via a HDR-dependent mechanism (Cesare 
and Reddel 2010).  This has been confirmed by experiments where a molecular tag was 
inserted into telomeres, and its duplication via HDR was monitored throughout the genome 
(Dunham et al. 2000).  Accordingly, ALT cells have recently been found to be sensitive to 
inhibitors of an HR protein, ATR (Flynn et al. 2015).  This dependence on HDR template 
copying between telomeres is coincident with extra-chromosomal, circular telomeric DNA 
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intermediates, termed C-circles, which are a strong marker of ALT activity (Henson et al. 
2009), and are perhaps mechanistically involved in the HDR-dependent telomere 
elongation.  In addition, ALT cells have been historically characterized by their lack of 
telomerase expression and extremely heterogeneous telomere length profiles that are 
likely to be derived from unregulated hyper-recombination between telomeres (Bryan et 
al. 1995). 
More recent work has uncovered a strong correlation between ALT cancers and 
mutations in ATRX (Heaphy et al. 2011, Lovejoy et al. 2012).  ATRX is a chaperone for 
histone H3.3, and along with DAXX, is responsible for H3.3’s replication-independent 
incorporation into the genome (Goldberg et al. 2010, Wong et al. 2010).  Specifically, H3.3 
deposition into telomeric regions seems to be altered in ALT cells and, correspondingly, 
telomeric chromatin dynamics are altered (Goldberg et al. 2010, Episkopou et al. 2014, 
Ivanauskiene et al. 2014, O'Sullivan and Almouzni 2014).  Because ATRX is mutated so 
frequently in ALT tumors this implies that ATRX’s chromatin regulation of telomeric 
chromatin may normally be repressive of the HR-activity observed in ALT cells.  How 
ATRX might contribute to the onset of ALT is still unknown (Amorim et al. 2016).  The 
mutation or deletion of ATRX, however, does co-segregate with the ALT phenotype in cell 
fusion experiments (Bower et al. 2012).  Additionally, the frequency of ALT immortalization 
events increases with shRNA knock-down of ATRX in human fibroblasts (Napier et al. 
2015, Hu et al. 2016).  Lastly, ectopic re-expression of ATRX in ALT cells diminishes the 
ALT activity of the cells (Clynes et al. 2015, Napier et al. 2015). 
Here, we report for the first time, direct genetic evidence that the loss of ATRX initiates 
ALT activity.  We demonstrate using genetic knockout experiments of ATRX in 
transformed, non-immortalized cells that correct gene targeting correlates 100% with 
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subsequent ALT immortalization.  Furthermore, we have devised a model system that, for 
the first time, is able to demonstrate the earliest effects of ATRX loss on cells undergoing 
telomere crisis. 
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Results 
 
Loss of ATRX in transformed, non-immortal cells enhances the frequency of 
immortalization 
We previously generated ATRX-null telomerase-positive human HCT116 cells by both 
rAAV- and CRISPR/Cas9- mediated gene targeting and demonstrated that the genetic 
deletion of ATRX did not lead to the activation of the ALT phenotype (Napier et al. 2015).  
Thus, the loss of ATRX activity in a tumor cell that is already utilizing telomerase as its 
primary telomere maintenance mechanism is, per se, not sufficient to trigger a switch to 
ALT.  We additionally showed that knockdown of ATRX by siRNA increased the frequency 
of ALT immortalization, but still required a natural selection process through telomere 
crisis where presumably the vast majority of cells with diminished ATRX levels did not 
initiate ALT.  This result implied that either the initiation of ALT was very sensitive to the 
levels of ATRX protein on a cell-by-cell basis, or that a second genetic or epigenetic event 
occurs during telomere crisis that is required for ALT immortalization.  The latter of these 
possibilities seemed more likely, as the genetic deletion of ATRX in a telomerase-positive 
cell did not initiate ALT.  To address this question, we initiated a genetic knockout study 
of ATRX in a more pathophysiologically relevant human cell culture system by using a 
SV40-transformed primary human cell line, JFCF-6/T.1P (henceforth JFCF).  Importantly, 
while these cells are oncogenically transformed, they are not immortalized, and thus 
closely resemble human cancer cells as they pass the Hayflick limit and move into 
telomere crisis (Yeager et al. 1999).  We reasoned that ATRX-mediated gene targeting in 
these cells would enable us to elucidate the genetic contribution of ATRX in repressing 
ALT.  JFCF cells can spontaneously immortalize in culture, but do so at a low frequency 
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of 10-7, and notably, can do so by utilizing either the telomerase or ALT pathways (Sprung 
et al. 1997, Yeager et al. 1999).  For our knockout approach, we employed rAAV-based 
gene targeting where exon 5 of the ATRX gene was replaced with a NEO drug resistance 
marker, according to previous rAAV-mediated targeting strategies (Leung et al. 2013, 
Napier et al. 2015) (Fig. 5.1A).  After three independent infections, drug resistant, single-
cell clones were propagated for about 2 months.  Across all three infections after two 
weeks there were hundreds of clones alive (n = 388), however after 2 months only 16 had 
survived and these were growing as if they were immortal (Fig. 5.1B, Table 5.1).  We 
confirmed their immortality by continuing to culture the clones for an additional 3 weeks 
with no indication of a growth defect (Fig. 5.1C), and were able to grow them in culture 
beyond 50 population doublings (PDs) for 3 months post-immortalization.  As 16 of 388 
original single-cell clones had immortalized, we conclude that the rate of immortalization 
in these experiments is ~4 X 10-2, which is between 104- to 105-fold higher than the 
spontaneous rate of immortalization for JFCF (Sprung et al. 1997, Yeager et al. 1999).  In 
order to assess whether these immortal clones coincided with correct gene targeting, we 
utilized PCR and confirmed that 100% of the clones were correctly targeted (Fig. 5.1D).  
This high frequency of correct targeting was striking as knockouts in previous studies with 
HCT116 had yielded targeting efficiencies of only ~4% (Napier et al. 2015).  Presumably 
the difference between targeting efficiencies in these cell types was due to the selection 
for immortalization in the case of the JFCF cells undergoing crisis.  To confirm this 
presumption, these PCR results were substantiated by Western blot analyses, which 
demonstrated that none of these clones expressed ATRX protein (Fig. 5.1E) in contrast 
to the parental JFCF cells, which did (Fig. 5.2).  Importantly, we also carried out a parallel 
experiment in which an irrelevant gene - phosphatidylinositol glycan anchor biosynthesis 
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class A (PIGA) - was targeted with a nearly identical vector.  Similarly, 173 drug-resistant 
clones were isolated after two weeks, but in this instance none of the clones immortalized 
(Table 1).  From these experiments, we concluded that the loss of ATRX correlated with 
immortalization in JFCF cells in 100% (16/16) of the clones analyzed and occurred at a 
frequency 4+ orders of magnitude higher than can occur spontaneously.  Importantly, the 
occurrence of crisis (Fig.  5.1C) demonstrates definitively that at least one additional step, 
in addition to complete ATRX loss, is required for immortalization. 
 
Loss of ATRX before telomere crisis is required for ALT immortalization 
The 16 immortalized clones were subsequently categorized for their telomere 
elongation maintenance mechanism.  TRAP analysis revealed that all of the immortal 
clones were telomerase negative (Fig.  5.3A), which by itself strongly suggested that these 
cells were ALT.  Second, by terminal restriction fragment (TRF) analyses all the clones 
had elongated ALT-like telomere lengths (Fig.  5.3B) (Bryan et al. 1995).  Third, all of the 
clones were positive for the presence of C-circles (although some were more strongly 
positive than others), a hallmark of ALT activity (Fig. 5.3C) (Henson et al. 2009).  A fourth 
characteristic of ALT cells is the incidence of the APBs (Yeager et al. 1999).  These 
nuclear protein conglomerates are postulated to be the molecular scaffolding required for 
the HR-dependent telomere lengthening characterized by the ALT-phenotype (Conomos 
et al. 2014).  Accordingly, we found a striking co-localization phenotype between large 
telomeric foci with the PML protein only in the ATRX-null clones (Fig.  5.3D-F).  In toto, 
these data strongly suggest that in cells undergoing telomere crisis the absence of ATRX 
results in the onset of ALT. 
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The absence of ATRX in telomerase-positive cells can induce ALT activity when 
combined with telomere stress 
After establishing a direct link between the absence of ATRX in cells undergoing 
telomere crisis and ALT activation, we sought to understand if this event was limited to 
cells which had yet to commit to a TEM pathway.  Given that we had shown that knockout 
of ATRX in telomerase-positive cells did not yield any evidence of ALT activity, we now 
asked whether inducing telomere-crisis in these cells would result in activation of ALT.  To 
answer this question, we utilized our ATRXNeo/o HCT116 cells (Napier et al. 2015) and 
expressed DN-hTERT in them to abrogate telomerase activity and induce telomere 
erosion.  We have validated this system in WT HCT116 cells (Hahn et al. 1999, Jones et 
al. 2014) where the expression of DN-hTERT led to telomere erosion, fusion and crisis.  
All (100%) WT HCT116 cells, however are ultimately able to escape crisis by achieving 
the reactivation of telomerase activity (Jones et al. 2014).  In the case of ATRXNeo/o 
HCT116 cells the expression of the DN-hTERT also led to an abrogation of telomerase 
activity (Fig.  5.4A).  A total of 33 clones were picked and their growth was monitored; in 
contrast to WT HCT116 clones only 5 (15%) of the ATRXNeo/o DN-hTERT clones were able 
to escape crisis, with 28 (85%) of these clones failing to escape crisis despite monitoring 
for up to 220 days at which point no cells were left in the cultures (Fig.  5.4B).  Thus, 
surprisingly, these data indicated that, in contrast to JFCF cells (where the absence of 
ATRX greatly increased the frequency of immortalization), the absence of ATRX 
compromises the ability of HCT116 cells to escape a telomere-driven crisis. 
Of the five clones that escaped crisis, 3 escaped rapidly (demarcated in black, Fig.  
5.4B), resuming a normal rate of growth after approximately 60 days from the point of 
single cell cloning, whereas the two remaining clones escaped crisis with slower kinetics 
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(demarcated in blue, Fig.  5.4B), resuming a normal rate of growth after 110 days.  We 
confirmed that these clones were genetically distinct by next generation sequencing, 
where unique SNPs in each clone were validated (Fig.5.5A).  An unbiased phylogenetic 
algorithm was used to determine that the clones were not all from an identical lineage 
(Fig.5.5B). We monitored the telomere length of these clones over time using single 
telomere length analysis (STELA) of the XpYp and 17p telomeres (Baird et al. 2003).  All 
of the clones analyzed displayed telomere erosion in the first sampling points prior to crisis, 
consistent with gradual end-replication losses following the abrogation of telomerase 
activity.  The clones that were not capable of escaping crisis displayed gradual telomere 
erosion all the way to the final sampling point (clones #1, #5, #8, #11, and #37; Fig.  5.4C 
and Fig.5.6).  Similarly, the two clones that escaped crisis with slower kinetics, displayed 
gradual telomere erosion that ultimately stabilized at a short, but apparently functional, 
length (clones #31 and #32; Fig.5.7).  The stable telomere length in these clones was 
consistent with the fact that both clones ultimately re-expressed significantly amounts of 
telomerase activity (demarcated in blue, Fig.  5.4A). 
In complete contrast, the three clones that underwent a rapid escape from crisis, 
displayed large and precise telomeric elongation events at both the 17p and XpYp 
telomeres (clones 2, 3 and 4, Fig.  5.4C).  The elongation events appeared to occur only 
on the shorter of the two telomeric alleles observed at 17p.  Intriguingly, the telomeric 
elongation events were apparently identical in all three clones and were specific to each 
telomere with extension to a mean of 6.8 kb at 17p and an extension to a mean of 2.1 kb 
at XpYp.  The rapidity (within several PDs) and extent (up to an additional 5 kb) of telomere 
extension was not consistent with telomerase addition, but was consistent with HR-
mediated processes. 
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We considered that the bimodal telomere length distributions observed with STELA 
represented either sub-clonal populations derived from a single cell that had exhibited the 
telomeric extension, or that the extension event had occurred at a single telomeric allele 
and that the distributions were consistent with a population displaying one elongated allele 
and one un-altered allele.  To distinguish between these possibilities, we undertook single 
cell subcloning of clone 3 at PD31 (Fig.  5.4C) and analyzed the telomere length profiles 
in the subclones after 17 to 22 PDs.  Of the nine subclones analyzed, all apart from one 
displayed bi-modal telomere length distributions at 17p consistent with the presence of 
one elongated and one un-altered telomeric allele (Fig.  5.8A).  The single subclone that 
was only able to survive 17 PDs before dying (clone 2, Fig.  5.8A), displayed a unimodal 
telomere length distribution and no evidence of telomeric elongation. 
We have observed that the escape from a telomere-driven crisis, in the presence of 
functional ATRX, is accompanied by large-scale genomic rearrangements that can result 
in the amplification of the hTERT locus.(Jones et al. 2014)  We considered that if the 
initiation of an ALT-like phenotype arose because of the induction of aberrant HR activity 
at telomeres, this may also lead to more widespread mutation across the genome.  We 
therefore undertook whole genome sequencing at the same PD points at which telomeric 
elongation was observed in the three clones.  All three genomes displayed relative 
stability, with only one clone exhibiting a single deletion at the 5p chromosome arm (Fig. 
5.9).  Thus, whilst the escape from crisis in the absence of ATRX can be associated with 
rapid, telomere-specific elongation, this does not appear to be accompanied by large-
scale genomic copy number changes. 
Taken together these data indicate that the absence of ATRX compromises the ability 
of HCT116 cells to escape a telomere crisis.  Of those clones that did escape, two of the 
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escapees (clones #31 and #32) appeared to utilize telomerase whereas three escapees 
(clones #2, #3 and #4) appeared to (at least initially) engage an ALT-like elongation 
process.  This elongation process was highlighted by rapid and precise chromosome-
specific telomeric extension of the shorter telomeric alleles and this did not have a 
significant impact on genome stability. 
 
ATRX represses ALT activity, but its loss is not sufficient for sustained ALT 
activation 
We now considered whether the maintenance of ALT was also ATRX-dependent by 
undertaking long-term culture to >70 PDs (>200 days) and analyzing telomere dynamics 
and telomerase activity in the five clones that escaped crisis (Fig.  5.10a, Fig.5.7 and Fig.  
5.11), as well as one sub-clonal population (clone #3, sub-clone 11; Fig.  5.8).  The two 
clones that displayed a slower escape from crisis (demarcated in blue, Fig.  5.4) showed 
an increase in telomerase activity (demarcated in blue, Fig.  5.4A) and a stabilization of 
telomere length (Fig.  5.7) consistent with that observed in clones transiting a telomere-
driven crisis following the up-regulation of telomerase activity (Jones et al. 2014).  A clear 
pattern of telomere dynamics emerged in the clones in which the telomere elongation 
event had occurred (clones demarcated in black, Fig.  5.4B); in these clones the extended 
telomeric allele exhibited gradual telomere erosion, with ongoing cell division, at rates that 
were indistinguishable from that observed in the absence of telomerase (mean 90 bp/PD 
(Baird et al. 2003); Fig.  5.8B, Fig.5.10A, Fig.11).  In contrast, the rate of telomere erosion 
of the shorter un-mutated alleles was less (mean 23 bp/PD) with lengthening of this allele 
in later passages such that the two alleles homogenized and appeared to stabilize (Fig.  
5.8B, Fig.  5.10A, Fig.5.11).  The specific elongation events at the 17p and XpYp telomeres 
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were reflected in the genome-wide telomere length distributions, where an increase in 
general telomere length and heterogeneity was observed in these clones via TRF; 
however both the telomere length and heterogeneity decreased with ongoing cell division 
in stark contrast to that observed in long-term ALT-positive cell cultures (Fig. 5.10B).  
Consistent with the observed telomere dynamics, the telomerase activity increased with 
ongoing cell division (clones demarcated in black, Fig.  5.4A) being virtually undetectable 
at PD30, but rising to 25% to 77% of the ATRXNeo/o HCT116 parental cell’s level after 
PD80+.  These data are consistent with a model where the absence of ATRX permits 
critically short telomeres to engage in an ALT-like recombination pathway but that this 
state cannot be stably maintained.  Over time, the telomeres begin to erode and ultimately 
the survival of the clones is dependent upon the reactivation of telomerase.  Consistent 
with the view that telomerase and ALT may be competing for telomere maintenance in 
these cells — with telomerase ultimately gaining the upper hand — we observed variable 
amounts of C-circles in these clones throughout the experiment but with the lowest levels 
observed at the latest time points (Fig. 5.10C, D). 
These data demonstrate that ATRX suppresses telomere elongation events, which are 
reminiscent of ALT, but that the long-term maintenance of this state in HCT116 cells is 
suppressed by some other factor.  Instead, following the initial telomeric lengthening in 
HCT116 cells, progressive telomere erosion of the elongated alleles ensues and 
continued survival occurs when telomerase is subsequently upregulated.  This leads to 
the preferential lengthening of the shorter telomeric allele, the homogenization of allelic 
telomere length and the maintenance of replicative lifespan.  This is in contrast to ATRX-
null JFCF fibroblasts that readily maintain the ALT state. 
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Discussion 
 
We and others, have established a strong link between ATRX and the ALT phenotype 
in various malignancies and cell culture models (Heaphy et al. 2011, Bower et al. 2012, 
Lovejoy et al. 2012, Clynes et al. 2015, Napier et al. 2015); whilst there has been a focus 
on the association of ATRX with such phenotypes or mechanistic contributions to 
repressing ALT activity, thus far it has not been possible to demonstrate that the loss 
ATRX alone is sufficient to induce ALT in human cells.  The lack of ALT-activity in ATRX-
null cells was surprising particularly given that the association of the lack of ATRX 
expression with ALT cancers is so high.  Adding to this complexity was the finding that 
genetic ablation of another H3.3 chaperone, ASF1, readily generated ALT-activity in 
telomerase-positive cells (O'Sullivan et al. 2014).  Here we present strong evidence that 
the loss of ATRX during telomere crisis activates ALT in transformed, but not-yet 
immortalized human cells, greatly increasing the frequency of ALT-immortalization events 
by >1 x 104.  While other recent experiments have been able to genetically derive ALT 
cells from a common non-immortalized progenitor by functional inactivation of TERC (Min 
et al. 2017), the work shown here lends insight to the consequences of the ATRX-status 
as cells transit crisis.  Moreover, the occurrence of subsequent periods of crisis in our 
clones provides definitive evidence for the first time that complete ablation of ATRX activity 
is insufficient to activate ALT and that an additional event(s) is required. 
The efficiency with which this putative second event in JFCF cells occurs may be 
facilitated by the absence of functional p53 (due to the expression of the SV40 tumor 
antigen).  In contrast, this second event did not appear to occur in p53-competent, ATRX-
null HCT116 cells that were forced to undergo telomere crisis, because while ALT activity 
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was initiated it was not maintained.  This model provides unprecedented insights into the 
events that are driven solely by ATRX loss.  For the cells that were able to escape crisis 
by apparently initiating ALT (n = 3), we used high-resolution telomere length analysis to 
track the dynamics of single telomeres during the transition through crisis and were able 
to observe elongation events that specifically occurred on the shortest telomeres.  At 17p 
we observed two different length telomeric alleles and following the expression of DN-
hTERT both alleles were subjected to telomere erosion.  We then observed a specific 
elongation event at 17p, that appeared to involve the shorter of two telomeric alleles.  
Intriguingly, all three clones (which were independent) exhibited an apparently identical 
telomere length change at 17p (mean of 6.8 kb).  This was mirrored at the XpYp telomere, 
where the single detectable telomeric allele was subject to similar elongation (mean of 2.1 
kb) in all three clones.  The clones that escaped with telomeric elongation, all did so with 
very rapid kinetics (all within 10 PDs).  This observation is simply not consistent with the 
escape of a single cell from crisis (which would require a minimum of 20 PDs to re-
populate the culture dish), but would be consistent with a mechanism where multiple cells 
from each single clone were capable of escaping from crisis.  These observations indicate 
that the specific elongation events occurred independently in multiple cells, within each of 
three independent clones.  The nature of these initial elongation events and the underlying 
genetic determinants remain to be elucidated, but the presence of distinct elongation 
events specific to each telomere, strongly suggest that this process is tightly controlled.  
We speculate a potential role for cis-acting sequence elements that provide a template for 
elongation and which result in telomere-specific lengthening events.  It is pertinent to note 
that “Template for ALT” regions that integrate into telomeres have been characterized in 
telomerase-null C. elegans survivors (Seo et al. 2015). Moreover, orphan nuclear receptor 
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NR2C/F-mediated bridging may be responsible for bringing telomeric and non-telomeric 
DNA into proximity to mediate cis-acting rearrangements (Marzec et al. 2015). Lastly, it 
should be noted that in our experiments we detected almost exclusively telomere-specific 
elongation events accompanying the loss of ATRX.  In contrast, in a mouse model for 
glioblastoma a reduction of ATRX was correlated with an accompanying significant 
genetic instability (Koschmann et al. 2016).  It is likely that these differences may reflect 
the known biological telomeric differences between human and mouse or the fact that 
additional genetic alterations were required to produce the glioblastomas. 
Our data in DN-hTERT-expressing HCT116 cells distinguished ALT-immortalization 
from ALT-like telomere recombinations. We suggest that ATRX functions at the molecular 
level to repress ALT-mediated recombinations, as ATRX-null HCT116 cells exhibited ALT-
activity at the time of telomere crisis escape.  This is consistent with the large body of 
biochemical evidence that ATRX-modulates telomeric homeostasis (Goldberg et al. 2010, 
Wong et al. 2010, Clynes et al. 2015, Eid et al. 2015).  Our results importantly imply that 
ALT-activity at telomeres is distinct from an ALT-state of continuous telomere 
recombinations.  One obvious explanation for this is the considerable amount of data 
supporting the model that telomere proteins coordinated by the Shelterin complex, actively 
repress DNA damage/recombination signaling (Denchi and de Lange 2007, Palm and de 
Lange 2008, Poulet et al. 2009, Sfeir and de Lange 2012, Rai et al. 2016).  Intriguingly, 
many of these DNA damage response pathways signal through p53 (Karlseder et al. 1999, 
Stagno D'Alcontres et al. 2007, Fujita et al. 2010), and HCT116 is notably a WT p53-
expressing cancer cell line (el-Deiry et al. 1994).  Recent work has additionally described 
an ALT-specific genome histone mark, H3.3 phosphorylated at S31 (Chang et al. 2015), 
which is of significant interest as both ATRX and ASF1 are H3.3 chaperones shown to 
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regulate ALT.  Independently, this has recently been shown to be a global histone 
modification that results from chromosomal mis-segregation at mitosis, and which triggers 
a p53-dependent cell cycle arrest (Hinchcliffe et al. 2016).  Because ALT cells are clearly 
not cell cycle arrested, the implication of these two findings is that that p53 signaling must 
be somehow disrupted in ALT tumors, which is indeed a common observation (Henson 
and Reddel 2010).  Another explanation for the lack of persistence of an ALT state in our 
HCT116 ATRXNeo/o DN-hTERT cells could be due to the presence of both DN-hTERT 
bound to the telomeric ends.  Recent work has suggested that hTERT expression in ALT 
cells can alter the G-overhang on the leading and lagging strands, which was proposed to 
influence the ALT-recombination activity (Min et al. 2017).  Thus, a DN-hTERT might alter 
the state of these overhangs and their recombinogenic potential and thus influence the 
persistence of ALT.  Future work should attempt to further clarify the genetic contributions 
to both ALT-recombinations per se, and an active ALT state. 
Our data indicate that the timing of telomeric elongation is dependent on telomere 
length and occurs when a single telomeric allele reaches a specific length threshold at 
which point the large-scale elongation event occurs.  The definition of this threshold 
requires detailed clarification, however it is pertinent to note that ATRXNeo/o HCT116 cells 
expressing DN-hTERT contain populations of cells with telomeres of less than 400 bp, 
which is the point at which telomeric elongation is observed [see for example clones 2 
(PD30), 3 (PD31) and 4 (PD29), respectively (Fig. 5.10 and Fig. 5.11).  In contrast WT 
HCT116 cells expressing DN-hTERT all entered crisis with telomere length distributions 
that rarely extended below 400 bp because these telomeres are subjected to fusion (Jones 
et al. 2014).  Our data imply that in the absence of ATRX, shorter telomeres are more 
likely to be processed for ALT-like elongation rather than telomere fusion.  Moreover, our 
  183 
data imply that even if telomere fusion occurs to drive genome instability in ATRXNeo/o 
HCT116 cells expressing DN-hTERT, the rapid elongation of the shortest telomeres 
provides a temporary relaxation of the stringent selective conditions for the upregulation 
of a telomere maintenance mechanism thereby accounting for the relative genome 
stability observed in cells immediately after telomeric elongation. 
Finally, in this study we utilized two cellular models of malignant immortalization: 
SV40-transformed mesenchymal JFCF cells and epithelial colon cancer HCT116 cells.  
We chose these two models to synergistically complement the strengths and weaknesses 
of the other: JFCF cells are a more “normal” cell line, but are limited for mechanistic 
studies; in contrast, HCT116 cells are already immortalized and transformed, but can be 
utilized for very detailed mechanistic studies.   Thus, while the functional inactivation of 
ATRX In JFCF cells resulted in a dramatic increase in the frequency of ALT 
immortalization, we could not molecularly determine the mechanism of that escape from 
crisis, as correctly-targeted clones could only be identified after cells had immortalized.  
Therefore, we can only presume that as these cells entered crisis, the absence of ATRX 
permitted telomeric recombinations similar to what was observed in our HCT116 studies.  
Interestingly, in JFCF these presumptive recombinations permitted the development of 
ALT whereas in HCT116 cells they did not.  These differences established in our two 
different cell-based studies are reflected in the telomere maintenance mechanisms 
adopted by different tumor types, as ALT predominates in tumors of mesenchymal original 
(similar to JFCF) and telomerase dependence in the majority of epithelial-derived (similar 
to HCT116) carcinoma (Henson and Reddel 2010).  
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Materials and methods 
 
Cells culture 
HCT116 cells were purchased from the ATCC and maintained in McCoy’s 5A media 
supplemented with 10% FBS, 1% glutamine, and 1% penicillin/streptomycin.  JFCF-
6/T.1/P cells(Napier et al. 2015) were maintained in DMEM supplemented with 10% FBS, 
1% glutamine, and 1% penicillin/streptomycin.  The JFCF and HCT116 cultures were both 
derived from males.  Notably, ATRX is located on the X-chromosome, and thus gene 
targeting strategies must only target one allele.  Cells were maintained in 10 cm plates 
and passaged every 3 to 5 days.  To initiate telomere erosion in ATRXNeo/o HCT116 cells 
expressing DN-hTERT, the cells were transduced with amphotropic retroviral vectors 
containing a DN-hTERT cDNA (Hahn et al. 1999), as described (Preto et al. 2004). 
 
Gene targeting and ATRX knockouts 
The ATRX knockout by exon replacement with rAAV was performed as described 
(Napier et al. 2015).  Briefly, homology arms were constructed by PCR, flanked by an 
IRES-Neo cassette, and ligated into an rAAV production vector.  Producer 293-AAV cells 
were co-transfected with pAAV Helper and pAAV Rep/Cap, as described (Khan et al. 
2011).  JFCF cells (5 x 105) were plated approximately 24 hr prior to rAAV-infection.  Cells 
were infected with virus-containing media, and 48 hr-post infection, the media was 
changed to include 0.5 mg/mL G418.  Drug-resistant colonies were counted 2 weeks after 
infection, and allowed to continue to grow for another 2 to 4 weeks until control-infected 
cells had succumbed to telomere crisis.  Independent clones were isolated by cloning 
cylinders and expanded for further analysis. 
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Telomere-relevant Southern blotting (TRF and C-circle analyses) 
Genomic DNA was extracted from ~1 x 107 cells, and 50 µg of genomic DNA was 
digested with HinfI and RsaI, as described (Henson et al. 2009).  For the TRF analyses, 
12 µg of digested genomic DNA was resolved overnight on a 0.7% agarose 1 x TBE gel.  
This gel was depurinated, denatured, and neutralized, followed by overnight capillary 
transfer to a nitrocellulose membrane.  For the C-circle assay, 30 ng of digested genomic 
DNA was incubated for 8 hr with phi29 DNA polymerase, in the buffer supplied by the 
manufacturer (New England Biolabs), supplemented with 1 mM dATP, dGTP, dTTP, and 
0.2 mg/mL BSA with 0.1% Tween-20.  Reactions were chemically denatured, neutralized, 
and dot-blotted onto a nitrocellulose membrane.  The membranes were pre-hybridized for 
1 hr with Church’s buffer, then hybridized overnight in 4X SSC at 55oC.  Membranes were 
washed 3 times with 4X SSC and once with 4X SSC + 0.1% SDS, each for 30 min, 
exposed to a phosphorimaging screen, and detected and quantitated with a Typhoon 
phosphoimager. 
 
Immunofluorescence and telomere FISH (IF-FISH) 
This assay was performed as described (Conomos et al. 2014, Napier et al. 2015).  
Cells (1 x 105) were plated on chamber slides, and allowed to grow for 24 hr.  Cells were 
washed once with PBS, then fixed with 4% formaldehyde in 1X PBS.  Blocking and 
RNAseA treatment (0.1 mg/mL) were performed in antibody dilution media (ABDIL; 20 
mM Tris-HCl pH 7.4, 0.2% fish gelatin, 2% BSA, 0.1% Triton X-100, 150 mM NaCl, and 
0.1% sodium azide) at room temperature for 30 min.  Cells were stained with a PML 
antibody (Santa Cruz BioTech sc-9862) diluted in ABDIL for 1 hr, washed 3 times with 1X 
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PBS + 0.1%Tween-20 (PBST), and incubated with Alexa-488 α Goat IGG secondary 
antibody diluted in ABDIL for 1 hr.  Cells were washed in PBST, fixed with 4% 
formaldehyde and prepared for FISH hybridization.  Telo-C (PNA Bio) PNA probe was 
hybridized to the slides at 80o in hybridization buffer (10 mM Tris-HCl pH 7.4, 4 mM 
Na2HPO4, 0.5 mM citric acid, 1.25 mM MgCl2, 0.25% blocking reagent (Roche) and 70% 
formamide).  Slides were washed, counterstained with DAPI, and mounted with ProLong 
Gold (ThermoFisher).  Microscopy was performed with a Nikon-TiE deconvolution bright-
field microscope with a 60X objective. 
 
Telomerase activity  
Telomerase activity was detected using the TRAPeze XL Telomerase detection kit 
(Chemicon international).  Cell pellets were lysed in 200 µL CHAPS buffer.  Each lysate 
was included in the TRAPeze reaction using the Amplifluor primers and Titanium Taq (BD 
Clontech).  Each experiment included positive control extracts, control template for the 
generation of a standard curve, heat-treated controls, no template control and an internal 
control to monitor PCR inhibition.  Telomerase activity was expressed as TPG (Total 
Product Generated) values.  Each unit of TPG corresponds to the number of TS primers 
extended at least 3 telomeric repeats by telomerase. 
 
Telomere Length Analysis (STELA) 
DNA was extracted from using standard proteinase K, RNase A, phenol/chloroform 
protocols.  For telomere length analysis we used the single telomere length analysis 
(STELA) assay as described (Baird et al. 2003, Capper et al. 2007).  The XpYp telomere 
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of HCT116 has one telomeric allele that is detectable using the XpYpC primer (5ʹ-
CAGGGACCGGGACAAATAGAC-3 ʹ) for the STELA reactions. 
 
Whole genome sequencing and copy number analysis 
Paired-end sequencing was performed on the Illumina HiSeq x10 platform to a median 
depth of 15X and a read length of 150 bp.  Reads were mapped to hg19 (2009) using 
bwa-mem (version 0.7.12) (Li and Durbin 2009).  To estimate relative copy number 
profiles, sequencing coverage was calculated over 10 kb non-overlapping windows and 
normalized to the median genome coverage of each sample.  De-noising of coverage 
values was then performed using a wavelet regression method through use of the 
PyWavelets package (available online at: http://www.pybytes.com/pywavelets).  Here, 
coefficients were obtained by decomposing the data using a multilevel discrete wavelet 
transform with a Haar wavelet (functional parameters were level = 2, mode = ‘per’) (Lio 
2003).  Denoised coverage values of each chromosome were then obtained by applying 
an inverse discrete wavelet transform over the thresholded coefficients, with the threshold 
defined by: λ=σ̂√2log(N) where σ is the median absolute deviation and N is the number of 
data points.  To determine the relative copy number change profile of each sample 
with respect to other samples, the “parental” copy number profile common to all samples 
was inferred by first excluding outlier bins.  At each genomic bin, outliers were detected 
as points with a median absolute deviation > 2. The “parental” copy number was then 
calculated as the median of inlier bins, and the relative copy number change profile for 
each sample was determined as the denoised coverage values - parental copy number 
profile. 
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Unique SNP identification 
To identify the unique SNPs in our cohort, candidate variants were first identified using 
the Genome Analysis Tool Kit (GATK v3.3) according to best practice guidelines 
(McKenna et al. 2010, DePristo et al. 2011). Variants with a genotype quality >30 were 
kept whereas multiallelic and indel sites were discarded. Variant locations were then 
intersected using BedTools to remove common call sites (Quinlan and Hall 2010). 
Additionally variants which overlapped simple repeat intervals as documented in the 
UCSC simple repeat track were discarded (Benson 1999, Rosenbloom et al. 2015). Due 
to the potential limited sensitivity of GATK for SNP calling, a further filtering step was 
conducted to remove sites with common variant allele mappings across more than one 
sample. Here the alignment files for each sample were crosschecked using Pysam for 
each candidate variant . If any reads could be identified in more than one of the samples 
which supported the variant allele, that allele was discarded. 
 
Phylogenetic reconstruction 
Using the table of unique SNPs generated for each sample, a distance matrix M = (dij) 
was calculated according to dij = (xi + xj) / 2 where xi, xj are the number of unique SNPs 
for samples i and j respectively. Tree reconstruction was performed using the neighbor 
joining algorithm implemented using the PyCogent software package (Knight et al. 2007). 
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Tables 
 
Table 5.1.  Results of immortalization experiments 
Experiment Number Number of 
Initial Cells 
# Colonies after 
2-weeks 
# Immortal 
Clones 
# Correctly 
Targeted 
#ALT 
1 1 x 106 117 1 1 1 
2 1 x 106 128 2 2 2 
3 1 x 106 143 13 13 13 
PIGA-Neo Control 1 x 106 173 0 0 0 
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Figures 
Figure 5.1 
 
Figure 5.1.  Genetic knockout of ATRX in pre-crisis cells correlates 100% with 
immortalization.   
A) Schematic of the rAAV-ATRX-Neo gene targeting construct.  Correct gene targeting is 
facilitated by HR-dependent gene replacement.  Pink arrows correspond to “exon screen” 
PCR primers and those in black and green are “targeting” PCR primers.  B) Schematic of 
the experimental setup.  C) Growth chart monitoring population doublings over time.  D)  
PCR confirming that all immortalized clones were correctly gene targeted by rAAV-ATRX-
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Neo.  E) Western blot analysis confirming the loss of ATRX protein expression in all the 
immortalized clones. 
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Figure 5.2 
 
 
Figure 5.2.  JFCF cells express ATRX protein. 
 Cell lysates from the indicated cell lines were collected and a subjected to a western blot 
for ATRX.  Pre-crisis JFCF cells do express ATRX, which is abrogated by gene targeting. 
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Figure 5.3 
 
Figure 5.3.  All cells that immortalize due to the loss of ATRX utilize ALT.   
A) Representative TRAP assay depicting that all JFCF ATRXNeo/o clones have no 
telomerase expression.  Wild-type HCT116 (WT HCT116) and U-2 OS were used as 
telomerase-positive and ALT-positive controls, respectively.  B) A TRF length analysis 
shows that most of the JFCF ATRXNeo/o immortal clones have elongated telomeres.  C) A 
C-circle assay demonstrates that all of the ATRXNeo/o clones are positive for the C-circle 
assay.  D) Immunostaining for PML combined with a PNA telomere-FISH probe to analyze 
the incidence of APBs.  There was a strong co-localization frequency between large 
nuclear PML bodies and large telomeric signals.  E) Quantification of the signal intensity 
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of the C-circle assay shown in (C).  F) Percent overlap of the PML- and telomere channels 
from (D) derived by computational 3D analyses. 
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Figure 5.4 
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Figure 5.4.  Telomere crisis in ATRX-null HCT116 cells enables ALT-like activity. 
Telomerase activity was abrogated following the expression of DN-hTERT in ATRXNeo/o 
HCT116 cells to induce telomere attrition over time.  A) Quantification of telomerase 
activity plotted as total product generated (TPG).  B) Population doublings (PDs) indicate 
that telomere crisis occurred approximately 20 PDs post-DN-hTERT expression.  Five 
independent clones survived crisis (blue and black lines) and 28 clones did not (red).  C-
D) STELA analysis of the 17p and XpYp telomeres in ATRXNeo/o HCT116 cells expressing 
DN-hTERT or an empty vector control at PDs from the point of single cell cloning as 
indicated above.  Clones 1 and 8 (in red) did not escape telomere crisis, and 
correspondingly exhibited no telomere elongation event, as did clones 2,3 and 4.  Mean 
telomere is indicated below in black, telomere length of elongated telomeres is shown in 
red and highlighted with a dotted red line on the gel image. 
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Figure 5.5 
 
Figure 5.5.  ALT-like clones that escaped crisis are genetically distinct. 
 A) Clones that escaped crisis were compared to the pre-crisis parental clone by NGS.  
Unique SNPs were unbiasedly identified, and plotted here.  B) Phylogenetic analysis of 
the SNPs reveals that the clones post-crisis are genetically distinct. 
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Figure 5.6 
 
Figure 5.6.  Clones that do not escape crisis are unable to maintain telomere length. 
STELA of the 17p telomere in serial passages of three clonal cultures of ATRXNeo/o 
HCT116 cells expressing DN-hTERT; all three clones failed to escape crisis.  Clones and 
PD points are detailed above with mean telomere length and growth curves below. 
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Figure 5.7 
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Figure 5.7.  Two clones that escaped crisis without allele specific telomeric 
elongation. 
STELA of the 17p telomere in serial passages of a long-term culture of ATRXNeo/o HCT116 
cells expressing DN-hTERT.  PD points are detailed above, with overall mean telomere 
length detailed below, together with the long or short allele specific means shown in red 
and green.  The changes in telomere length (Δ bp/PD) of the two alleles are detailed. 
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Figure 5.8 
 
Figure 5.8.  Survival is dependent on multiple, end-specific, telomere elongations in 
ATRX-null cells undergoing telomere crisis. 
Clone 3 of ATRXNeo/o HCT116 cells expressing DN-hTERT that survived crisis was single 
cell sub-cloned at PD31, and analyzed by STELA.  A) Only clones that exhibited the 
specific 17p elongation events were able to survive, with one that did not (subclone 2, in 
red) dying at PD17.  Sub-clone numbers and PD points from the point of single cell sub-
cloning are detailed above, with the longer and shorter allelic telomere length distributions 
indicated in red and green, respectively.  B) Sub-clone 11 was passaged up to PD59 and 
telomere length monitored, the changes in telomere length (Δ bp/PD) of the two alleles 
are detailed. 
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Figure 5.9 
 
Figure 5.9.  Telomeric elongation in the absence of ATRX in cells undergoing a 
telomeric crisis is not accompanied by large-scale genomic rearrangements. 
Relative copy number change profiles from whole genome sequencing data derived from 
three ATRXNeo/o HCT116 cells expressing DN-hTERT that escaped crisis with telomeric 
elongation. 
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Figure 5.10 
 
Figure 5.10.  The absence of ATRX is not sufficient to maintain an ALT phenotype. 
A) STELA of the 17p telomere in serial passages of a long-term clonal cultures of 
ATRXNeo/o HCT116 cells expressing DN-hTERT.  Following the initial elongation event 
observed at PD 30, both telomeric alleles exhibited telomere erosion with ongoing cell 
division.  PDs points are detailed above, with overall mean telomere length detailed below, 
together with the long or short allele specific means shown in red and green.  The changes 
in telomere length (Δ bp/PD) of the two alleles are detailed.  B) A TRF depicting telomere 
lengths at late PDs after crisis, which depicts heterogeneous telomeres that shorten and 
compact over time.  C) C-circle analysis of clones throughout the aging of the HCT116 
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DN-hTERT-expressing cells, depicting intermittent ALT activity.  D)  Quantification of the 
absorbance depicted in (C) relative to WT in log-scale. 
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Figure 5.11 
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Figure 5.11.  The absence of ATRX is not sufficient to maintain an ALT phenotype. 
STELA of the 17p telomere in in serial passages of two long term clonal cultures of 
ATRXNeo/o HCT116 cells expressing DN-hTERT.  Following the initial elongation event 
observed at PD 30, both telomeric alleles exhibit telomere erosion with ongoing cell 
division.  PD points are detailed above, with overall mean telomere length detailed below, 
together with the long or short allele specific means shown in red and green.  The changes 
in telomere length (Δ bp/PD) of the two alleles are detailed. 
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Chapter 6 
Discussion and Future Directions 
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Implications of my work 
 
The work I have described here is focused on both the details of — and the 
connections between — DNA DSB break repair, telomere maintenance, and cellular 
immortalization.  First, in Chapter 2, I showed how the subpathways of NHEJ are 
genetically regulated and identified the existence of a Ku-independent, LIG4-dependent 
NHEJ reaction.  As discussed, the function of telomeres is to repress the recognition of 
the end of a linear chromosome as a DNA DSB.  Ironically should that occur, which DSB 
repair pathway mistakes the end of the chromosome for a DSB dramatically influences 
whether the cell will die, or whether it will have a chance to survive and escape the ensuing 
telomere crisis and potentially immortalize.  In Chapter 3, I showed that PARP1 is an 
important regulator of telomere homeostasis, and its mutation is causative of DNA damage 
at telomeres and that it results in telomere shortening.  In Chapters 4 and 5, I described 
how the genetic inactivation of ATRX, which is strongly associated with ALT-positive 
cancers, is not a bona fide repressor of ALT, but that its mutation does dramatically allow 
for ALT to occur, presumably due to ALT-like telomere recombinations.  Taken together, 
in the work presented throughout this dissertation, I have attempted to gain new insight 
into the regulation of DNA DSB repair, how some of these repair proteins regulate normal 
telomere homeostasis, and how ALT immortalization is functionally repressed by ATRX. 
Chapter 2 is focused on the regulation of NHEJ, and how C-NHEJ influences A-NHEJ.  
I showed that while LIG3-null cells are largely aphenotypic when it comes to DNA repair 
and survival, in Ku-deficient cells, LIG3 is primarily responsible for A-NHEJ.  This likely 
underlies the many observations that A-NHEJ, while rare, is nonetheless consistently 
detectable (Simsek and Jasin 2010).  Independently, other members of our laboratory 
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showed that LIG3 was essential for telomere immortalization, whereas LIG4 rather 
mediated lethal interchromosomal fusions (Oh et al. 2014).  Thus, one implication of my 
work is that the Lig3-dependent telomere fusions are repressed by Ku.  This implication 
fits nicely with the telomere phenotypes observed in the Ku-deficient cells, which appeared 
to consistently undergo intrachromosomal fusions (Wang et al. 2009).  Furthermore, the 
requirement for a rare DNA repair event for cellular immortalization is consistent with the 
low incidence of cells in telomere crisis that survive and immortalize. 
Another implication of my work in Chapter 2 is that there is a requirement for LIG1 in 
some form of end-joining, which arises from the observation that while all of the Ku-
repressible A-NHEJ is LIG3-dependent, there is always some level of A-NHEJ detectable 
in the absence of both proteins (Figs 2.9 and 2.10).  Notably, deletion of LIG4 did not 
abolish A-NHEJ levels in either WT or Ku-deficient cells, thus precluding any role for LIG4 
in A-NHEJ (Fig 2.10).  The only remaining candidate DNA ligase is LIG1, which 
presumably must be functioning to enable A-NHEJ.  There are two possible models to 
explain how LIG1 is participating in A-NHEJ; either LIG1 is functionally redundant with 
LIG3, or there are at least two subpathways of A-NHEJ present in human cells.  Support 
for the functional redundancy between LIG3 and LIG1 comes from the evolutionary history 
of LIG3.  Many organisms, including the model organism, Saccharomyces cerevisiae, do 
not have a third DNA ligase, and in such instances, this role is filled by DNA LIG1 (Simsek 
and Jasin 2011).  As the essential role for LIG3 is in the mitochondria, it appears that LIG3 
is required during mitochondrial DNA replication for sealing Okazaki fragments, thus 
implicating a functional redundancy between it and the primary role of LIG1 in the nucleus 
of eukaryotes (Simsek et al. 2011).  Furthermore, the complementation of LIG3-null cells 
with a mitochondrially-directed LIG1 can completely rescue LIG3’s essential function 
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(Simsek et al. 2011).  Our laboratory has recently constructed LIG1F/- conditionally-null 
cells.  As has been previously observed in most, but not all species, LIG1 is essential in 
humans.  Thus, while I have shown in Chapter 2 that LIG3 may be partially redundant 
with LIG1, the converse is not true; i.e. LIG3 cannot compensate for the absence of LIG1. 
With respect to the two possibilities of LIG3 and LIG1 either being functionally 
redundant or being discrete subpathways of A-NHEJ, I favor the later argument.  Models 
based off the earlier work in budding yeast have predicted this idea, which describe two 
subpathways of A-NHEJ (Decottignies 2013).  These models predict a LIG3-dependent, 
HDR-breakdown pathway, consistent with previous observations that the upstream HDR 
genes impact A-NHEJ (Rass et al. 2009).  The other pathway is proposed to be a 
polymerase-dependent as well as replication-dependent pathway, which would require 
specific polymerases and LIG1. 
This LIG1-dependent A-NHEJ pathway is intriguing as recent work in the context of 
cellular immortalization has shown that telomeres can undergo intra-chromosomal fusions 
in the absence of both LIG3 and LIG4, implicating a role for LIG1 in such events (Liddiard 
et al. 2016).  This was surprising, as a requirement for LIG3 in cellular immortalization was 
presumed to be due to LIG3 being responsible for a discrete end-joining pathway which 
permitted survival (Jones et al. 2014); however, LIG1 appears to be able to perform such 
repair events as well.  These two observations beg the question, “what is the essential 
role for LIG3 in cellular immortalization”, especially if LIG1 is redundant with LIG3?  One 
simple answer to this question might be that if LIG3 is epistatic to LIG1, then the genetic 
requirement for LIG3 may be to prevent LIG1-dependent A-NHEJ.  However, other 
explanations are also plausible and should be addressed in future studies.  This emerging 
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subpathway of A-NHEJ may be of significant clinical interest, as it likely influences the 
immortalization of many different cancers. 
In Chapter 3 I characterized the role of PARP1 in human cells, which was initiated 
because of previous implications of PARP1 in A-NHEJ (Wang et al. 2006).  However, 
unlike in the case of LIG3, I was unable to detect any significant contribution of PARP1 to 
A-NHEJ.  I attribute the differences to likely be a combination of the organisms in which 
previous data were collected and the difference between chemical inhibition of PARP1 
and the genetic ablation of PARP1.  I have discussed these differences in both Chapter 
1 and Chapter 3 in detail.  Yet, the more surprising discovery I present in Chapter 3 was 
a strong role of PARP1 in maintaining telomere homeostasis. 
Telomeres are notoriously difficult regions of the genome to replicate, and are 
considered genomic fragile sites (Sfeir et al. 2009).  They are prone to the formation of G-
quadruplexes, are inherently repetitive, and are unlikely to be rescued by dormant origins 
in the case of replication stalling (Gilson and Geli 2007).  Preferential recruitment of 
telomere accessory factors such as WRN and BLM by Shelterin are critical for telomere 
stability as the telomeres are replicated (Ye et al. 2010).  Notably, mutations in WRN are 
causative of Werner’s syndrome, which is a disease of premature aging (Martin 1978), a 
classic phenotype for telomere dysfunction diseases.  Thus, WRN likely functions to 
enable proper telomere replication, and its absence is causative of accelerated ageing. 
Importantly, PARP1 physically interacts with WRN (von Kobbe et al. 2003), which 
implicates them in a similar or common pathway.  PARP1 also travels with the replication 
fork and is responsible for DNA damage signaling specifically related to single-strand 
breaks (Min et al. 2013).  Thus, it seems likely (albeit as of yet unproven) that PARP1 and 
WRN may cooperate to help with stalled replication forks.  While compensatory 
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mechanisms exist for dealing with stalled forks in genomic regions, fragile sites are more 
prone to DNA damage and fork stalling when they are located in telomeric regions.  It is 
for this reason that I suggest that PARP1 (and probably WRN) is preferentially recruited 
to telomeres to ensure the fidelity of their replication. 
In Chapter 3, I present evidence that PARP1-null cells have short telomeres and that 
spontaneous DNA damage markers are enriched at these telomeres.  It is important to 
note, however, that the absence of PARP1 may only be tolerated in a human cancer cell 
that is over-expressing telomerase.  Notably, the asymmetry of the gene targeting I 
observed in the generation of PARP1-/- cells suggested that there is a strong evolutionary 
selection to retain at least one allele of PARP1 (Table 3.1).  This observation may also 
explain why there are no known inherited PARP1 genetic diseases in humans.  While the 
role of PARP1 in DNA repair may have redundant components, its ancillary role in 
enabling sufficiently long and stable telomeres may have been more strongly selected for.  
This is especially intriguing, as PARP1-null mice are both viable and fertile (Wang et al. 
1995).  Taken together, my results suggest that there may be a uniquely essential role for 
PARP1 in the telomere maintenance of healthy human cells.  The use of CRISPR/Cas9 
to try editing the PARP1 gene in normal (non-immortalized, non-transformed) fibroblasts 
would be one way to experimentally address this hypothesis. 
In Chapter 4, I describe the foundation of a large series of work regarding the role of 
ATRX in ALT.  Given the incredibly strong association between ALT and ATRX mutations, 
it was surprising that the genetic mutation of ATRX in telomerase-positive cells did not 
convert them to ALT.  This was especially true given that mutation of a different H3.3 
chaperone, ASF1, was sufficient to induce ALT activity in telomerase-positive cells 
(O'Sullivan et al. 2014).  These results are seemingly incongruent, as ATRX mutations are 
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very frequent in ALT cancers whereas ASF1 mutations are not.  Nonetheless, the 
relatively high frequency of ATRX mutations in telomerase-positive cancers supports my 
finding that the absence of ATRX appears to be necessary for the initiation but not the 
maintenance of ALT, as there are also many known cancers with ATRX mutations that 
are not ALT (Fishbein et al. 2015).  This complex genotype to phenotype correlation is 
most likely a reflection of the role of ATRX in regulating both DNA replication and DNA 
repair (Leung et al. 2013), as it has been well established that ATRX facilitates chromatin 
remodeling in regions other than just the telomere (Goldberg et al. 2010).  Thus, the loss 
of ATRX may impact multiple regulatory processes required for the Darwinian selection 
occurring in the oncogenic development of a malignancy.  Since some of these other 
regulatory processes have built in redundancies and some do not, the requirement for the 
loss of ATRX is not consistent from cell type to cell type and from tumor to tumor.  This 
may also explain why in ALT cancers, mutation of ATRX is far more common than 
mutation of DAXX (whose only known function is that of a histone H3.3 chaperone), 
although they function in the same telomere-specific H3.3 histone deposition pathway. 
I thus next tried to address the extent to which ATRX regulates the genesis of ALT in 
Chapter 5.  My primary finding was that the inactivation of ATRX significantly enhances 
the frequency of ALT by between 4 to 5 orders of magnitude.  This observation, in and of 
itself, probably explains the frequency of ATRX mutations in ALT.  From a molecular 
perspective, my work also provides insight into what role ATRX is likely normally playing 
in preventing ALT from initiating, which is that it represses the recombination of telomeres 
during crisis.  My work also suggests that the telomeric recombinations may be impacted 
by cis-acting DNA regulatory elements, likely specific to each sub-telomere, as the 
recombinations in multiple independent clones resulted in elongation to a specific length.  
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One fascinating explanation for these site-specific recombinations could be that the 
incorporation of H3.3 by ATRX is tightly controlled by sequence specific elements.  One 
report found ATRX-dependent H3.3 incorporation into regions of the genome in areas as 
little as ~100 bp long (Levy et al. 2015).  These areas are predicted to be sites prone to 
the formation of G-quadruplex DNA, structures that are also common in telomeres (Smith 
and Feigon 1992).  Thus, the site-specific recombinations seen in the ATRXNeo/o clones 
during their escape from crisis may be correlated with regions normally occupied by H3.3. 
 
Future Directions 
In the remaining text, I will discuss outstanding questions relevant to my work and 
propose experiments that could address these unknown issues. 
 
1) What is the mechanistic contribution of PARP1 to telomere maintenance? 
My work implicates PARP1 as a suppressor of stochastic replication-induced DNA 
damage at a telomere.  However, it is unclear whether this role is simply due to PARP1’s 
ubiquitous role in resolving SSBs and damage at a replication fork, or if there exist discrete 
(identifiable perhaps by separation-of-function mutations) mechanisms.  Thus, I would 
propose to determine if PARP1’s recruitment to the telomere via its interaction with TRF2 
is required to prevent the damage that occurs in the telomeres during its absence.  
Notably, although this interaction has been biochemically confirmed (Gomez et al. 2006), 
the functional consequence of this interaction remains speculative.  PARP1 contains a 
TRF2-docking motif 737-Y-T-L-I-P-741, and the mutation of this motif in other proteins 
abrogates their telomere localization (Chen et al. 2008).  Thus, I would propose to 
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complement the PARP1-null cells with a mutant PARP1∆TRF2 cDNA and propose the 
following experiments. 
 
Sub-aim 1: Determine the functional consequence of PARP1’s interaction with TRF2 
In PARP1-null cells complemented with either, WT, PARP1∆TRF2 or empty vector, I 
would address PARP1 localization to the telomere by a ChIP experiment.  Telomere ChIPs 
are relative easy to perform because they can utilize a well-optimized telomeric DNA probe 
for detection by Southern blotting.  Cell lysates from each of the genotypes would be 
collected, and the proteins would be crosslinked to the DNA with 4% formaldehyde.  I 
would then IP PARP1, dot blot the lysate onto a membrane and probe it using a γP-32 
radiolabeled 5’-(CCCTAA)3-3’ oligonucleotide.  Such techniques have been used to 
monitor other specific protein:telomeric DNA binding interactions (Sfeir and de Lange 
2012).  The telo-ChIP approach is especially quantitative as it does not require any 
additional PCR amplification.  I would hypothesize that PARP1’s recruitment to the 
telomere would be dramatically reduced in the PARP1∆TRF2 cells.  Nonetheless, PARP1 is 
a SSB binding protein, and if such a break does occur anywhere in the genome, it will 
likely still be able to access it (the TRF2 interaction domain does not overlap with PARP1’s 
DNA binding domain) (Satoh and Lindahl 1992).  To understand if PARP1’s interaction 
with TRF2 is required for DNA damage sensing at the telomere, I would treat the cells with 
1 Gy of ionizing radiation, which while known to produce ~10 to 20 DSBs per cell, is 
estimated to cause ~30X the amount of SSBs/cell than DSBs/cell (Blocher and Pohlit 
1982).  I hypothesize that while PARP1 usually binds to DNA breaks throughout the 
genome, at the telomere it is occluded from binding to such breaks without its proper 
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interaction with TRF2, as Shelterin is well documented to prohibit DNA repair enzymes 
from accessing the telomere to initiate DNA repair (de Lange 2010).  Thus, I would repeat 
the telomere-ChIP assay with the aforementioned panel of cell lines, to determine if 
PARP1’s binding to the telomere can be enhanced by exogenous damage.  The relative 
amount of DNA damage +/- radiation could be confirmed by immunofluoresence for the 
DNA DSB markers 53BP1 and γH2AX.  
Lastly, I have suggested that PARP1’s role at the telomere is likely to prevent 
replication-induced DNA damage, which if unrepaired, would be causative of telomere 
shortening.  My hypothesis is that PARP1’s prevention of replication-induced DNA 
damage requires its interaction with TRF2 and localization to the telomere.  To evaluate if 
PARP1 is contributing to the fidelity of telomeric replication, I would perform telomere 
molecular combing.  This technique combines the molecular combing of DNA, which 
linearly stretches genomic DNA on a microscope slide, with telomere FISH (Suram et al. 
2012).  Molecular combing is a technique that stretches out a chromosome as one single 
molecule on a microscope slide, which enables the examination of the molecular dynamics 
of various DNA loci on the same chromosome (Lebofsky and Bensimon 2003).  One 
application of molecular combing is the visualization of DNA replication orientation and 
progression along a chromosome by utilizing pulse-chase experiments with nucleotide 
analogs that can be detected by fluorescently conjugated antibodies.  Following molecular 
combing, to visualize the telomere, telomeric FISH is performed to label the telomere 
(Suram et al. 2012).  Thus, this hybrid assay enables the examination of whether 
telomeres become fully replicated.  To determine if PARP1 is facilitating proper telomeric 
replication, I would perform this assay on each of the PARP1-null cells complemented with 
either WT, PARP1∆TRF2, or empty vector.  Furthermore, to enhance the frequency of these 
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replication-induced damage events, I would treat each of these cells with or without 
aphidicolin, which is a DNA polymerase inhibitor and should thus increase the number of 
replication-induced DNA damage events per cell.  Based on the observation that I 
detected ~2 to 3 TIFs per cell in untreated PARP1-/- cells (Fig 3.9), I would predict that the 
PARP1-null cells exhibit some detectable un-replicated telomeres even if untreated.  I 
would further predict that these cells would be especially sensitive to aphidicolin treatment.  
Additionally, I would expect that the PARP1∆TRF2 cells would phenocopy the PARP1-null 
cells for their capacity for telomere replication.  One final interesting examination would be 
the difference between the genome-wide effects on replication fidelity of the PARP1-/- and 
PARP1∆TRF2 cells, where I posit that if there is a true separation-of-function between these 
two mutants, then the PARP1∆TRF2 cells would be proficient for fork stabilization throughout 
the genome. 
 
Sub-aim2: Determine if telomere maintenance is PARP1’s essential function in human 
cells 
The gene targeting experiments in Chapter 3 revealed that human cancer cells prefer 
to maintain and express PARP1, as only 3/72 targeted cells were correctly targeted (Table 
3.1).  During these gene targeting experiments there was no evidence of any 
haploinsufficiency of PARP1+/- cells, thus it may be possible that human heterozygotes 
are viable, but that homozygous nulls are embryonically lethal — in any event a human 
PARP1-null patient has never been described.  This prediction is in stark contrast to the 
observation that PARP1-null mice are viable and fertile (de Murcia et al. 1997).  This 
difference might be attributable to the fact that laboratory mice have many notable 
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differences compared to humans, including: having longer telomeres, expressing 
telomerase in most of their somatic cells, and being inherently resistant to telomere 
defects (Martinez and Blasco 2010).  PARP1’s absence from a list of very similar DNA 
repair genes such as ATM, ATR, NBS1, XPC, and others, is notable, as the mutation of 
all of these other genes are each causative of uniquely corresponding human diseases 
(Negrini et al. 2010).  My hypothetical explanation for this is that if PARP1 is essential for 
proper telomere length maintenance (even in the presence of telomerase, as my work 
suggests), the loss of PARP1 may cause developmental failure in humans, as human 
stem cells are especially sensitive to telomeric stress (Wong et al. 2010).  In order to test 
this hypothesis, I propose to create conditionally-null PARP1F/F iPS cells using 
CRISPR/Cas9 gene editing.  I would then subject these cells to differentiation assays as 
described (Weltner et al. 2012), either in the presence or absence of PARP1.  I would 
predict that in the absence of PARP1, the proliferative capacity of these cells would be 
dramatically reduced.  Notably, healthy stem cells would be more sensitive to DNA 
damage at telomeres than cancer cells, as they are not transformed and thus responsive 
to senescent/apoptotic signals (Ju and Lenhard Rudolph 2008).  Thus, in these cells I 
would propose to monitor the kinetics of DNA damage at telomeres, either by 
immunofluorescence for TIFs, or by a telomere-ChIP for proteins such as 53BP1 or 
γH2AX.  Additionally, in PARP1-null stem cells, I would expect to see evidence of cellular 
senescence, detectable using Western blot analyses for p21, a common senescence 
marker (el-Deiry et al. 1994).  Moreover, I hypothesize that these anticipated growth and 
differentiation defects in PARP1-/- stem cells could be rescued genetically, via a 
compensatory mutation of tp53.  Similar approaches in mice enable healthy MEFs to grow 
in the absence of fully functional telomeres (Celli and de Lange 2005).  If the predicted 
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phenotypes were indeed observed, it would serve as further evidence that PARP1 is 
preventing a telomere shortening-cellular senescence program.  In total, these 
experiments would determine if PARP1’s role in preventing telomeric damage in healthy 
human cells is essential for life. 
  
2) What additional factors are required for ALT-immortalization? 
In Chapter 5 I showed that mutation of ATRX in HCT116 is sufficient to enable critically 
shortened telomeres to recombine and escape crisis, in an ALT-like manner.  This finding 
implicates a distinct role of ATRX in repressing telomere recombinations and some other 
factor(s) which promotes/enables the ALT-state.  Hence it is critical to identify that second 
regulatory element(s) that is responsible for maintaining the ALT state.  Here, I propose a 
genetic screen to identify such factors in human cells.  Additionally, because tp53 is very 
commonly mutated or inactivated in ALT tumors, I would seek to clarify if its mutation or 
misregulation is required and/or sufficient for the perpetuation of the ALT state. 
 
Sub-aim1: Identify the factors responsible for perpetuating the ALT state 
Recent work has reported that genetic mutation of TERC is an excellent tool to 
generate ALT cells (Min et al. 2017).  This study utilized a fibroblast cell line, SW39, which 
is similar to JFCF and which can spontaneously immortalize using either ALT or 
telomerase.  Given that in Chapter 5 I could detect ALT-like activity, but not the 
continuance of an ALT-state, I suggest that while HCT116 is repressive of ALT, it retains 
the molecular capacity to produce it.  Thus, HCT116 is an excellent cellular model to 
identify the minimum number of genetic alterations required to induce ALT.  Notably, such 
other modifications are presumably either already present, or readily activated, in JFCF 
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and SW39 cells.  Thus, I propose to generate conditionally-null TERCF/F cells in the 
HCT116 ATRXNeo/o background using CRISPR/Cas9 gene editing.  Notably, TERC-/- cells 
cannot escape telomere crisis (this contrasts with the DN-hTERT technique I presented in 
Chapter 5 where cells can readily escape crisis by telomerase over-expression or 
mutation of the integrated DN-hTERT construct) (Jones et al. 2014).  HCT116 
ATRXNeo/o:TERCF/F cells would then be subjected to a CRISPR/Cas9 whole-genome gene 
knockout screen (Koike-Yusa et al. 2014).  Notably, in this genetic screen, once the TERC 
gene is deleted the vast majority of cells will be negatively selected by the ensuing 
telomere crisis.  Thus, any surviving clones would be of significant interest.  These screens 
utilize a CRISPR/Cas9 lentivirus, in which the guide RNAs directing the Cas9 contain a 
barcode to report which gene they have inactivated (Koike-Yusa et al. 2014).  Therefore, 
in any clone that does immortalize, the mutation responsible can easily be identified by 
PCR amplification of the lentiviral CRISPR and sequencing the resulting product.  Mutation 
of the target gene of the CRISPR, and any likely off-target hits, could then be confirmed 
by PCR and sequencing.  This approach would enable the identification of putative ALT-
state regulatory genes.  Candidate hits could then be validated by mutating these genes 
in a different telomerase-positive cancers, to ensure that the results weren’t cell-line 
specific. 
 
Sub-aim2: Discern the role of p53 in suppressing the ALT-specific chromatin mark, 
H3.3S31P.  
Recent work has additionally described an ALT-specific genome histone mark, 
H3.3S31P (Chang et al. 2015), which is of significant interest as ATRX is a regulator of 
H3.3 genomic localization.  Independently, the H3.3S31P modification is a global histone 
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modification that corresponds to chromosomal mis-segregation at mitosis, and triggers a 
p53-dependent cell cycle arrest (Hinchcliffe et al. 2016).  The implication of these two 
findings is that p53 signaling may be somehow disrupted in ALT tumors, which has actually 
been commonly observed in ALT cells (Henson and Reddel 2010), but without true 
mechanistic insight.  Since the H3.3S31P mark is rapidly induced during mitotic anaphase 
(Chang et al. 2015), the anaphase promotion complex (APC) may be the DNA damage 
sensor, as it is the primary mechanosensory complex that regulates chromosomal mis-
segregation. Thus, my hypothetical model is that in ALT cells (which are frequently 
polypoid) the H3.3S31P histone mark is constantly activated.  This signal is first 
recognized by the APC and transduced by some unknown factor to initiate p53-dependent 
senescence.  Presumably, the easiest way for cells to escape this cellular checkpoint 
would be via p53 mutation, which perhaps explains the frequency of its mutation in ALT.  
In order to characterize this signal transduction network, I would propose to compare 
common ALTp53-negative cell lines to those rare ones which do express p53 (ALTp53-postive) 
(Henson and Reddel 2010).  Specifically, I would attempt to identify the H3.3S31P signal 
transduction pathway by comparing the proteins which interact with H3.3S31P in ALTp53-
postive and ALTp53-negative cells.  As a positive control, I would utilize primary, normal IMR90 
fibroblasts (which presumably have a functional checkpoint) and initiate chromosome 
segregation using an established rapid chilling/rewarming protocol (Kasuboski et al. 
2011).  To identify this pathway in ALT cells, ALTp53-negative and ALTp53-postive cellular extracts 
would be collected, the protein:protein interactions would be crosslinked, followed by 
immunoprecipitation for H3.3S31P.  Following a purification of the H3.3S31P-bound 
proteins, the crosslinking would be reversed.  Differential binding partners would be 
detected by quantitative mass spectrometry-coupled proteomics.  Any putative interactors 
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could be functionally confirmed by editing of the corresponding gene in an ALTp53-negative 
cell, followed by re-expression of p53.  I would hypothesize that the absence of the 
H3.3S31-interacting proteins would render the ALTp53-negative cells not sensitive to the 
restoration of p53 expression.  If successful, this would identify another regulatory network 
which is repressive of ALT that is likely independent of ATRX and thus would enhance the 
predictive power of using molecular pathology to identify the drivers of a patient’s tumor.  
In the future, gene therapy of a patient’s cancer designed to restore these mutated 
repressors of ALT could serve as an excellent treatment option. 
 
3) How does ATRX repress ALT? 
The work I present in Chapter 4 and Chapter 5 indicates that ATRX represses ALT 
initiation.  At a molecular level, as ATRX-null HCT116 cells transit telomere crisis, there 
appears to be site-specific telomere-recombination events.  While this suggests that ATRX 
is directly repressing recombination at telomeres, the molecular mechanism of this activity 
remains unknown.  In addition to telomeric H3.3, ATRX also controls a portion of the H3.3 
incorporation into various genomic regions in addition to telomeres.  These regions are 
usually GC-rich and include: structural elements such as the pericentric chromatin 
(Filipescu et al. 2013), G-quadraplex-prone regions (Levy et al. 2015) and even 
endogenous retroelements (Goldberg et al. 2010).  These series of genomic regions are 
intriguing as they represent areas that are all inherently recombinogenic, either due to the 
repetitive nature of the sequence, or for the likelihood of DNA damage to occur, as has 
been observed in telomeres (Sfeir et al. 2009).  The objective of this Aim would be to 
determine if H3.3 serves an anti-recombinogenic purpose.  To address this, I propose to 
first map the genomic distribution of ATRX-dependent H3.3, then determine if these 
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regions are resistant to gene conversion using gene editing technologies. These 
experiments would enable a mechanistic explanation for the apparent H3.3 enrichment in 
areas which are conceptually recombinogenic, but somehow repressed from such activity. 
 
Sub-aim1: Map the Genomic Distribution of ATRX-dependent H3.3 
To determine how genomic H3.3 influences recombination, the specific regions of the 
genome in which H3.3 is incorporated need to be identified.  While this has been done 
previously in MEFs (Goldberg et al. 2010) and various mouse tissues (Levy et al. 2015), 
it has not been done in human cells.  Unfortunately, given the difference between humans 
and mice with respect to telomere maintenance and the regulation of DNA repair, there is 
inherent risk in simply extrapolating the murine data to humans, and thus I propose that 
similar experiments need to be performed in human cells.  Therefore, I would map the 
distribution of H3.3 throughout the genome by Chip-Seq in HCT116 and HCT116 
ATRXNeo/o cells, as well as in the non-immortalized, untransformed, healthy human lung 
fibroblast lines, IMR90 and MRC5.  In brief, this technique works by immunoprecipitation 
of H3.3 crosslinked to its cognate DNA, then the reversal of that crosslinking, and finally 
the identification of the H3.3-bound DNA sequence by next-generation sequencing.  By 
performing this technique in these four different cell lines, we could determine where H3.3 
can generally be found in the genome, what specific regions were ATRX-dependent, and 
if any of these regions were cell or cancer- specific. 
 
Sub-aim2: Determine the effect of H3.3 on genomic gene conversion 
Recent advances in gene editing technologies have rapidly expanded the ease of 
gene conversion studies in human cells.  Notably, gene conversion between a genomic 
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site and a plasmid donor has been well established as a representative measurement of 
recombinogenic activity (Kan et al. 2014).  Using the H3.3 distribution data from SA3.1, I 
propose to design multiple (~5) CRIPSR/Cas9 targeting constructs and plasmid donors 
which incorporate a promoter-driven NEO resistance gene into regions of the genome 
where H3.3 incorporation was ATRX-dependent in HCT116.  24 hours following the 
transfection of these targeting constructs into cells, I would single-cell subclone the 
transfected cells in drug-containing media. Subclones would be screened by PCR to 
identify those cells that were correctly targeted.  The number of correctly targeted clones 
in each cell line would be representative of the relative amount of recombination potential 
at each locus. I hypothesize that the absence of ATRX-mediated H3.3 incorporation in 
these regions would facilitate an enhanced frequency of gene conversion at these sites.  
This would provide strong evidence that the genomic incorporation of H3.3 by ATRX 
serves to prevent recombination.  Follow-up studies could address the mechanistic role of 
H3.3 in repressing recombination by examining potential differences in the recruitment of 
HDR-factors to these sites such as MRN, BRCA1, Rad51, etc., where I would hypothesize 
that CRISPR-mediated DNA breaks in H3.3-regions would be repressed for the active 
recruitment of such HDR-initiating factors. Such studies would begin to explain how ATRX-
mediated H3.3 incorporation into the genome represses HDR at those specific sites. 
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